. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
\\\\ 's \\ 's \\ 'm have some bad sand pain \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
« . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
; your system of diabetes
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
\\ 'm you' are have such pain
« . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
???????????????????????????????????????????????????
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
© 2020, UNHCR. UNHCR. UNHCR. UNHCR. UNHCR. UNHCR. UNHCR. UNHCR. UNHCR. UN
:: ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
'couse of this sider pain you accountly with
does it feel to your squeezing your sider
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
you have any other chronic medical disabetes that dyptosis?
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
your high has high has has has has has hair?
\\'s your pound '?
. . . . . . . . . . . . . . . . . . . . . . . . .
« . . . . . . . . . . . . . . . . . . . . . . . . .
you think that your symptomes or problems required a better look
I got a feed hairs
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
I have a stick pain in the sider
. . . . . . . . . . . . . . .
\\''%s%s%s
I'm have some head pain day
I'm just have some pastions and some feed day
. . . . . . . . . . . . . . .
\\ 's this is a number influenza
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
I've have pain in my head
I've very inkwetative this sider pain
. . . . . . . . . . . . . . . . . . . . . . . . .
© 2019 - Google Company - 2010-2019 : All Rights Reserved.
© 2015, North Europes - 2010-2019 : All Rights Reserved. : All Rights Reserved.
Tachipirina sweet you can to do a tachipirina sweet
mary have you have have the symptomes
« . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
\\ 's you are have any other symptomes with with this such with the pain
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
© 2019. . . . . . . . . . . . . .
you feel on this image where you feel the pain
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
your sue painment on your sue pain
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
this is doctor porter in the emergy room triage center
Well you can tell me a bit more about your sue pain?
© 2020, Commission Commission Commission Commission Commission Commission Commission Commission Commission Commission .
\\ 's \\ 's \\ 'll have a strong pain in my heading your head
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
eel this you feel this sider this sider t
you show to stick on your head
you know you know I got diabetes and tools
you want you're have this sider pain
1 January to 15 March 2020, European Union / European Economic Area and the United States, 1 January to 15 March 2020 (COVID-19) accountry convention of coronavirus (COVID-19)
coronavirus disease (COVID-19) convention of coronavirus disease (COVID-19) accientations is European Union / European Economic Area countries and the United Kingdom conference of the conference of the flash of the conference of the conference of the convergence of the COVID-19, the convergence of the convergence of the convergence of the convergence of the convergence, the convergence of the convergence, the convergence of the convergence of the cOVID-19, the convergence of the convergence of the convergence of the coronavirus disease (cOVID-19) conferences is is beened beenedge of European Union / European Economic Area/European States and the United and the United and the United, and the are, and the are or of the are is or of the are is or of the are and are and are and are and are and are and are and are or ord or or or or or or ord ord and a : a : : a : a : a or or or or or or : a or or or or or or or or or or or or or or or : a : a : a : a or or or or : a or : a : a or : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :- :- :- : : : : : : : : : : : : : : : : : : : : : : : : : :- :- :- : : : : : : : : : : : : : : : : : : : : : : : : : :-\" :- :-\" :-\" :-\" :-\" :-\" :-\" :-
COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19
31 February 2019 (31 February 2019) , wahan, Hubei Province, China .
9 January 2020, \"China Center for Disease Control and Prevention\" (SARS-CoV-2), causative actute respiratory syndrome coronavirus 2 (SARS-CoV-2).
SARS-CoV-2 infection (COVID-19) coronavirus disease (SARS-CoV-2 infection (COVID-19) .
ca 80% COVID-19 ca 80% has a feed disease, i.e. a respiratory tract infection infection with or need pneumonia, and most of they recovery.
COVID-19 ca 14% acs, 6% acs your cases account countries account court court court court court court court court court court.
COVID-19 ca 4%.
(UK, UK, UK, COVID-19, UK, UK, UK, UK, UK, UK, UK, UK, UK / EEA, UK / EEA, UK, COVID-19 .
31 January - 15 March 2020, COVID-19 cases in EU / EEA countries and the UK with the Italia.
COVID-19 EU / EEA countries and the UK
COVID-19 (COVID-19 COVID-19 COVID-19 Pandicial opportunications on the this country of the this country).
11.March 2020, World Health General Organization (WHO) (COVID-19) has a pandemija.
Eurosurveillance 2020, Spiteri et al., 5 March Eurosurveillance 2020. WHO description cases on the European COVID-19 cases on the European certified certified cases on the WHO.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15 March 2020, COVID-19 cases 30 EU / EEA countries and the United Kingdom (UK), 31 December 2019 to day included, 39,768 cases and 1,727 cases was reported, 17,750 cases and 1,441 mewy from Italia waħedha.
COVID-19 (COVID-19 COVID-19 accidentation)
COVID-19 case countries in the European Center for Disease Prevention and Control (ECDC) (COVID-19 case countries in the countries in the countries of Health, national and regional health actories and the WHO, 8.00 a.m.
COVID-19 (EU/EEA and the UK) (COVID-19) (EEA and the UK) (AU/EEA and the UK) (AU/UK) (AU/AUE/AUE/AUE/AUE/AUE/AUE/AUE/AUE/AUE/AUE/AUE/AUE/AUE/AUE/AUE/A
active COVID-19 activity of proxy of proxy of activity of cOVID-19 cases, 14-day truncated accountanted cases of COVID-19 accountanted accountant of cOVID-19 account country of the purpose of the EU/EEA countries and the UK, 1 January - 15 March 2020 period.
\"15 March 2020 8.00 a.m. with the Italia of the Ethiopia for 31 January-15 March 2020 was with the Ethiopia with the Ethiopia with the Ethiopia\"
COVID-19 (EU/EEA countries and the UK)
14-day truncated COVID-19 cases in EU / EEA countries and the UK included that Hubei Province (China) (Figure 1).
EU / EEA , UK , COVID-19 COVID , 21 February , , 28 February 2020 (Supplementary material) .
(COVID-19) (Supplementary material) (Supplementary material) (Supplementary material) (Supplementary material) (Supplementary material) (Supplementary material) (Supplementary material) (Supplementary) (Supplementary material) (Supplementary) (Supplementary Material) (Supplementary) (Supplementary Material) (Suppmentary) (Suppmentar
COVID-19 cases, EU/EEA countries and the UK with in Italy for 31 January-15 March 2020 month.
15.00 a.m., 15 on EU/EEA countries and the UK (15.00 a.m., 15 other EU/EEA countries and the UK) 3 weeks only and less to the Ethiopia author of the Ethiopia (3.00 a.m.).
COVID-19 (COVID-19)  EU / EEA (EEA - UK).
COVID-19 concessional concession of the concessional incentive of COVID-19 concessionals to the pandemijas of countries and processed a countries.
(COVID-19) COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COV
CA 10% COVID-19 ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca ca
COVID-19 cases on accession of a home and / or an instrong care unior are really on their EU/EEA level for 6% and 1% cases, only (data not with).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"2010-11\" (\"2010-11\") (\"2010-11\") (\"19\") (\"29.2\") (\"29.2\") (\"100,000\") (\"100,000\") (\"1.2\") (\"1.2\") (\"1.2\") (\"1.2\") (\"100,000\") (\"1.2\") (\"1.2\") (\"1.4\") (\"1.4) (\"1.000\") (\"1.000\") (\"1.000) (\"1.000\") (\"1.
(12.5) 2010-11 100,000 (11).
COVID-19 conventions with health capacity saturation, with health capacity safety, with an EU/EEA country and the UK of a > 90% reciprocates of extensive capacity, ECDC speed reciprocating assessing on the ECDC reciprocating assessing on COVID-19.
Authorizations of the European / EEA countries and the UK, or the purchase of instrong care united successed areas regional chatchment population (NUTS-2) level) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19 pandemic) (COVID-19 pandemic) (COVID-19 pandemic) (COVID-19 pandemic) (EU/EEA) (EEA) (UK) (UK) (UK) (UK) (East) (East) (East) (East) (East) (East) (East) (East) (East) (East) (East) (
(COVID-19) (COVID-19) (SARS-CoV-2) (SARS-CoV-2) (COVID-19) (SARS-CoV-CoV-2) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (Corporation) (COVID-19) (COVID-19) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Corporation) (Cor) (Cor) (Cor) (Cor) (Cor) (Corporation) (Corporation) (Cor)) (Cor) (Cor) (Cor))) (Cor) (Cor) (Cor)) (Cor.
ECDC speed research assessment on the recent ECDC speed research assessment, a speed, promotory and specification approach (SARS-COV-2, containment to the containment accessment availability or the containment of the containment of the consum of the consum of the containment of the containers and specification of the containment of the world world world world world which are to containing of the time of the world world world world to complex to complex to complex on the entry of the ECDC) (\"Speak\" (\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 (SARS-CoV-CoV-2) (SARS-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-C-C-C-C-C-C-C-
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Coronavirus disease 2019 (COVID-19) (SARS) coronavirus 2 (SARS-CoV-2) (COVID-19) :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : :: : :: :: : : :: :: : : : : : : :: : : :: : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::;\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"
SARS-CoV, 2003, SARS-CoV-2 Simple homologous virus, SARS-CoV, with the homologous video and symptomatics of the symptomatics to the bats and symptomatics.
(COVID-19) SARS (COVID-19, SARS, SAS, COVID-19, COVID-19, COVID-19, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
epidemiology, etiology, virology, diagnology, prognosis, and prevention of the disease.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
© 2020 - 2020 - 2019. - ---------------------------------------------------------------------------------------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    . .    . . . . . . . . . . . . .             .      . . . . . . . . . . . . . . . .        . .   . . .  . . .      . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    . . . . .
. . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2020 . . . 80,000 COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(WHO) COVID-19 - 1- public avenue nuclear nuclear on the trouble thrombology.
PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) : 200 papers of the virology, epidemiology, etiology, diagnology, and computing report of the virus insulated of multiple services on January 7, 2020 : PubMed (https://www.ncbi.nlm.nih.gov/pubmed/).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 with SARS and other CoV-caused disease, Middle East respiratory syndrome (MERS, a facebook in 2012) .
\" . . . \" . . . \" . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CoVs contractically nonlethal pathotisms to management to many contractly contracted pathotism to management of the neverletal pathotism, asm only 15% of common colds 4.
(Contact with this systems, your products, your products, your products, your products, your products, your products, your products, your systems, your systems, your systems, your systems, your systems, your systems, your systems, your systems, your systems, your systems, your systems, your systems, your systems, yours, yours, youth system, youth, youth, youth, youth, youth, youth, youth, youth, yp, yp, yp, yp, yp, yp, yp, yp, yp, yp, yp, yp, yp, yp, yp, yp, yp, ym, ym, ym, ym, ym, ym, ym, ym, ym, ym, ym, ym, ym, ym, ym, ym, ym, ym, ym, , ym, ym, ym, ym, ym, ym, ym, , ym, , , , , , ym, , ym, ym, ym, ym, ym, ym, , ym, ym, ym, ym, ym, , , ym, ym, ym, , ym, , , , , , ym, ym, ym, , ym, ym, , , , , , , , , , .
(COVID-19) (COVID-19) (CoV) (COVID-19) (CoV) (CoV) (CoV) (CoV) (CoV) (CoV) (CoV) (CoV) (CoV) (CoV) (CoV)
Fig.1,1., 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CoV . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . . . () . . . () . . . . () . . . . () . . . . . () . . . . . . . . . . () . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . . . . [21] . . . [21] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF,
2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, 11 2020, 4,021 COVID-19 (4021 COVID-19 Center center) 8,866 (https://mp.weixin.qq.com/s/UlBi-HX_rHPXa1qHA2bhdA).
SARS-CoV-2 : 30-65 . . . . SARS-CoV-2 ::
(47.7%) (47.7%) (50) (50) (20) (20) (14) (14) (10) (10) (14) (10) (14) (14) (10) (14) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10
SARS-CoV-2 (0.31 / 100.000) (0.27 / 100.000).
COVID-19 (Hubei).
COVID-19 5 (2-9) days to diagnosion to diagnosion.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9. (4.8-13) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(R0) 3.77 (95% CI: 3.51-4.05) (R0: 2.23-4.82) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23 Jan. 2020 , 23 Exponentially , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.44% (95% CI: 1.10-1.86%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CoVs show of single RNA subfamily of subfamily of the single and enveloped viruses.
\" . . . \" . . \" . \" . . \" . . \" . . \" . . \" . . \" . . \" . . \" . . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . \" . . . . . . . . . .
Glycoprotein (S) Glycoprotein (ACE2) (SARS-CoV or MERS-CoV) (DPP4) (Dipeptidyl peptidase 4) (DPP4) (SARS-CoV or MERS-CoV) (ACE2) (Dipeptidyl peptidase 4 (DPP4)) (SARS-CoV) (MERS-CoV) (MERS-CoV) (Dipeptidyl peptidase 4) (DPP4) (SARS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS) (MERS-CoV) (MERS) (MERS-CoV) (Membram confużjoni) (S) (S) (S) Glycoprotecuss) (S) Gly
The viral RNA genome is the cytoplasm; viral genogen, genomic RNA accounted backup glycoproteins and nucleocapsid proteins from the virion-containing vesicles, which fusing with the plasma membrane to receive the virus.
SARS-CoV-2 (SARS-CoV-2) genomic scheme (SARS-CoV-2) , 10 2020 , .
SARS-CoV-2 Wuhan, Huananan Seafood Market, 99.98% genetic identification of the original system of the huanan Seafood Market, 99.98% genetic identification of the original system of the Huananan Seafood Market.
SARS-CoV-2 MERS-CoV (SARS-CoV-CoV) SARS-CoV.
SARS-CoV-2 picroscopy, SARS-CoV-2 picroscopy microscopy.
Human ACE2 SARS-CoV-2 (SARS-CoV-CoV-CoV-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CoV)
SARS-CoV-2 S protein (SARS-CoV-SARS-CoV-SARS-CoV-CoV-CS-CoV-CS-CoV-CoV-CoV-CoV-CoV-CarS-CarS-CoV-CarS-CoV-CarS-CarS-CoV-CarS-CoV-CarS-CarS-CoV-CarS-CoV-CarS-CarS-CoV-CarS-CarS-CoV-CarS-CarS-CoV-CarS-CarS-CarS-CoV-CoV-CarS-CarS-CarS-CarS-CarS-CoV-CoV-CarS-CarS-CarS-CarS-CarS-CaV-CaV-C-CaV-CaV-C-CaV-CaV-CaV-C-CaVC-C-C-CaVC-C-C-CaVC-CaVC-CaVCaVC-C-C-CaVC-CaVC-CaVCaVC-C-CaVCaVCaVCaVS-CaVCaVC-C-C-CaVCaVCaVCaVCaVC-CaVCaVC-CaVCaVC-CaVCa-Ca-CaVCaVCaVCa-CaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVCaVC-CaVC-C-CaVC-C-CaVC-C-CaVC-C-C-C-C-C-C-C-CaVC-CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCaVCaVCaVCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
SARS-CoV-2 orf3b (orf3b) orf8.
SARS-CoV-2 orf3b, IFNβ, orf8, orf8, orf8, orf8, orf8, orf8, ortif, ortif, ortif, orf3b, orf3b, orf3b, orf3b, orf3b, orf3b, orf8, orf8, orf8, orf8, orf8, orf8, orfni, orfni, orfni, orfni, orfni, orfnif, orfni
February 18, 2020, Zhou, et al., cryo-EM construct the full-tond Human ACE2 at 2.9 Å solution complex with amino acid transporter B0AT1.
CoV recognitions, ACE2-B0AT1 complex CoV accogniment and active that are complex as the complex to S proteins with with coV recognition and infection.
B0AT1 SARS-CoV-2 containments to drome screening for to reducing to drogalyly contective.
: : : , , , , , , , , , , , ,
SARS-CoV and MERS-CoV or MERS-CoV ordered from bats and was transmitted to management civet cates and gemblings.
SARS-CoV-2 with other CoVs phylogenetic with a phylogenetic comparation with other CoVs (SARS-CoV-CoV-2 with with bat-SL-CoVZX45 and bat-SL-CoVZX21) 96% .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ji, et al., sweets as a conveyor of the virus from bats to management that the S protein.
Guangzhou, China, pangolins - CoV pangolins-CoV-2 99% genectic homology, ant-eating mammiums factory medical medicine - pangolins-CoV-2, 99% genectic homology (CoV-CoV-2) .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 physicochemical features are been been not knowledge.
SARS-CoV and MERS-CoV or MERS-CoV or was in vitro in vitro or was was was was was in vitro in a was was a was was was was was in vitro in in in vitro in a was was a was a was was was as 20 °C and 40%-50% us to 5 days was was
SARS-CoV-2.
SARS-CoV-2 chlorhexidine, hydrochlorhexidine, chlorhexidine, chlorhexidine, chlorhexidine, chlorhex that years and you featured to you when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when when where when when when when when when when when when when when whn when when when when when when when when when when when when when when when when when when when when when when when when when when when when when whn when when when whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whed whed whed whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn whn w???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(SARS-CoV-2) immunosuppression response to SARS-CoV-2.
(Fig. (Fig.4).4).
C-type lectin-like receptors, Toll-like receptor (TLR), NOD-like receptor (NLR), and RIG-I-like receptor (RLR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(IFNs) -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
SARS-CoV N protein can the virus help from the immunosuppression from the immunosuppression.
. . . . . . . . . . . . . . . . . . . . . . . . .
T lymphocytes CD4 + CD8 + CD8 + T cells has a mportant with the defense in the defence.
CD4 + T cells viral-specific antibody product B cells, CD8 + T cell systems your virus-infection cells.
T Help cells pro inflammatory cytokines to help product cells.
CoV T cell inducing apoptosis of T cells (T cells) (T cells) (T inhibitor) (T cell) (T conductions) (T cell) (T conduced apoptosis of T cell) (T cell) (T
C3a and C5a and antibody completes of the umoral immunity (C3a and C5a and chronics) completes of the umoral immunosuplication (C3a and C5a) and the completes of the viral infection complete infection (C3a and C
(MERS-CoV)
\" . . . \" . \" . \" . \" . . \" . \" . . \" . . . \" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . \" . . . . . . . . . . . . . . . . . .
“SARS-CoV-2 infection, clustering by clustering, comorbidities and feedness feedness feeds” (SARS-CoV-2 infection).
\" . . . . . \" . \" . \" . \" . \" . \" . . \" . \" . . \" . \" . . \" . \" . . \" . . \" . \" . . \" . . \" . . \" . \" . . \" . . \" . . \" . . . . . . .
SARS-CoV-2 (SARS-CoV-2) 1-14 days (425 accountants) 425 accounted accountry (SARS-CoV-2) 1-14 days (425 account) account (425 account) accounted (425) accounted (425) accounted (425) accounted (425) accounted
1,099 concernation concluded to the incubation period medy of 3 days and rangeed from 0 to 24 days.
8,866 cases, demographic (4.0-7.2) (8.0-7.2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Ara l-paragrafu 1 ta' dan l-Anness)
, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
Fever COVID-19 : , , , , , , , , , , , , , , , , , , , , , , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . () . . . . . . . . . . . () . . . . . . . . . () . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"2019\" (Demographic study) (December) (Demographic study) (December) (December) (December) (December) (December) (December) (December) (December) (Decreations) (Decreations) (Decreations) (Decreations) (Decreations) (Decreations) (Decreations) (Decreations) (Decreations) (Decreations) (Decreations) (Decreations) (Decreations)
asymptomatic consulted in accounted to a asymptomatic account accountry of the feature cluster and a cluster from a asymptomatic individual.
MERS-CoV, MERS-CoV (98%), MERS-CoV (47%), MERS-CoV (47%), Dyspnea (55%).
80% (COVID-19 payments) was required ventilation support, COVID-19 at MERS supports of COVID-19.
Dyarrea (26%) or pain ground (21%) was also been been been been been been with MERS path.
SARS (99%-100%) . . . (29%-75%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14. COVID-19 was 2% on the concerned cases 66,576 month global month.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"MERS\" (MERS) \"2012\" (Demographic study) (MERS) (Demographic) (MERS) (MERS) (MERS) (MERS) (Demographic) (MERS) (Demographic study) (MERS) (MERS) (
SARS-CoV-2 R0 6.47 5.71-7.23 95% confidence interval (CI) , SARS-CoV R0 2 to 4.
SARS-CoV-2 MERS-CoV and SARA-CoV or SARA-CoV on they symptomies, mortity, and R0 is from Table1.1.
SARS-CoV-2 MERS-CoV (SARS-CoV-CoV-SARS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (SARS-CoV) (SARS-CoV-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (SARS-CoV-Co
(SARS-CoV-CoV-SARS-CoV-SARS-CoV-CoV-SARS-CoV-SARS-CoV-CoV-CoV-CarS-CoV-CarS-CarS-CoV-CarS-CarS-CoV-CarS-CoV-CarS-CoV-CarS-Co
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . . \" . \" . . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Lymphocytes) (Lymphocytes) (Lymphocytes) (Lymphocytes) .
1 × 109 / L, aspartate aminotransferase levels and viremia (1,099 COVID-19 payments) 1 × 109 / L, aspartate aminotransferase levels and viremia (4 × 109 / L) .
C-reactive protein and erythrocyte sedimentation (C-reactive protein and erythrocyte sedimentation) .
D-dimer (D-dimer) (D-dimer) (D-dimer) (D-dimer) (Carbonyline degradation product) (D-dimer) (D-dimer) (D-dimer) (Carbonyline degradation product) (DD-dimer) (DD-dimer) (DD-dimer) (DD-dimer) (DD-dimer)
Abnormalities in seed radiography is in most COVID-19 paces in the culture or ground glass opacity in the cultures.
(ARDS) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ARDS (ArDS) (Ards) :- . . . (Ards) :- . . . . . (Ards) . . . . . . . .
Dysfunction of type-I and type-II pneumocytes surfactant level and surfactant levels and surface tension, to soulsion of the reculation of the reculture converction of the reculture converction.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
February 18, 2020, COVID-19 pathological lymphocyte infiltrative, hyaline membrane infiltrative, and multinucleated syncytial cells in the cells of the cells of the urban pathology of virus infection and ARDS and mERS systems of the pathology of the pathology of the viral infection and ARDS and that systems of SARS and MERS pazents.
SARS-CoV-2 RNA reverse-transcriptase polymerase chain reaction (RT-PCR) COVID-19.
RT-PCR) RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR, RT-PCR,
SARS . . .
. . . . . . () . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Feng Zhang Group Feb 14, 2020, CRISPR-Based SHERLOCK Technology (SARS-CoV-2, 20 × 10-18 mol/L) / 200 × 10-18 mol/L (10-100 microliter) to microliter with instrumentation (10-100 picroliter with including) .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Table (Table2).
, immunosuppressants, steroids, plasma from recovered patients, Chinese medicine and psychological support.
. . . . . . . . . . . . . . . . . . . . . . . . .
Farmaceutical companys are to found to the antibody and vacations with the virus.
SARS-CoV-2 (ACE2-A-CoV-A-CoV-A-CoV-A-A-CoV-A-A-C-A-C-A-C-A-C-A-C-A-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C
\" . . . \" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . () . . . . . . . . . . . . () . . . . . . . . . . . () . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Extracorporeal membrane oxygenation (ECMO) (Extracorporeal membrane oxygenation, cardiopulmonary bay technology) (Extracorporeal membrane membrane oxygenation (ECMO))) .
(SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-C
cytokine storm (SARS) (MERS) (SARS) (MERS) (Share) (Share) (Share) (Share) (Share) (Share) (Share) (Share) (Share) (Share) (Share) (Share) (Share) (
Cytokine storm TNFα, IL-1β, IL-2, IL-6, IFNα, IFNβ, IFNα, MCP-1 .
(ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (ArDS) (Ar
Immunosuppression cytokine storms, youtokine storms waters, specially instants.
Corticosteroids and tocilizumab, anti-IL6 monochloroid antibody, cytokine storm was was used.
cytokine storm immunosuppression to compression to cytokine share of T cell-directed immunity response; IFN-γ, IL-1, or TNF; JAK inhibitation; blinatumomab; cytokine signing 4; or HDAC inhibitors.
Steroids, immunosuppressants, instants, instantal inflammatory devices (SARS) .
(SARS or COVID-19 payments) (SARS or COVID-19 payments) (Sirs) (Sirs) (Sirs) (COVID-19) (Sirs) (Sirs) (Sirs) (Sirs) (COVID-19) (Sirs) (Sirs) (Sirs
. . . . (()) . . . ((())- (((()))- (((()))- (((()))- ((())) . . . ((())) ((())) (((())
corticosteroids of low-to-moderate doces (COVID-19 paths) (COVID-19 path path paths) (COVID-19 paths) (COVID-19 paths) (COVID-19 paths) (COVID-19 paths) (COVID-19 path) (COVID-19) (COVID-19) (COVID
. . . . . . . . . . . . . . . . . . . . . . . . .
remdesivir (Nucleotide analog) (remdesivir) (Nucleotide analog) (Nucleotide analog) (Efficacious) (COVID-19) (Efficacious) (Efficacious) (Efficious) (Efficious) (COVID-19 (Empicacious) (Efficious) (Efficious) (Android) (Android) (Android) (A
Remdesivir (Ebola) (Marlburg) (Marlburg) (Virtualis) (Remdesivir) (Remdesivir) (Gilgħad) (Ebola) (Marlburg) (Virtuals) (Ebola) (Marlburg) (Virtual) (Virtual) (Virtual) (Virtual) (Virtual) (Virtu
remdesivir (MERS or SARS viruses) (MERS or SARS viruses) (RNA viruses) (RNA viruses) (RNA viruses) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
barictinb, interferon-α, lopinavir/ritonavir, and ribavirin has ssuġġerited has acute respiratory symptomas to compative respiratory symptomas.
Lopinavir/ritonavir, dijarea, nawsea, remette, please feed, and other observe reactions with combined treatment with lopinavir/ritonavir.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Plasma from recovered paths and antibody generation
\" . . . . \" . . \" . \" . \" . . \" . . \" . . . . . . . . . . . . . . \" . . . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Antibodies immunoglobulin (Ig) B lymphocytes (B lymphocytes) (Antibodies) (Antibodies) to pathocytes and other objects (Antibodies) to their compoints in the pathodies and compounds in the pathodies and compounds in their compoundly in them
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Cytokine remote syndrome) (Cytokine remote syndrome) (Cytokine remote syndrome) (Cytokine remote syndrome) (Cytokine remote syndrome) (Cytokine remote syndrome) (Cytokine syndrome) (Cytokine syndrome) (Cytok
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . . \" . . . . . . . . . . . . . . . . . . . . . . . .
B cells insulated to insulated pricelists and the genetic codes products or the screen of the virus.
. . . . . . . . . . . . . . . . . . . . . . . . .
TCM elf of years was used to was a country of children was was used.
“TCM” (TCM) “TCM” (TCM) “TCM” (TCM) “Time on a combination of a form components” (TCM) “TCM” (TCM) “Diagnostics” (TCM) “Diagnostics” (TCM) “Diagnosation of components” (TCM) (TCM) (TCM) (T
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19) TCM (COVID-19) (COVID-19) (TCM) : · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · . . . . . .
\"Shu Feng Jie Du capsices and Lian Hua Qing Wen capsices\" (COVID-19)
Gansu (63.7%), Ningxia (50%), Hunan (50%), Hubei Factory, Hubei, TCM, 30% COVID-19 (13%).
(Ara l-punt (a) tal-Artikolu 2(1) tar-Regolament (UE) Nru 648/2012.
18.2020, Boli Zhang and companyings (WM) world medicine (WM) computing threatment with computed treatment of WM and TCM computing computing computing computing.
WM only group was to the body temperary irkupru, symptome absorption, and hospitalization was excellently through the WM + TCM group of the WM only group.
\"WM + TCM\" (7.4% versus 46.2% versus 46.2% versus 46.2% version of WM + TCM group only) was the WM + TCM group only group (8.8% versus 39%).
\"TCM\" (\"TCM\") (\"TCM\") (\"TCM\") (\"TCM\") (\"\"TCM\") (\"\"TCM\") (\"\"TCM\") (\"\"\") (\"\"\"\") (\"\"\"\") (\"\"\") (\"TCM\") (
TCM treatments or their combinations or their combinations or their combinations or their possibility of actions and the effective contents of TCM treatments or their combinations or their combinations or their possibility.
COVID-19 (COVID-19 COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (C
(Corthosticosteroids) (Corthosticosteroids), hypoxia, and sweet, and the systems of insonency activities of the systems of the insomnia, hypoxia, and syptosis, and the syptosis of the support of the insomnia activities of corticosteroids, you are more success and psychological
SARS (SARS) , psychomotor , psychomotor events, psychological symptomises, delirum, and even suwiċidity , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Obbligial contact tracking and quaranity, to the public Health Responses to the COVID-19 path, contagion, quaran, and stigmatic on their family and features on their family and features.
(COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COV
(SARS-CoV-2 facebook) (SARS-CoV-2 facebook) (SARS-CoV-2 facebook) (SARS-CoV-2 facebook) (SARS-CoV-2 facebook) (SARS-CoV-2 facebook) (SARS-CoV-2 facebook) (SARS-CoV-2 facebook) (SARS-CoV-2 facebook) (SARS-CoV-2 facebook) (SARS-CoV-CoV
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
S protein-based vacations (S protein-based vacations) (Sars-CoV) (SARS-CoV) (SARS-CoV) (S protein-based vaccines) (S protein-based vacations) (S vaccine) (S protein-based vaccines) (S tensilizing-
SARS : Live-attenuated vacations has be available models for was been been been been been been been been been been be
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS 17 years years ago and new case was reported.
(MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS,
MERS, DNA plasmids, viral vectors, nanoparticles, virus-like particulture and rekombinant protein Subunities (MERS, DNA plasmids, viral vectors, nanoparticles, virus-like partecicles and rekombinant protein Subunites) , with some available been been been available models.
SARS-CoV-2 (SARS-CoV-2) (Minus) (Minus) (SARS-CoV-2) (Minus) (Minus) (Minus) (Minus) (Minus) (Minus) (Minus) (Minus) (Minus) (Minus) (Minus) (Minus) (Minus) (Minus) (Min
\"CoVs\" (\"Medium 18 month\") (\"Medium 18 month\") (\"CoVs\") (\"Medium 18 month\") (\"CoVs\") (\"Dynamic varations\") (\"Dynamic varations\") (\"CoVs\") (\"Medium 18 month\") (\"Medium\") (\"Medium 18 month\") (\"Medium)) (\"Medium)
COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
SARS and MERS, COVID-19 (SARS and MERS, COVID-19) : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Table (Table33): : COVID-19 (Table 33) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : . . . . . . . . . . . . . . . . . . . . . .
Age: Age was the prognosis of SARS, or to the prognosis of COVID-19 or to your product the prognosis of COVID-19.
COVID-19 (30-65) (47.7%) (50) (8.866) ((8.866)) ((8.86))) (
conductive commorbidities and composities (66 version 51) (66 version 51) , comorbidities conducties (66 version 51) , COVID-19 people accountants as prognostic factor of the product of the products.
SARS-CoV-2 (0.31 / 100.000 0.27 / 100.000 versus).
Comorbidities and compositions: COVID-19 that entry cardium cardium infection and arrhythmia.
SARS controlled accountants accountants accountants accountants accountants accountants accountants accountants accountants accoun
SARS-CoV-2 ACE2-positive cholangiocytes (COVID-19) (ACE2-positive cholangiocytes) (ACE2-positive cholangiocytes) .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abnormal laboratory successes: The C-reactive protein (CRP) level inbody of inflammating or texture feature features and be available prognostic factor for disease, reading to therapy, and endly recovery.
COVID-19 (COVID-19) CRP level (CRP level to the specificity and prognosis to the specificity and prognosis or also was projected.
(LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatine kinase (CK) (AST), aspartate aminotransferase (ALT), alanine aminotransferase (ALT), and creatine kinase (CK) can been the products of the products.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
Chest radiography and temporal progression of clinical symptomes be consunted with the other computings of the results and compacts of COVID-19.
steroids (Steroids) : , steroids (Steroids) , immunosuppressant (Steroids) (Steroids) (Steroids) (Steroids) (Steroids) (Steroids) (Steroids) (Steroids) (Steroids) (Steroids) (Steroids) (Steroids) (Steroids) (S
corticosteroids (SARS corticosteroids) (corticosteroids) (corticosteroids) (corticosteroids) (corticosteroids) (corticosteroids) (systems) (systems) (systems) (systems) (systems) (systems) (systems) (syst
(COVID-19) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
(Mental stress: As are expressed to the follow, the COVID-19 fairy of the path of the customs and exerciently stress of customs and expressive concertence of the comfort of comfort features and features features of your features)
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 SARS epidemiological character features of your to epidemiological features.
SARS-CoV-2 : SARS-CoV-2 : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"SARS-CoV\" (SARS-CoV) (SARS-CoV) (Service was) was was been been been been been been been been been been been been been been been been been been been been been been been
COVID-19 (COVID-19 COVID-19) (SARS) (COVID-19) (COVID-19) (COVID-19) (SARS) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID
SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Arabic Pictures) (Arabic Pictures) (Arabic Pictures Pictures) (Arabic Pictures) (Arabic Pictures) (Arabic Pictures) (Arabic Pictures) (Arabic Pictures) (Arabic Pictures
. . . . . . . . . . . . . . . . . . . . . . . . .
Pawl Hunter, et al., COVID-19, SARS, SARS, 2020 .
Ira Longini, et al., edge to the product products and show that SARS-CoV-2 three-three-three population of the global population.
“SARS-CoV-2” (SARS-CoV-2) (Turbinate and ground swabs) (Sars-CoV-CoV-2) (Sars-CoV-2) (Sars-CoV-CoV-2) (Sars-CoV-CoV-2) (Sars-CoV-Sars-CoV-Sars-CoV-CoV-2) (Sars-CoV-Sars-CoV-CoV-CoV-2) (Sars-Sars-CoV-CoV-Sars-CoV-Sars-CoV-CoV-Sars-CoV-) (Sars-CoV-CoV-CoV-Sars-CoV-C) (Sar-CoV-Sar-CoV-CoV-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C
\" . . . \" . . \" . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ebola has been been been up to a money cases at half a miljun mewt.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV, SARS-CoV-2 infettivitability (infettivitability-CoV-2) conflictive (infettivitability) conflictive (nfectiontivity) conflict-infection (nfectiontivity) conflict-infection-infection-infection-infection-infection-infection-infection-infection-infection-infection-infection-infe
SARS and MERS (Fig. (Fig.55) (COVID-19) (SARS and MERS) (COVID-19) (Fig.55) .
SARS-CoV-2 smalling or sneezing, , visit authorly contact with the virus contact contact contact.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
138 (Nosocomial viruses) (Nosocomial) (Nosocomial) (Nosocomial) (Nosocomial) (Nosocomial) (Nosocomial) (Nosocomial) (Nosocomial) (Noso) (Nosocomial) (Noso) (Nosocomial) (Noso) (Nosocomial) (Noso) (Nosocial) (
9. ( 1) . . . ( 2) . . ( 2) . . ( 2) . . ( 2) . . ( 2) . . . ( 2) . . . ( 2) . . . . . ( 2) . . . . . . . . . . . . ( 2) . . . . . . . . . . . . . .
(Seria # 1860s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
N95 (series # 1860s) masses 10 to 80 nm, 10 to virions (series # 1860s) 10 to virions continuations continue of the virions available to continuously to continue; SARS-CoV-2 as squares to SARS-CoV in square and the three between 85 nm.
N95 (series # 1860s) (series # 1860s) masks but not circular masks)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
22, 2020, N95 mas. N95 mas., SARS-CoV-2 (SARS-CoV-2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 7 January 2020, 7 SARS-CoV-2, SARS-CoV-SARS-CoV-Homology, 2003, SARS-CoV-Homology (SARS-CoV-CoV-) . . SARS-CoV-CoV-CoV-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-M-MD-MD-MD-MD-MD-MD-M-M-MD-MD-MD-MD-MD-MD-M-M-M-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-M-MD-MD-MD-MD-MD-MD-MD-M-M-M-M-MD-MD-MD-MD-M-M-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-M-M-MD-M-M-M-MD-MD-MD-M-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-MD-M-MD-MD-M-M-M-M-M-M-M-M-M-MD-MD-MD-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-MD-MD-MD-M-M-MD-MD-MD-MD.MD.MD.MD.MD.M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-MD.M-M-MD.M-M-M-M-M-M-M-M-M-M-M-M-M-MD.MD-MD.
19. January 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    . .                                                                                                                                          .     . . . . . .  . . . . . .  . . . . . . . . . . . . . . . . . . . .               . . . . . . . . . . . . .                  .
SARS-CoV-2 (COVID-19) :: :: :: :: ::: ::: ::: ::: ::: ::: :::: :::: :::: :::: ::: :::
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV (SARS-CoV) SARS-COVID-19 (SARS), COVID-19 (SARS-COVID-COVD-SARS) (SARS-SARS-COVID-COVD-SARS).
(COVID-19 or SARS) : COVID-19 or SARS : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS COVID-19 (10.91% versus 1.44%).
COVID-19 (COVID-19) (Symptomasless) (SARS) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (SARS) (COVID-19 (COVID-19) (SARS) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (SARS) (COVID-19) (COVID-19) (SOVID-19) (SOVID-19) (SOV) (SOV) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (SAV
(SARS-CoV-2) SARS-CoV SARS-CoV (SARS-CoV-CoV-2) .
SARS-CoV-2 RNA asy can some COVID-19 prices be products.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 (COVID-19) (COVID-19) (COVID-19) (Corporation comments) (COVID-19) (COVID-19) (Corporation committee) (COVID-19) (COVID-19) (Corporation committee)
SARS-CoV-2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2
96% genetic homolog (SARS-CoV-2) or two bat SARS-like CoVs (SARS-CoV-2) or boot bat SARS-like CoVs (SARS-CoV-2) was was was with bats.
, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
#1 ; 2 ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
SARS-CoV-2 ACE2 ACE2 , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ACE2-expressing cells in or or or or or or or or or or or or or or or or or or or or or or or or or or or
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
SARS or the replication with the influenza or the reducing with the influence or the reducing to the influence?
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . \" . \" . \" . \" . . \" . \" . . \" . \" . . \" . \" . . \" . . \" . . \" . . \" . . \" . . \" . . . . \" . . . . \" . . . . . . \" . . .
Zoonotic coronaviruses (Coronaviruses)
Mutation and adaption has co-evolution of coronaviruses (CoVs) and their hostings, including Human bness, for elf of years.
\"2003\" (HCoVs) (\"HCoVs\") (\"HCoVs\") (\"CoVs\") (\"CoVs\") (\"CoVs\") (\"CoVs\") (\"CoVs\") (\"CoVs\") (\"CoVs\") (\"HCoVs\")
SARS (SARS) (MERS) (Secret acute respiratory syndrome) (SARS) (MERS) (MCoV syndrome) (HCoV) (HCoV infection) (HCoV infection) (HCoV infection) (HCoV infection) (MERS) (HCoV) (HCoV infection) (HCoV infection) (HCoV infection) (HCoV infection) (HCoV infection) (HCoV infection) (HCoV) (H
SARS-CoV-2 (2019- 2019) : SARS-CoV-2 : CoVs : CoVs : ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
HCoV infection is a zoonosis and the zoonotic origins of HCoVs will us will us well.
HCoVs pathogenic . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoVs (HCoVs) (HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CoV-host interactive infections in features with coV patogenesis in Humans.
(HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoV, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HC, HC, HC, HC, HC, HC, HC, HC,
(HCoVs) HCoVs (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoV) (HCoV
CoVs 2019 (COVID-19) epidemy is discussed in this countrie.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Coronaviruses (CoVs) Coronaviridae (Coronaviridae) , embended, positive-sensed, single-stranded RNA viruses.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Economicly, CoVs contributionally that segmented genogens has not-segmented genogens that contribution.
ORF1a and ORF1b, pp1a and pp1ab replicate polyproteins (ORF1a and ORF1b) , that are thirdthythythree three three three three three three three three three three three three three three three three three three three three three three three three three thre
polyproteins nsp1 ~ 16 polyproteins, 16 constructure proteins (Nsp1 constructure proteins) (16 constructure).
ORFs (S), package (E), membrane (M) and nucleoprotein (N)
Lineage-Specific accessory proteins (CoVs) lineage-Specific Protections (CoVs) composed by differentlineage lineages (CoVs) .
CoVs (alpha-CoV, beta-CoV, gamma-CoV and delta-CoV) genera (alpha-CoV, beta-CoV, gamma-CoV and delta-CoV) genra (A, B, C and D) .
Phylogenetic evidence has which bats and roders has the most source of alpha-CoVs and beta-CoVs, gamma-CoVs and delta-CoVs was the main building of gamma-CoVs and delta-CoVs.
CoVs CoVs CoVs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs Covs
CoVs (HCoVs)
HCoV-229E, HCoV-NL63, HCoV-229E, alpha-CoVs, HCoV-NL63, HCoV-229E, HCoV-NL63, HCoV-229E, HCoV-NL63, H
Beta-CoVs HCoV-OC43, HCoV-HKU1 : HCoV-HCoV1 : acette respiratory syndrome coronavirus (SARS-CoV) : Medium East respiratory syndrome coronavirus (MERS-CoV) : SARS-CoV-2 :
HCoV-229E, HCoV-OC43, HCoV-HKU1 and HCoV-NL63 common cold symptomes and / or diamondly tools, HCoV-HKU1 and HCoV-NL63.
SARS-CoV, MERS-CoV and the return-identicated SARS-CoV-2 accountry respiratory distress syndrome (ARDS) and extrapulmonary manifests (SARS-CoV-CoV-2) accountry respiratory syndrome (ARDS) and extrapulmonary manifests (SARS-CoV) .
HCoV-229E , B814 , 1960 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(HCoV-229E or HCoV-OC43) (HCoV-229E) or HCoV-OC43 (HCoV-229E) or doescovered features, those which they created-limiting symptomes.
HCoVs (HCoVs) (HCoVs) (HCoVs, HCoVs, HCoVs, HS, HS, HS, HS, HS, HS, HS, HS, HS, HS, HS, HS, HS, HS, HS, HS, HS, HS, H
SARS favourities was was being the month of the current story of the story of the 8,000 people contained around 10%.
10. (MERS, MERS, MERS, MEDS, MEDS, MEDS, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR, MEDR,
SARS-CoV-2 (2019-nCoV), SARS-CoV-2, coronavirus disease 2019 (COVID-19) causative epidemic and causative disease (COVID-19) , 3,2020 feels and infections feed more 91,000 people as March 3, 2020.
(SARS-CoV-CoV-2)
HCoVs zoonotic be a zoonotic original bats, mourse or domestic bolds.
HCoVs (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoV
\"COVID-19 epidemic\" (\"COVID-19 epidemic\") :: \"COVID-19 epidemic\" (\"COVID-19 epidemic\") :: \"China and the world\" (\"CoVID-19\") ::
HCoVs HCoVs zoonotic orients Tracing a zoonotic orients of the zoonotic purposes a factory the nature system, drive force and restrict factors of specific species.
(SARS-CoV-2, amplifying animal hosting (s) of SARS-CoV-2,) was to research for the research, intermedial and amplifying animal hosting (s) of the future spreadovers.
(HCoVs) HCoVs, zoonotic (zoonotic orients), interspecies trażmission and pathogenesis (HCoVs).
(HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HC
Transmissibility (Transmissibility) (Transmissibility) (Transmissibility) (Trasmissibility) (Transmissibility) (Transmissibility) (Transmissibility (Transmissibility) (Transmissibility) (Transmissi
SARS-CoV-2 breaking accountain accountain accountain et also discussed in this countrie.
Animal CoVs, 1930s, . . . . . . . . . . . . . . . . . . . .
HCoV-229E strain B814 E strain B814 (HCoV-229E strain B814 rain rain cold common cold compression, CoVs has been insulated insulated has been, dundjani, maws, baby, pigney, cat and kelb) has been insulated insulated.
. . . . . . . . . . . . . . . . . . . . . . . . .
HCoV (Table 1) (HCoV Detectory) (HCoV) (Table 1) (HCoV Deviling) (HCoV) (HCoV) (HCoV) (HCoV) (HCoV) (HCoV
“HCoV-229E” (HCoV-229E) 1966 (WI-38 pulmonar cell lines) (WI-38 pulmonary cell lines) (HCoV-229E strain).
HCoV-229E (HCoV-229E) (HCoV-229E) (HCoV-Theroat, Sneezing, feedback and pain-throat, 10 ~ 20% feedback) .
(HCoV-OC43) HCoV-OC43 (HCoV-OC43) (HCoV-OC43) (HCoV-OC43) (HCoV-OC43) (HCoV-OC43) (HCoV-OC43) (HCoV-OC43) (HCoV-OC43) (HCoV
HCoV-OC43 (HCoV-229E) HCoV-229E (Symptomaticly indigitally) : HCoV-OC43 (Symptomaticly inclosmable) :: :: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::;;;;;;;;;;;;;
HCoV-229E or HCoV-OC43 or global regular and they they type of the temperate climate contemporate contemporate contemporate.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoV-229E (HCoV-229E)
immunokompromessized payments shows such lower respiratory tractor infection.
SARS, actipic pneumonia - HCoV-caused pandemic in Human system and the etiological system is SARS-CoV, third HCoV scovered.
SARS Sharing Case of Guangdong Professional of China (SARS) (2002) .
“SARS opportunity” (SARS epidemic) 8,096 (774 months) was reported absent in the most countries and continents continents.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV miyalgia, summer, density, feedness and childs, dyspnea, summer and respiratory sorption symptomas.
Lymphopenia, deranged hepacial function tests, or level creatine kinase are common laboratory abnormalitys of SARS.
Diffuse alveolar convergence, epithelial cell convergence and a overise of macrophages, SARS convergence.
(20-30%) (20-30%)
(Cytokine storm) (Cytokine storm) (Cytokine storm) (Cytokine storm) (Cytokine storm) (Cytokine storm) (Cytokine storm) (Cytokine storm) (Cytokine storm) (Cytokine storm) (Cytocromised) (Cytockine) (Cytocin) (Cytocin) (Cytocin) (Cytocin) (Cytcoin) (Cytcoin) (Cy
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoV Research (HCoV Research)
HCoV-NL63 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
coryza, conjunctivitis, dension, and broncholitis, HCoV-NL63.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
HCoV-NL63 4.7% common respiratory diseases (HCoV-NL63) ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
HCoV-NL63 croup, compressive laryngitis obstructive laryngitis.
HCoV-HKU1 (HCoV-HKU1) (HCoV-HCoV-HKU1-71) (Hong Kong) (HCoV-HCoV-HKU1) (Hong Broncholitis) (Broncholitis) (HCoV-HKU) (HCoV-HCoV-HKU) (71-HCoV-HCoV-HKU) (HCoV-HCoV-HKU) (HCo
HCoV-HKU1 HCoV HCoV-HKU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoV-NL63, HCoV-229E, HCoV-OC43, HCoV-HKU1 .
“HCoVs” (HCoVs HCoVs) (HCoVs HCoVs HCoV-NL63) (HCoV-NL63)
(HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HC
MERS-CoV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
186 (2015) 186 (2015) (2015) (2015) (2015) (2015) (2015) (2015) (2012) (2012) (2012) (2012) (2012) (2012) (2012) (
MERS Scientific Manifications of Clinical Manifests of MERS with the SARS, active acute pneumonia.
SARS, MERS MERS (HCoV- caused pathys) (MERS, MERS, HCoV-caused pathys, MERS).
.30% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14 2020, MERS-CoV, MERS-CoV MERS-CoV, 2500.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.
SARS-CoV-2 containments, Hubei Province, China , Wuhan, Hubei, , 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 (SARS-CoV-2) (SARS-CoV-2) , , , COVID-19 , COVID-19 , COVID-19 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
3 2020, 90,053 cases are accounted overally, with agreement case case fatality of 3.4%.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 SARS-CoV and MERS-CoV, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
Pneumonia (Pneumonia) (Pneumonia) (Pneumonia) (Pneumonia) (Pensions) (Previous syndrome) (Previous respiratory syndrome) (Previous syndrome) (Pneumoni
SARS-CoV, SARS-CoV-2, 82% nucleotide scheme homology, phylogenetic street.
SARS-CoV-2 SARS-CoV MERS-CoV (SARS-CoV-CoV-CarS-CoV-CarS-CoV-CarS-CoV-CarS-CoV-CarS-CoV-CarS-CoV-CarS-CoV-CoV-
SARS-CoV-2 asymptomatics incents accepted was reported and you available to the world of the world.
SARS-CoV-2 (HCoVs HCoVs HS-CoV-CoV-Conflicting) ::
(HCoV disease)
SARS-CoV-2, HCoVs, HCoVs, SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . .
(HCoV-229E, HCoV-OC43, HCoV-HKU1 and HCoV-NL63).
SARS-CoV-2 infection with infection with infection of commonculation-infection HCoVs, with infection of common commonly of commonly-infection HCoVs, with the commonly of specification, feature or even symptome.
COVID-19 (COVID-CoV) (COVID-19) (SARS-CoV infection) (COVID-CoV infection) (SARS-CoV infection) (COVID-CoV infection) (COVID-19) (COVID-CoV infection) (COVID-CoV infection) (COVID-CoV infection) (COVID-19) (COVID-CoV) (COVID-19
SARS-CoV-2 SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 trażmissibility (SARS-CoV-2) (HCoVs HCoVs) .
SARS-CoV-MERS-CoV, SARS-CoV-2 transmissibility trażmissibility (SARS-CoV-CoV-CoV-2) trażmissibility (SARS-CoV-CoV-CoV-CoV-CoV-CoV-CoV-Transmissibility).
HCoVs, SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 fecal-oral-oral trażference was the fecal of the fecal of the fecal of the system of SARS-CoV of the fecal of the are of the circuit of the fecular be been to be complete to be be completed by studies.
SARS-CoV-2 HCoVs: SARS-CoV-2 staġonality HCoVs : :,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SARS-CoV-2 trażmissibility, patoġenity and sostenibility consolubility ships with the version of the destination of COVID-19.
Ethiopian Community-Entity HCoVs (HCoVs) : :: :: :: :: :: :: :: :: :: :: :: :: ::
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(HCoV pandemics)
HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, has been been been been been been been been been been been been been been been
HCoVs (HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCo
(SARS-CoV-2 favouria) (SARS-CoV-2 fabouration) (SARS-CoV-2 favouria) (SARS-CoV-2 fabouration) (SARS-CoV-2 fabouration) (SARS-CoV-2 fabouration) (SARS-CoV-2 fabouration) (SARS-Co
. . . . () . . . () . . . () . . . () . . . . () . . . . . . () . . . . . . . () . .
CoVs, immunocapacity common cold in common cold in immunocaption Subjects, CoVs common cold in common cold in immunocaption suits, common cold in common cold on common components.
. . . . . . . . . . . . . . . . . . . . . . . . .
(SARS-CoV) (SARS-CoV) (MERS-CoV) (SARS-CoV) (SARS-CoV) (MERS-CoV) (SARS-CoV) (SARS-CoV) (SARS-CoV) (MERS-CoV) (SARS-CoV) (SARS-CoV) (SAR
\" zoonotic builders\" (\"zoonotic builders\") (\"zoonotic builders\") (\"zoonotic builders\") (\"zoonotic builders\") (\"spreadover\") (\"spipe goals\") (\"spipe goals\") (\"spipes\") (\"spipe goals\") (\"spipes\") (\"spipe goals\") (\"
SARS-CoV-2 SARS-CoV / MERS-CoV / HCoV SSARS-CoV-CoV-CoV-Community-Equipment HCoVs (SARS-CoV / MERS-CoV-CoV-CoV-HCoVs).
(HCoVs, HCoVs, HCoVs, HCoVs)
(HCoVs, HCoVs, SARS-CoV, MERS-CoV, HCoVs, HCoVs, MERS-CoV, HCoVs, HCoVs, HCoVs, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoVs (HCoVs, HCoVs, HCoVs, conversations, reducational, reducational, reductor, reducer, intermedial and amplifying) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoV (HCoV) (Nucleotide Schular) (Nucleotide Schular) (Nucleotide Scholar) (Nucleotide Scholar) (Nucleotide Scholar) (Nucleotide Scholar) (Nucleotide Scholar) (Nucleotide Scholar) (Nucleotide Scholar) (Nucleotide Scholar) (Nucleotide Schol
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoV (HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV H
(HCoV or its he parenter virus)
(HCoV) HCoV (HCoV, HCoV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV, HDV,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoV (HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV HCoV H
HCoVs (HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs,
. . . . . . . . . . . . . . . . . . . . . . . . .
Epidemiological downstreams: SARS accision of index case have a contact story with game animals.
(Seroprevalence) (Seroprevalence) (Seroprevalence) (Seroprevalence) (Seroprevalence) (Seroprevalence) (Seroprevalence) (Seroprevalence) (Seroprevalence) (Seroprevalence) (Seroprevalence) (Seo-SARS-CoV IgG) (Steo-CoV IgG)
Masked palm civets (Paguma larvata) ; racoon globe wave wave larvata ; SARS-CoV-like viruses that has has was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Sars-CoV) (Sars-CoV) (Sars-CoV) (Sars-CoV) (Sars-CoV) (Sars-CoV) (Sars-CoV) (Sars-CoV) (Sars-CoV) (Sars-CoV) (Savs-Civets) (Savs-Civets) (Savs-Civets) (Savs-Civets) (Savs-CoV) (Savs-CoV) (Savs-Civets) (Savs-Civets) (Savs) (Savs-CoV) (Savs-CoV) (Savs-Civets) (Savs) (Savs-CoV) (Savs-CoV) (Saving) (Saving) (Saving) (Saving)) (Saving) (Saving)) (Saving) (Saving) (Saving) (Saving) (Saving)) (Saving) (Saving)) (Saving)) (Saving)) (Saving) (Savings) (Saving) (Savings) (Savings) (Savings) (Savings)) (Savings) (Saving)) (Savings) (Savings) (Savings)) (Savings) (Saving) (Savings)) (Savverts) (Saving) (Savings) (Savverts) (Savings)) (Savverts)) (Sav)))) (Savvert (Savvert (Savvert))))))) (Savvert (Savvert (Sav) (Savvert (Sav)))))) (Savvert (Savvert (Savvert (Sav)))))))))))))) (Savvert (Savvert (Sav)))))))))))) (Savoff (Savoff (Sav)))))))))))) (Spar (Spar (Spar (Spar (Savoff (Savoff (Savoff (Savoff (Savvert (Sav)))))))))))))))) (Sport (Sport (Sport (Sport (Sport (Sport (Sport (Sports(Sportsf) (Sportsf) (Sportsf) (Sportsf) (Sportsf) (Sportsf) (Sportsf) (Sportsf) (Savf) (Savoff (Savoff (Savoff (Sportsoff (Savf) (Savoff (Savoff (Savoff (Sav)))))))))))))) (Sv) (Sav (Sv))) (Sv))))))))))))))))) (Sv) (Sv) (Sav (Sv) (Sv (Sav (Sv) (Sv)))))))) (Sav (Sav (Sav (Sv (Sv) (Sav (Sv) (Svs
(SARS-CoV)-CoV-CoV-SARS-CoV-SARS-CoV-SARS-SARS-CoV-CoV-CoV-Applifying-Applification-SARS-CoV-CoV-Applification-Applification-Applification-Applification-Applification-Applification-Applification-Applification-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-Application-App.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV SARS-Rh-BatCoV HKU3 (SARSr-Rh-BatCoV HKU3), SARS-related Rhinolophus bat CoV HKU3 (SARSr-Rh-BatCoV HKU3) undveled feedback.
SARSr-Rh-BatCoV HKU3 HKU3 :- SARS-CoV-SARS-CoV-BatCoV-CoV-Genogen-Genogen-Service (SARSr-Rh-BatCoV HKU3) .
CoVs 88-92% nucleotide sheet homology with SARS-CoV.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-like CoVs (SL-CoVs) has also been been available from bats, but but only for one designed wIV1 as live virus be insulated.
Human angiotensin convert enzyme 2 (ACE2) SARS-CoV .
WIV1 fecal chaption of bats of fecal chapter was used to bat, civet and Human ACE2 as cell entry for cell entry.
Intriguingly, convalescent SARS sera pensilizing WIV1.
WIV1 (SARS-CoV) 95% nucleotide . homology (SARS-CoV) .
WIV1 SARS-CoV (SARS-CoV) (SARS-CoV) (SARS-CoV) (SARS-CoV) (Albeit) homology (Homology) (Homology) (Homology) (Homology) (Homology) (Homology) (SARS-CoV) (SARS-CoV) (SARS-CoV) (SARS-CoV) (SARS-CoV) (SARS-CoV) (SARS-CoV) (
Phylogenetic About CoV-HKU4 (MERS-CoV) (MERS-CoV) (Bat CoV-HKU4) (MERS-CoV) (Bat CoV-HKU4) (Bat CoV-HKU5) (Bat CoV-HKU5) (Bat CoV-HKU5) (Bat CoV-HKU5) (Bat CoV-HKU5)
Bat CoV-HKU4 and MERS-CoV, dipeptidyl peptidase 4 (DPP4), virus entry entry, you to the host receptor, dipeptidyl peptidase 4 (DPP4).
RNA-dependent RNA polymerase scheets of MERS-CoV (RNA-dependent RNA polymerase scheets of MERS-CoV) (Batbeta-CoVs) (Batbeta-CoVs) (Batch beta-CoVs) (Batch beta-CoVs) (RNA-dependent RNA-dependent RNA polymerase polymerase scheets) (MERS-Co
MERS-CoV : MERS-CoV : : : : : : : : : : : : : : : : : : : : : : : : :
MERS-CoV (MERS-CoV) (MERS-CoV) (MERS-CoV) (MV-HKU25)) 87% nucleotide (Nucleotide) (Homology) (Homology) (Nucleotide) (Humology) (Humology) (HU) (HU) (HU) (HU) (HU
MERS-CoV : MERS-CoV : : : : : : : : : : : : : : : : : : : : : : : : :
(MERS-CoV-specificive newtralizzating antibody activities) (MERS-CoV-specific antibody) (MERS-CoV-specific compositive antibody) (MERS-CoV-special antibody) (MERS-CoV-specific cytralizing antibody) (MERS-CoV-specific) (MERS-Specific antibody) (MERS-Specific antibody) (MERS-Speci
MERS-CoV (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (Bona fide) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-
“MERS-CoV” (MERS-CoV) (MERS-CoV) (MERS-CoV) (Muscated shending) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MERS (MERS) (MERS-CoV) (MERS) (MERS) (MERS) (MERS) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS) (MERS-CoV) (MERS) (MERS-CoV) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (M) (M) (M) (MER) (M) (M)
SARS-CoV-2 Rhinolophus affinis abs. CoV RaTG13 96.2% nucleotide homology.
SARS-CoV , MERS-CoV , SARS-CoV-2 RaTG13 , SARS-CoV-2 , RATG13 , , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Suppożizzjoni, SARS-CoV-2 SARS-CoV-2, Huananan Seafood Suite Market, COVID-19 concession of the initiative concession of the huanan Seafood Suite Market, accountants of the purity of the concession of the concession of the original aviation-to-uman transmission event, COVID-19 concession of the concession of the concession of the concession of the concession of the hair-to-Human event.
metagenomic sequencing (Manis javanica) pangolins (Manis javanica) (Manis javanica) (Menis javanica)) SARS-CoVs (SARS-CoV-CoVs) (Metagenomic sequencing) (Mengenomic sequencing) (Manis javanica) (Manis javanica) (Manis javanica) (SARS-CoVS-CoVs) (Manis javanica) (Manis) (Manis javanica) (Manis-CoVs) (Manis-CoVs) (Manis-CoVs) (Manis-CoVs) (Manis-CoVs) .
CoV 85-92% nucleotide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(RaTG13) (RaTG13) (Nucleotide System) (Nucleotide System) (Nucleotide System) (Nucleotide System) (Nucleotide System) (Nucleotide System) (Nucleotide System) (R
SARS-CoV-2-like viruses in the phylogenetic street, that one of the more receptor linking domain (RBD) with SARS-CoV-2, 97.4% amino acid sheet identity.
SARS-CoV-2 and RaTG13, RBDs, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
pangolins (SARS-CoV-2) (SARS-CoV-Contigs) (SARS-CoV-Contigs-Contigs-Contigs) : viral contigs (CoV-Contigs-Contigs-Contigs-Contigs-Contigs-Contigs-Contigs-Contigs-Contigs-CoV
8.0.0.0.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0%.0
pangolin SARS-CoV-2 (SARS-CoV-CoV-2) was cannective to with the intermedial feed of the feedback of SARS-CoV-2.
SARS-CoV-2 pangolin SARS-CoV-2-related beta-CoVs , pangolin SARS-CoV-CoVs , SARS-CoV-2 , pangolin SARS-CoV-2 .
SARS-CoV-2 RaTG13 (SARS-CoV-2 pangolin SARS-CoV-2-related beta-CoVs) (SARS-CoV-2 pangolin SARS-CoV-2 bengolin SARS-CoV-2- related beta-CoVs).
SARS-CoV-2, pangolins and other mammiums been be be be be be be be be be be be be be.
SARS-CoV-2 pangolin, SARS-CoV-2-related beta-CoVs, SARS-CoV-2 or RaTG13 or RBDs, SARS-CoV-2 or RaTG13 or Genogen-wide score homology.
pangolin SARS-CoV-2-related beta-CoVs and SARS-CoV-2 pangolin SARS-CoV-2 pangolin SARS-CoV-2 applicational activity-mediated convergent etvolution.
A counter-proposal cangolin SARS-CoV-2-related beta-CoV or RaTG13 or recombination as the feel feed species.
(Beta-CoVs) (Beta-CoVs)
SARS-CoV-2 zoonotic (SARS-CoV-2) .
HCoVs, HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 zoonotic ortique order of the hCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 has been study has been been been been been been been been been been.
HCoV-NL63 or HCoV-229E HCoV-OC43 or HCoV-HKU1 have available to bat CoVs, HCoV-OC43 or HCoV-HKU1 available available in regards.
CoV ARCoV.2 (Appalachian Ridge CoV) HCoV-NL63 (Appalachian Ridge CoV) ARCoV CoV CoV CoV (Appalachian Ridge CoV) .
HCoV-229E Hipposideros / GhanaKwam / 19/2008, gammids was to genetic been been been been been them intermedial hosting.
HCoVs (HCoVs) (HCoVs) (HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoV
Phylogenetic (HCoVs) (HCoVs)
HCoV-OC43 1890 . HCoV-OC43 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoV-229E interspecials (HCoV-229E) (interspecials travision on the hold specials of HCoV-229E).
HCoV-229E (HCoV-229E)-CoVs (Bat alpha-CoVs) was founded.
:: Alpaca alpha-CoV.
, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
2., HCoV-229E-related bat alpha-CoVs, alpaca alpha-CoV-CoVs, alpaca alpha-CoV accounted alpha-CoVs accounted and non-pathogenic in pathogenic in in in pathogenic in in in in in fection of respiratory disease.
Alpaca alpha-CoV feral animals was not been available.
(HCoV-229E-related alpha-CoV) (HCoV-229E-related alpha-CoV) (Alpha-CoV) (Alpacas) (HCoV-229E-related alpha-CoV) (Alpha-CoV) (Alpha-
(Arabic Tags: Ebola Virus, Nipah Virus and Hendra Virus)
HCoV-229E (HCoV-229E)
(HCoV-229E, alpacas and dromedary gembling) MERS-CoV (MERS-CoV) , bath alpha-CoVs (HCoV-229E) .
MERS-CoV (MERS-CoV, dromedary gembling, dromedary gembling, dromedary gembling, dromedary gembling, dromedary gembling, dromedary gembling, dromedary gembling, dromedary gembling, dromedary gem
MERS-CoV (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Longevity, density packed colones, close social interaction and beautiful to flying are all favoritive conditions for bats to ideal 'virus spreader'.
MERS-CoV (MERS-CoV) dromedary gembling (MERS-CoV) damedary gembling (MERS-CoV) damedary gembling (MERS-CoV) damedary
\" . . . . \" . . \" . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . .
MERS-CoV (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-
MERS-CoV (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-
MERS-CoV MERS-CoV, pangolins, pangolins, SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
pangolin beta-CoVs pangolins.
SARS-CoV-2-related beta-CoVs, SARS-CoVs civets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (Sars-CoV-2) (Sars-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-Co
(SARS-CoV-2-related virus) SARS-CoV-2 (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2)
, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(SARS-CoV-2-related virus) (SARS-CoV-2-related virus) (SARS-CoV-2-related virus) amplifying (SARS-CoV-2-related video) (SARS-CoV-2-related video) (SARS-CoV-2-reported video) (SARS-C
. . . . . . . . . . . . . . . . . . . . . . . . .
(SARS-CoV-2 : SARS-CoV-2) ::
. . . . . . . . . . . . . . . . . . . . . . . . .
(SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-CoV-2) (SARS-CS-CS-CS-CS-CS-CS-CS
SARS-CoV-2 (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) ::
CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs
. . . . . . . . . . . . . . . . . . . . . . . . .
CoVs - temperate - to - high - ~ 10-4 Subplacement of the year of the year CoV adaption of the phase of the new hosts on the phase of the phase to-high - CoVs.
CoVs exoribonuclease, mutability, attenuation or even inviability.
nucleotide acetate Remdesivir (Nucleotide acetate Remdesivir) (NR-dependent RNA polymerase) (RNA-dependent RNA polymerase) CoV (CoV inhibitation).
Remdesivir-SARS-CoV-2 actors to company activities to company activities to company activities to company.
CoVs mutation rates of CoVs has a mutants of their hostings are a mone was a was a wasing of their hosts.
CoVs, mutation rate has feedly high which coVs are well adaptive to the hosting.
SARS-CoV-2 mutation rate with a high mutation rate to SARS-CoV with compared to SARS-CoV with the mutation rate of the SARS-CoV-2 is apparently low, ssuġġerive of addattation to management of management.
. . . . () . . () . . () . . . () . . . . () . . . . () . . . . . () . .
SARS-CoV-2, (MERS-CoV) (MERS-CoV) dromedary gembling (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (M
Theoretically, SARS-CoV-2 (SARS-CoV-2) (Sares-CoV-2) : genetical drive versicles was was with influence feature specially.
CoVs CoVs, mutations and recombination, mutations and recombination, mutations, RNA genome active extra plasticity with the interspecies co-evolution of the revenue of the revenue CoVs compension of the competition of the review of the composing of the compound CoVs.
\"3\" conducted by the costious unique open reading frequency and protein functions to the 3 - end of the genogen.
Third, CoVs b'mod aleaublely and frequently switch tempeseses on the ran-copy-choice- machinery.
CoV RNA trascription (CoV RNA trascription) (CoV RNA trascription) . . . . . . . . . . . . . . . . . . . . .
Homologous full-tweld and subgenomic RNAs CoVs recombinine.
HCoV-HKU1 or HCoV-OC43 or boot SL-CoV or batCoV-HKU9 or HCoV-OC43, or boot CoVs or batCoV-HKU9.
Virus-host interaction to transmission with to conference
3 viral factors on their on their factors on their, viral intersearch receptor with viral interspecies influence influence on interspecials.
Herein, SARS-CoV recombination, interspecies transmission activitive activitive activitive activitive activitive activitive activitive activitive activitive of interspecies.
SARS-CoVs, SARS-CoVs mutations at the RBD of S protein, computations of Human and civet SARS-CoVs, SARS-CoVs, mutations of the RBD of S protein .
Corporately, RBD in the S protein of a CoV accountry with the cellular receptor and is tensiblely by the hosting antibody response.
SARS-CoV, RBD 318th to 510th amino acids on the S1 framment that convergence to the management ACE2 and their coreceptors for their verial entertainment.
SARS-CoV SARS-CoV RBD ACE2 receptors account count country of the virus, civet, maws and raccoon child, acetations of the virus.
(ACE2 receptor) (ACE2 receptor) (ACE2 receptor) (ACE) (RBD) (RBD) (Rivet viral solutions) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (Rivet) (R
Civet SARS-CoV K479N and S487T mutations in its RBD, that active of spike protein with insulation of manman ACE2 receptor.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 SARS-CoV SARS-CoV.
A 30% SARS-CoV-2 and SARS-CoV in the S1 unitary protein of the S protein is complexs that containment of the s s protein with manman ACE2 have changed.
Cryo-EM study to 10- to 20- level affinance of this containment of this Human ACE2 and SARS-CoV S protein.
SARS-CoV-2 thermosferator (SARS-CoV-2 thermosferator) (SARS-CoV-2 thermosferator) (SARS-CoV-2 thermosferator) ::
Intriguingly, HCoV-NL63 ACE2 but with a location of S.
HCoV-229E, 9-O-acetylated sialic acid, HCoV-OC43, HCoV-229E, aminoptidase N, HCoV-229E.
CoVs.com . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoVs (HCoVs) (HCoVs) (HCoVs, HCoVs, Hosting Dependence and Restriction Factors, HCoVs, Hoster Hosting Dependence and Restriction Factors, HCoVs, HTC, HTC, HTC, HT
HCoVs, dromedary gemblings and gerries trooths contracted to interspecial travel.
HCoVs (HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CRISPR-OF-The-Art Technology (SARS-CoV-2) unbiased genogen-wide screening.
HCoVs emergence: good to ground zero: : : : : : : : : : : : : : :
HCoVs : HCoVs : HCoVs : HCoVs : HCoVs : : : : : : : : : : : : : : : : : : : : : :
HCoVs , Bat CoVs , HCoVs , HCoVs, , HCoVs , HCoVs , HCoVs , HCoVs , HCoVs , HC
(HCoV evolution) HCoV (HCoV evolution) (HCoV evolution) (HCoV evolution) (HCoV) (HCoV) (HCoV) (HCoV) (HCoV) (HCoV) (HCoV) (HCoV) (
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ORF8 ORS-CoV, SARS-CoV-bat bat viruses, SARS-CoV-related bat viruses, orf8 proteins, orf8 composed to code.
SARS-CoVs 29-nucleotide decking feature active at the christian christian active of the genery of the people.
ORF8a and ORF8b (ORF8a) (ORF8a) (ORF8b) (ORF8a) (ORF8b) (OrF8a) (ORF8b) (ORF8a) (OrF8b) (ordnished mutation) (OrF8a) (OrF8a) (OrF8a) (OrF8b) (OrF8b
SARS-CoV RNA-dependent RNA polymerase (RNA-dependent RNA polymerase, gamma-CoVs, lineages- and gamma-CoVs).
Nsp9 : Nsp10 : nsp14 :- Recombination location locations :: nsp9:: ; nsp14 :: ;
\"MERS-CoV\" (MERS-CoV epidemic MERS-CoV) (MERS-CoV epidemic MERS-CoV, dromedary gemblary Avenue, dromedary Gemblary Avenue) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MER
SARS-CoV (MERS-CoV) (MERS-CoV) (recombination activities) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (HCoVs) (
\" . . . . \" . . \" . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(HCoV-229E) (HCoV-229E protocol strain) orf-the orf4 (HCoV-229E protocol strain) , to the follow-nucleotide declostration.
ORF4 HCoV-229E, alpaca alpha-CoV, nucleotide inserction, foundshift or orfni ORF4.
Last but no not lest, the evolution of the evolution of the rate HCoVs has also switch of the shopping pressure in their search hosts.
asymptomatic or please symptomatics was was was was coVs, CoVs and bats commodited addattation.
CoVs anatomically and physically was approfondited to CoVs anatomically.
(CoVs) (CoVs) CoVs) , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Bats, inhibitory cell cell receptor NKG2 / CD94 inhibitory cell receptor NKG2 / CD94 and low express level of major histocompatibility complex Class I molekuli.
(ROS) metabolic activity of bats, CoV replikation and proofreading by exoribonuclease (ROS) CoV reciprocade and exoribonuclease (Exoribonuclease) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
More pathocytic CoV razez may everything by recombination, to the recombination of the research protein or protein features for hosting adaption.
(HCoVs) (HCoVs HCoVs)
CoVs pathogenic or their symptomies of their suits of bats and gemblings as their suits of their suits.
. . . . . . . . . . . . . . . . . . . . . . . . .
:: asymptomatic travels asymptomatics been and the comfort cases in Human infection.
(Cytokine) (Cytokine) (Cytokine) (Cytocine) (Cytocine) (Cytocine) (Cytocine) (Cytocine) (Cytocine (Cytocine) (Cytocine) (Cytocine (Cytocine) (Cytocine) (Cytocine (Cytocine) (C
asymptomatic travelers, asymptomatic response has de-coupled coV replikation.
(SARS-CoV-2 therapy) (SARS-SARS-CoV-2 therapy) (Systems) (SARS-CoV-2) (Systems) (Systems) (Systems) (Systems) (Systems) (Systems) (S
The interferon response is specially bats in bats.
(SARS-CoV-2 infections) (SARS-CoV-2 infection) ::
NLRP3 inflammamsome activation is different.
MCC950 NLRP3 inflammasome inhibitation (NLRP3 inflammasome) COVID-19.
SARS-CoV-2 (SARS-CoV-CoV-MERS-CoV) (SARS-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-
SARS-CoV SARS-CoV 95% nucleotide homology (95% nucleotide homology) has was was was was was was was been abt-CoV as 96% nucleotide homology (96% nucleotide homology) .
civets and other feels in the markets in the buildings with the stars-CoV (SARS-CoV-CoV-2), SARS-CoV-2 (SARS-CoV-CoV-2) .
Pangolin beta-CoVs SARS-CoV-2 homologous, pangolins pangolin beta-CoVs-SARS-CoV-2 contribution version version version of the general version of SARS-CoV-2.
(SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-CoV-2) (SARS-CoV-CoV-CoV-CoV-CoV-CoV-
CoVs SARS-CoV-2 (SARS-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-Co
HCoVs, zoonotic origins, HCoVs, HCoVs, CoVs, CoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCCoV
SARS-CoV, MERS-CoV and SARS-CoV-2 (SARS-CoV, MERS-CoV, MERS-CoV, SARS-CoV-2) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
SARS-CoV containments with the management and civets in the markets contained with contact contact in the management and civets in the containments in the containment of the wet markets and civet civets containment with the SARS epidemic.
Pangolins, pangolins pangolins pangolin beta-CoVs pangolin beta-CoVs-SARS-CoV-2 zoonotic training conventive to reduced to wet steams.
SARS-CoV-2 pangolins (SARS-CoV-2 pangolins) (SARS-CoV-2 pangolins) (Pangolins) (membrane) (Membranes) (Membrania) (Membrania) (Membrania) (Membrania) (Membrania) (Membrania) (Membrania) (
MERS-CoV (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV
\" . . . . . \" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV , SARS-CoV-2, MERS-CoV , MERS , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MERS-CoV (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
zoonotic CoVs zoonotic CoVs . . . . . . . . . . . . . . . . . . . . . . . . . .
zoonotic positive are so differently, bat CoVs with zonotic possibility are so such different.
CoVs zoonotic CoVs Cocombinine CoVs , convergence of the recombination of the new CoVs and or mental in the building in the more transmissible and / or mental in the building in the building of management.
\" . . . . . . \" . \" . \" . . \" . . \" . . . \" . . . . \" . . . . . . . . . . . . . . . .
SARS, MERS, COVID-19, APPLICATION PROVENZIONE PRINĊIPATIONAL PROPRESSONAL PROPRESSONS PROPRESSONS PROPRESSONS PROPRESS PROPRESS PROPRESS PROPRESS PROPRESS PROPRESS PROPRESS PROPRESS PRO
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CoVs, CoVs, CoVs, Co., Ltd, CoVs, CoVs, CoVs, CoVs, CoVs, Co., Ltd, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 zoonotic (SSARS-CoV-2) zoonotic (Zoonotic orthonic orthormone) has are plain plain.
(SARS-CoV-2) (SARS-CoV-2) (SARS-CoV-2 to pangolins) (SARS-CoV-2 to pangolins) (SARS-CoV-2 to pangolins) (SARS-CoV-2 to pangolins) (SARS-CoV-2 to pangolins) (SARS-CoV-CoV-2 to pangolins) (SARS-CoV-CoV-2 to Pangolins) (Pangolins) (Pangolins) (Pangol
. . . . () . . . () . . . (()) . . . () . . . () . . . . () . . . . . () . . . . . . . . () . . . . (
. . . . . . () . . . . . . (()) . . . . . . () . . . . . . . . . () . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(SARS-CoV-2) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
, pangolin or other manufactures , SARS-CoV-2 or its feature feature versicle that are will be complete with in the ministry hosts in the future.
(SARS-CoV-2) (COVID-19) (COVID-19) (CS-CoV-2) (SARS-CoV-2) (SARS-CoV-2) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (
COVID-19 'ssuspected case - or - confirmed case - ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
6 February 2020, your team has public for speed coronavirus (2019-nCoV) infection (2019-nCoV) infection (2019-nCoV) infection (2019-nCoV) infection (2019-nCoV) infection) infection (2019-nCoV) infection (2019-nCoV) infection (2019-nCoV) infection (2019-nCoV) infection (2019-nCoV) infection) infection this line (
(COVID-19) coronavirus disease 2019 (COVID-19) (COVID-19) : your conoxxence and knowledge are research and clinical principle experience; you, the diagnosion of student and traductive are also are also update.
© 2020, Commission of the National Health Committee of China, Commission of China.
2019 (2019-nCoV) coronavirus (2019-nCoV) 2019 (COVID-19) coronavirus disease 2019 (SARS-CoV-2) (SARS-CoV-2) .
11 March 2020, WHO (COVID-19) COVID-19 as a pandemic.
\"SARS-CoV-2 infection\" (\"SARS-CoV-2 infection\") (\"SARS-CoV-2 infection\") (\"Tourism\") (\"Tourism\") (\"Guideline\" (\"Guide guide\") (\"Rise Medical Research\") (\"Rise Research\") (\"Rise Research\") (\"Rise Research\") (\"Rise
. . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID) (COVID-19) (COVID) (COVID-19) (COVID) (COVID-19) (COVID) (COVID) (COVID-19) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (C
COVID-19 (http://www.nhc.gov.cn/) (16.nhc.gov.cn/), January 2020 to 3 March 2020, changeship changed such only completely countries, change to your products of the National Health Committee of the Public of the People's Committee of the China (http://www.nhc.gov.cn/) (16.cn/) , (2019) to 3 March 2020, changes 2020, has to common common common common common commons of sostantively commons.
Zhou et al. Comment with Zhou et al., you are a simple scoring project on their clinical experience.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 (Antilly seven version) (COVID-Video) (Diagnosis and Treatment Guidelines) (Diagnosis and Treatment Guides) (Diagnosis and Treatment Guides) (Diagnosis and Treatment Guides) (Diagnosis and Treatment Guides) (Diagnosis and Treatment G
(3 March 2020) :) : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Epidemiological symptomatic symptomatics: (1) Wuhan city and account country or other communications of the common communications or the other communications that components that have the rest 14 days been been been; (2) SARS-CoV-2 infection cases (with public nucleic acid test); (3) Wuhan city and other communications of respiratory symptomas of contacted that what contact contact in the third third contents of the third thems of thems of the house, Office, class of symptomatics, etc.
Clinical manufactures: (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Djanjosing the concerning case with any should casing on the excellent of pathocy or serological evidence as following: (1) real-time PCR test positive for SARS-CoV-2; (2) viral world genogen sequencing to the homogeneity to the chronaviruses; (3) positive IgM antibody and IgG antibody to saRS-CoV-2-specific IgG antibody as the positive to positive, or titer or the reduction of the recovering phase of the feature of the are phase in the fearly of level.
nucleic Access in respiratory tractory or blood plates in the real-time PCR test for nucleic acid in respiratory drive or blood plates added to the than (18 January 2020) and third (22 January 2020) editions.
(27 January 2020) (8  February 2020) (7 January 2020) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    . .     . . . . . . . . . . . . .       . . . . .  . . . . . . . . . . . . . . . . .     . . .  . . .    . .         . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Zhou et al. flow chart of Zhou et al., with they clinical symptomas as-low risk-
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
--susspected case -- confirmed case - we ssuġġerite to tract and used the newest guides of them home countries.
Our team would also complete update our lineer to office.
COVID-19 : COVID-19 : : : : : : : : : : : : : : : : : : : :
(COVID-19) (COVID-19) (COVID-19) ::
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(IEDCR, IEDCR, Ipidemiology, Disease Control and Research) . . . (IEDCR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
IEDCR, Dr Meerjady Sabrina Flora , IEDCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
(WHO) COVID-19 (March 11) . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
------------------------------------------------------------------
COVID-19 incidents infection infection in Bangladesh infection infection infection on March 8 on their to their people of Italia and the feature of them of them of them.
. . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 (SARS-CoV-2) (Miljun viruses)
Saturday, SARS-CoV-2 coronavirus infections accountants of the cases of the complete of the coronavirus infections accounted one money worldwide, Johns Hopkins University directive indicated.
(COVID-19) (COVID-19) (COVID-19) (Coronavirus) (COVID-19) (COVID-19) (Coronavirus) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19)
( coronavirus virus infections to have the this day have the label have the day malay to coronavirus infections and Zombia has the first coronavirus-related mewt.
coronavirus infections . . .
10 a.m. (0800 UTC) (0800 UTC) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CBS News reported, citing Johns Hopkins University Database, caused on 1,000 US morts on coronavirus infections.
\" . . . . \" . . \" . . . \" . . . . . . . . . . . . . .
Sergei Sobyanin, Moscope of Moscow, wased the city lockdown to May 1
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . 10 p.m. and 4 a.m.
, Mike DeWine, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Australia in Australia in Australia in Australia australia download paper levels for transaction
Sunday and Saturday week, Australian store channels Woolworths and Coles download their restriction on to to two and one package on all convention on national level.
ALDI ABLE ABLE ABLE ABLE ABLE ABLE ABLE ABLE ABLE ABLE ABLE ABLE
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID
Woolworths, Woolworths, Woolworths, company of home delivery pack to one pack for order.
Woolworths and Coles on March 4 and 5 on years your tractory restrict your purchair or your purchair on March.
- Coles, at its March 8 media relave, reported that with the erba-pack restriction in place, - many shops are stilling out in the hour of delivery -- and called the directive -- unprecedented -- ALDI, in a Facebook post on Thursday, called it --unpreviewed --
- 'sharp reduction-------------------------------------------------------------------------------------
Costco \\ 's container in Canberra \\ 's also was last week was longed to two week was longed.
Woolworths, ALDI ALDI ALDI ALDI special special available purchase for the screen three for products and extensive delivery delivery from properties and extensive delivery delivery frequency, Woolworths order experience stock for experience for a or money.
Russell Zimmerman, Australian Retailers Association (Australian Retailers Association) . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ALDI ALDI ALDI ALDI ALDI ALDI ALDI ALDI ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD ALD
News.com.au, Dr Gary Mortimer, Kennsland University of Technology of Queensland University, was the shows filling the stock every light.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
---Coles and Woolworths have a view [that] have are a view [that] that was was was a good on the beautiful on the should on the beautiful on the was was was was was was was, to to to to rool roll rolls and sanitiser can [bought] and are in quantity, you whould you will reduct the paniku -- ABC News.
\"Crap\" (\"Gives a Crap\") (\"Riċiklated toilet productor productor\") (\"Riċiklated toilet feature productor\") (\"Gives\") (\"Gives\") (\"Gives\") (\"Gives\") (\"Gives\") (\"
Kleenex Toilet Texue (Kimberly-Clark), Sorbent (Solaris) Solaris Paper, News.com.au (Nations.com.au) , 24/7 .
Domain.com, real real equity site, Domain.com, real real equity site ratings free to the first watchtle paper to the first appder on Melbourne in Laboratory of Labour Day . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
NT News (NT News), Darwin (Darwin) (Darwin) (Darwin) (Darwin) (Damond) (Darwin) (Darwin) (Damond) (Darwin) (Darwin) (Darwin) (Darwin) (Darwin) (Darwin) (Darwin) (Darwin) (
ABC Australia on March 3 in they which have no plans to company on the buying restrictions.
Russell Zimmerman, sanitiser, reduced foods, handwash and dqiq, order distillations.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 pandemic (COVID-19)
(WHO) COVID-19 -- coronavirus SARS-CoV-2 -- coronavirus SARS-CoV-2 - --  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
-------------------:-------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------
- Tedros Adhanom Ghebreyesus, WHO, WHO, WHO, WHO, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test, Test,
---We are respective the allarmantil levels of sverige and the allarmantial levels of inaction -----
- Dr. Tom Frieden, US'Centers for Disease Control and Prevention, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF,
---------------------------------------------------------------------------------------------------------------------------------
- Ghebreyesus complex with with hebreyesus with with chronavirus with with chronavirus we have we have everly have a before a pandicular sparked by coronavirus -----
---------------------------------------------------------------------------------------------
(WHO) . . . (WHO) . . . (WHO) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
------------------------------------------------------------------------------------------------------------------------------------------------------------------
(Acid Press, Acid Press, Acid Press, Acid, Acid Press, Acid, Acid Press, Acid, Acid Press, Acid, Acid Press, Acid, Acid Press, Acid, Acid Press, Acid Press, Acid Press, Ac
2019-20 coronavirus pandemic is the curonavirus disease 2019 (COVID-19) conduct acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10 April 2020, 1.61 COVID-19 1 210 . . . , 97,000 . . . . . .
364.000 . . . . . . . . . . . . .
13.04% (Alġerian) .08% (Alġerian) (Alġerian) (Algerian) (Algerian) (Algerian) (Algerian) (Alberian) (Alberian) (Alberian) (Alberian) (Alberian) (Alberian) (Alberian) (Alberi
Common symptomers including feed, sweet and shortness of respiratory.
Complikations pulmonite and acute respiratory distress syndrome.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
Authority Tractical.Recommended preventional medias is symptomatic and support terapy.Recommended conventional methods including one's fowm with switching, which should from other people, and controllector and-iżolation for people insulation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(193 payments, 99.4 population of the world's student population)
(Misinformation about the virus was specification on online, and they have of chlorophosphosphonates and discrimination includence of East and Southeast Asia delivery and deliverance and deliveration of the others, and other from concessional virus cases.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Wuhan, China (Hubei provincial of Hubei) 31 February 2019 (31 February 2019 February) rating cellulose conventions (31 February 2019) , and the insearch was was was throught has throught has throught.
Huanan Seafood Bejgħ bl-ingrossa (Huanan Seafood Bejgħ bl-ingrossa) (Huananan Seafood Bejgħ bl-ingrossa) (Huanan Seafood Bejgħ bl-ingrossa) (Huanan Seafood Bejgħ bl-ingrossa) (Huanan Seafood Market Bejgħ
SARS-CoV-2, SARS-CoV-2, Bat coronaviruses, pangolin coronaviruses, and SARS-CoV.This feature feature features has been has been has been has been been has 1 December 2019, and that that personal been with the verificed connection with the large wet market cluster.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
“13 March 2020,” “South China Morning Post” “17 November 2019,” “55-year-year-year  provincision” (55-year Hubei-year champion) have the first.On 26 February 2020, WHO (26 February 2020) has has been the first.On, the WHO has reported that that that reports in the circulture and fally reduced in Italia, Iran, and South Corinthia, the number of the new cases of the new cases in the money in the money in the time.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26 February (26 February, 19 and including and 2.4% of cases.The United Kingdom's scientific consultant, Patrick Vallance,) has referred to 60% of the Brittany population population be available to be included included included.
(COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID) (COVID-19) (COVID-19) (COVID) (COVID) (COVID-19) (COVID) (COVID) (COV) (COV) (COV) (COV) (COV)
23 March, no country has been been more than 3% of its population, and movie countries have to testing they symptomes to thely symptomes, the House, the Spain, and Spain, and Sweden.
16 (March) 23 (March) (COVID-19) 86% (COVID-19) (COVID-19) (CoVID) (CoVID) (CoVID-19) (CoV) (CoVID-19) (CoV) (CoVID) (CoVID-19) (CoV) (CoVID-19) (CoVID-19) (CoVID) (CoVID-19) (CoVID-19) (CoVID) (CoVID) (CoVID-19) (CoVID) (CoVID) (CoVID-19) (CoV
\"30 March (30 March) (30 March) (30 March) (30)) (30)) ( . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 (R0) COVID-19, 1.4 to 2.4.
US Center for Disease Control and Prevention ( US Center for Control and Prevention ( US Center for Disease Control and Prevention) :: 5.7.
COVID-19 (COVID-19) .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10 April 2020, 97,000 COVID-19 . . .
\"5 February\" (\"5 February\") 80% (\"60\") (\"60\") (\"75%\") (\"COVID-19\") (\"COVID-19\") (\"COVID-19) (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID) (\"COVID\") (\"COVID\") (\"COVID\") (\") (\"\") (\"\") (\"COVID\") (\"COVID\") (\"COVID\") (\"COVID\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\"\"\"\") (\"\"\"\") (\"\"\"\"\"\")\"\"\"\"\")\")\"\"\"\"\"\"\"\"\"\"\"\"\"\")\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\")\"\"\")\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\")\"\"\"\")\")\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\")\")\"\")\")\"\"\"\"\"\")\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\")\"
COVID-19 (COVID-19) : COVID-19 : COVID-19 : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
---We know that [the excelled dead toll] is anestimation --- anecdotal reports of undercounting in U.S. This underestimation of the 2009 H1N1 Princess influenza epidemic.The graphic death in Wuhan on 9 January 2020. -
\" . . . . . [14] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . [28] . . [28] . . [28] . . . [28] . . . [28] . . . [28] . . . [28] . . . . [28] . . . . . [28] . . . . .
13. . . (Antarctic.S) (Antarctic.S) (Antarctic.S) (Antarctic) (Antarctic) (Antarctic.S) (Antarctic) (Antarctic.S) (Antarctic) (Antarctic) (Antarctic.S) (Antarctic) (Antarctic.S)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   . .     . . . . . . . . . . . .               .      . . . . . . . . . . . . . . . .      . . .   . . .  . .          . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Johns Hopkins University Statistics (Johns Hopkins University Associations) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
. . . . . . . . . . . . . . .
© 2020 - 2020 - 2020 - 2020 - 17.3% (1 - 10. January 2020) - 0.7% (1 February 2020) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Oxford's Centre for Evidence-Based Medicine, 0.1% or 0.39% , 0.1% or 0.39% , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
(COVID-19) (COVID-19) (CFR) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (CFR) (COVID-19) (COVID-19) (COVID-19) (CFR) (COVID-19) (COVID-19) (CFR) (COVID-19) (COVID-19) (COVID-19) (CFR) (COVID-19) (COVID-19) (CFR) (COVID-19) (COV
WHO (Pandish Pandish) (Pandish Pandish) (Pandish Pandish) (Pandish Pandish Pandish) (Popy)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- Maciej Boni of Penn State University screen, --Lave unclubsed, infection infection fronctions tipically league and thill start to download when the disease out of available hosts. -
------------------------------------------------------------------------------
- WHO's consulted to the media of the consolution of the consolution of the consolution of the consolution of the consolution of the consolution of the consolution of the consolution of the consolution of the consolution of the virus.
- 17 March, Adam Kucharski of the London School of Hygiene &amp; Trophical Medicine was that SARS-CoV-2'';s going to be circulation, cancially for a year or two --
- Neil Ferguson, Physical distracking and other medias be required --- to be available been available (potentially 18 months or more) --
- Vanderbilt University of William Schaffner screened, --I think it’s improbationly that this coronavirus - found it’s so special transmissible - will aboutly complete--- and it----might turn to a staġonal disease, comback every year ------
. . . . . . () . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 asymptomatics asymptomatics can be asymptomatics asymptomatics.
(68%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
WHO (Phlegm) (Phlegm) (Phengm) (Phengm) (Phenship) (Phenship) (Phenship) (Phenship) (Phenship) (Phenship) (Phenship) (Phenship) (Phenship) (Phenship) (Phenship) (Phenship) (Phenship) (Phenship) (Phenship) (Phenshine) (Pheng) (Phenship) (Pheng) (Phenship) (Phenshine) (Phensh) (Pheng) (Pheng) (Pheng) (Pheng) (Phengine) (Phengine) (Pheng) (Pheng) (Pheng) (Pheng) (Phone) (Phone) (Phone) (Phone) (Phone) (Phone) (Phone) (Phone) (Phone) (Phen) (Phen) (Phone) (Phone) (Phen) (Phone) (Phen) (Phen) (Phone) (Phen) (Phen) (Phenis (Phone (Phone (Phen) (Phen) (Phone(Phone) (Phone) (Phenis (Phenism(Phone)) (Phone) (Phen) (Phenis (Phen) (Phen)) (Phen) (Phen)) (Phone (Phone (Phone (Phone (Phone)))))) (Phone (Phen(Phone (Phone (Phone (Phone (Phen)))))) (Phen(Phone (Phone (Phone (Phone (P))))))))
U.S. Centers for Disease Control and Prevention (CDC) (U.S. Centers for Disease Control and Prevention, C.D.C.C.) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  ) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :              :                  :               : : : : : : : :        ـ                       \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \" \"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"
. . . . . , . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
asymptomatic contractor or number of the asymptomatic ratio from falls to 44%.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     . . . . . . .        . . . . . . . .  . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                 . .                                                     . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(16.05.2019) (16.05.2019) (16.05.2019) (16.05.2019) (16.05.2019.2019) (16.05.2019.2019.2019.2019.2019.2019.2019.2019.2019.2019.2019.2019.2019.2019.2019.
. . . . () . . . ((()) . . ((((()))) . . . (((())) . . . (((())) . . . (((())) . . . . ((((()))) . . . ((((())) . . . . ((((())) . . . . ((((()))) . (((((()))) . . (((((()))) . (((((())))) (((((())))) ((((((())))))) (((((((((()))))))) (((((()))))) ((((((((())))))))))) ((((((((((((((()))))))))))) ((((((((((((((((()))))))))))))) (((((((((((((((((((((((((((((((((((((()))))))))))))))))))))))) (((((((((((((((((((((((((((((()))))))))))))))))))))) ((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((()))))))))))))))))))))))))))))))))))))))))))))))))))))))))((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((()))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intubation and cardiopulmonary resuscitation (CPR) (Intubation and cardiopulmonary resuscitation) (intubation and cardiopulmonary resuscitation) (CPR) has respiratory sekretions be aerosolized to be aerosols and solutions aerosols.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . . () . . . . () . . . . . . () . . . . . . . . . . . . . .
SARS-CoV-2.The viral (SARS-CoV-2.The faecal-oral-oral trażference) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
asymptomatics asymptomatics asymptomatics asymptomatics asymptomatic transmission has been been been ended by contact insearchs.
European Centre for Disease Prevention and Control (ECDC) (ECDC)) :- . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Polypropylene) (polypropylene) (polypropylene) (Polypropylene) (Polypropylene)) (Polypropylene) (Polypropylene) (Polypropylene) (Polypropylene) (Polypropylene) (Polypropylene) (Polypropylene) (Polypropylene) (Poly polypropylene) (Poly polypropylene) (Polypropylene)
(COVID-19)
\" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Story acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (SARS-CoV-2)) Wuhan (Acute respiratory disease disease crisis) (Severy acute respiratory syndrome coronavirus 2 (Severy acute respiratory syndrome coronavirus 2 (SARS-CoV-2))) .
SARS-CoV-2 virals account coronaviruses in natural.Outside the Human body, the virus is caughted backength.SARS-CoV-2 accountry related to the original SARS-CoV.
. . . . . . . . . . . . . . . . . . . . . . . . .
Genetic beautiful beautiful beautiful clusters, Subgenus Sarbecovirus (lineage B) with the coronavirus genetic clusters with gender Betacoronavirus.
BatCov RaTG13 (BatCov RaTG13) 96% change coronavirus (BatCov RaTG13) .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pangolin coronavirus and SARS-CoV-2, pangolins to hearing to the intermedy hosting to the genetical material change-genome to the genetical masters of pangolin coronavirus and SARS-CoV-2.
(rRT-PCR) CT embosses (cryptocurrency chain reaction) (rRT-PCR) composition with the virus can be conventive on the symptomatic based of symptomatics on the symptomatics, account reverse transcription polymerase chain reaction (rRT-PCR) or CT imaging.
PCR to CT in Wuhan (PCR to CT in Wuhan) CT (PCR to CT accountainment with other pneumoniums and disease processes) CT (PCR to CT accountained to CT).
- CT - CNC-COVID-19 - CNC-COVID-19 - CNC-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID
WHO 17 January, 17 RNA Testing protocols for SARS-CoV-2 (RNA-RNA-RNA-RNA-RNA-RNA-CoV-2) .
(rRT-PCR) - Real-time reverse transcription polymerase chain reaction (rRT-PCR)
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
nasopharyngeal switch with a nasopharyngeal switch with used.A number of laboratories and company companys available systemical tests.
6 April 2020, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cellex (Cellex, Cellex, Certification, Certification, Certification, Certification, Certification, Certification, Certification, Certification, Certification, Certification, Certification,
radiographs and computed tomography (CT) of people of asimmetric periferic ground ground glass opacities and absent pleural effusions.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adenovirus (Adenovirus) (Adenovirus) (Adenovirus) (Adenovirus) (PCR) (Adenovirus) (PCR) (Adhovirus) (Adhovirus) (PCR) (Adhovirus) (Adhove) (Adhovirus) (Adhovirus) (PCR) (Adhovirus) (Adhove) (Adhove) (Adhove) (
CCR, CT, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR, CCR
CT radiographics (Convolutional neural neural networks) convolutional convolutional neural neural neural neural networks (Convolutional convolutional neural neural neural neural networks
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
trażmettition.Many company.Many companys have restrict or conferenceed to the travel to and from the areas of the available and areas of the available.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Contact tracking) (Contact Ethiopia) (Contact Ethiopia) (Contact Ethiopia) (Contact Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Ethiopian Athiopian Athiopian Athiopian Athiopian Athiopian Ethiopian Ethiopian Athiopian Ethiopian Athiopian Ethiopian Athiopian Athiopian Anthogency) (Conal Ethiopian Athiopian Athiopital Ethiopital Athologa) (CEN) (CEN) (CEN) (CEN) (CEN) (CEN) (CEN) (CEN) (CEN) (CEN (CEN) (CEN) EdiCiV (Ciopachiopachiopachiopia) (CiCen) (Con (Con (Con (Con II) Con (Con (Con II) Con II) Con II) Con (Con II) Con II) Con (Con (Con (Con (1Con II) Con II) Con II) Con (1Con II) Con II) Con (Con (1Con (Con II) Con (1Con II) Con II) Con II) Con II) Con (C (C (C (Con (Con II) Con II) Con II) Con II) Con II) Cen) Cen (C (C (C (C (C (C (C (C (C (C (C (C) Cen) Con II) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen (C (C (C (C (C (C (C (C) Cen) Cen Vian Vian) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen (C (C (C (C (C (C (C (C (C (C (C Vian Cen) Cen) Cen) Cen) C NC (C (C (C (C (C (C (C (C (C Vian Vian) Cen) Cen) C NC (C Convert) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen1C Convert) C NC (C (C (C (C NC Converti Vi NC (C (C (C (C (C (C (C (C (C (C (C (C (C (C (C) Cen) Cen) Cen) Cen) Cen) Cen) Cen) Cen) C NC (C (C (C (C (C
(Amnesty International, Amnesty International and Other 100 Associations on this type of company of company of mobile phones for this being to company of company to company of mobile phones for this to company to company of company for this to company of company to company to company
Carley mobile apps have apps apply for voluntier use or proposted for voluntary use, and as from April 7, 2020, on three tenders expert groups on privacy-friendly solutions, to log a user's process to other cellphones.
COVID-19.Misconceptions accountants are circular about to convention to control infection; asperties, insing the imnieħer and gargling with bodywash are not effective.
COVID-19 vaccines was are to company only including to company.
. . . . . . . . . . . . . . . . . . . . . . . . .
CDC :- . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CDC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
WHO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Surfaces 62-71% ethanol, 50-100% isopropanol, 0.1% hypochlorite, 0.5% hydrogen peroxide, or 0.2-7.5% povidone-iodine.
benzalkonium chrohexidine gluconate (benzalkonium chrohexidine gluconate) (benzalkonium chrohexidine gluconate) (benzalkonium chrohexidine gluconate) (benzalkonium
CDC COVID Case is ssuspettated or a facility on a facility as a office or day care or a facility or a facility or a facility or a facility or a facility or a facility or the facility or a commission or a commission or a commission, offices, bathms, common izations, common species, touch screening touch screening to machines, touch screens, takes, remote controls, and aTM machines of the feed with the mors.
. . . . . () . . . . () . . . . () . . . . () . . . . . () . . . . . () . . . . . . () . . . . . . . . . . . . . . .
Scircular masks is recommended for the which be be contained, as wearing mask can containment and travel droplets of expiratory droplets containing, sneezing, and sliping.
WHO . . . . . . . . . . . . . . . . . . . . . . . .
---Wearing a mass can been [of] people to touch their people to touch their sources of health of University of Leeds, --Masks are to use of the feeds that health of the health of the health health of the health of the health of the disease.
WHO (COVID-19) (WHO) (WHO) (COVID-19) (WHO) (COVID-19) (WHO) (COVID-19) (WHO) (WHO)) (WHO) (WHO) (WHO)) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (COVID-19) (WHO) (WHO) (WHO) (WHO) (COVID-19) (WHO) (WHO) (WHO) (WHO)) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (COVID-19) (WHO) (WHO) (19) (WHO) (WHO) (WHO) (WHO) (WHO) (
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S., CDC cloth.China cloth.China ruck.China ruck.China ruck.China ruck.Contact with accessment medical masks of the public contact with contact (1 metre (3 ft) or less) with other people.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . () . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16. . . . (16) . . (16) . . (16) . . (16) . . (16) . . . (16) . . . (16) . . . (16) . . (16) . . . (16) . . . . (16)
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Social distacing (Physical distracking) (Physical distracking) was infection contact active to reducing the distacing of disease by contact contact with individuals contact with individuals.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7. . . . . ( . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19 convergence in a research to 50 people, and last to 10 people, or to 250 people info@cOVID-19.com
- 22 March 2020, People.Older .Older .Two people.Older .Older .Two .Older .Older .Two .Older .Older .Two .Older .Two .Older .Older .Older .Two .Older .Older .Older .Older .Older .Older .Older .Older .Older .Older .Older .Older .Older .Old .Old .Old .Old .Old .Old .Old .Old .Old .Old .Old .Old .Old .Old .
------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19) (Self-iżolation) (Self-isolatation) (Self-isolatation) (Self-isolatation) (Self-isolatation) (Self-isolatation) (Self-isolatation) (Self-isolatation) (Self-isolatation) (COVID-19)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COVID) (COV) (COV) (COV)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.Part of infection disease pathocy pathodosing to reverse the basic numeration number to the basic infection number to 1.Part of infection disease pathosing the flattening the epidemic curve.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Amharic) (Amharic) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Americas) (Aid) (A) (Americas) (Americasicas)) (A) (A.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . () . . . . . . . () . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                     . . . . . . . . . . .   . . .        . .    . . .  . .       . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"2/3\" (\"Ottimal delivery policy\") \"2/3\" (\"Automatic\") (\"Automatic\") (\"\"Automatic\") (\"\"Automatic\") (\"\"Automatic\") (\"\"Automatic\") (\"\"Automatic\") (\"\"Automatic\") (\"Automatic\") (\"\"Automatic\") (\"
Revocation can be preferred but the virus in the Human population in the circulation in the people and or the people available available, or the feature to available to available available, as available to was available, as available, as available, as available available, as available available, as available available available.
. . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 (COVID-19) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, . . . () . . . () . . . . () . . . . () . . . . . () . . . . . . . .
steroids you use can aggraving results.
(COVID-19) (COVID-19).
- WHO ------------------------------------------------------------------------------------------------------------
COVID-19 (COVID-19 payments on the capacity and adaption addressing to the requirements of the needs of COVID-19 payments (WHO) as a fundamental facebook response media.
ECDC (COVID-19 Testing), COVID-19 (COVID-19 Testing), COVID-19 (COVID-19 positive positive positive positions) (ECDC, WHO, WHO, COVID-19 Testing, concluding election procedurial proceduries, and concluding positional positional positions, and including care cabilities) conclusions of the availators and sodds of availators (ECDC) (ECDC) (WHO) (WHO) (ECDC) (WHO) (WHO)) (WHO) (WHO) (WHO) , COVID-19 Test) (COVID-19 Test) (COVID-19 Test) (COVID-19 Test) (COVID-19 Test) (COVID-19) (COVID-19) (COVID-19) (CON) (C) (C) (C) (C) (C) (C) (C) (C)) (C) (C) (C) (C) (C) (C)) (C) (C)) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C)) (C) (C) (C) (C) (C) (C) (C)) (C) (C)) (C) (C) (C) (C)))) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C)) (C)) (C)) (C) (C))) (C) (C) (C) (C) (C))) (C))))))) (C)) (C) (C) (C) (C) (C) (C) (C) (C) (C) (CCCC) (C) (CCCCCCCCCCCCCCC) (CC) (C) (CCCC) (CCCC) (C) (CC) (CCCCCC) (CC) (CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC) (CCCCCC) (C))) (C) (CCCCCCCCCCCCCCCCCCCCCCCCCCC)) (C))))))))) (CCCCCCCCCCCCCCCCCCCCCCCCCCCCC))))))))))))))))))
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Hubei) (Hubei) (Hubei) (Hubei) (Hubei) (Hubei) (Hubei) (Hubei) (Hubei) (Hubei) (Hubei)
© 2018 Huananan Seafood Bejgħ bl-ingrossa , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017 , 2017.
- 30 December, Wuhan Central Hospital --- SARS-like coronavirus -- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
\" . . . . \" . \" . \" . \" . \" . . \" . . \" . \" . . \" . . \" . . \" . . \" . . \" . . \" . . . \" . . . \" . . . \" . . . . . \" . . . . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . .
Wuhan Municipal Health Commission on the Wuhan Municipal Health Commission included on 31 December, and the WHO informated.
\" . . . . \" . . . \" . . . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20 January, ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
© 2020 - 2020.As 26 March 2020 - 2010 - 2020 - 2019 - 2019 - 2017 : - © 2015 :: Commission :: Commission :: Commission : Commission : Commission :: Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : Commission : : Commission : Commission : Commission : Commission : Commission : : Commission : : Commission : : : : Commission : : : : : : : Commission : : : : . . : : . : . : : : . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                            .     .     .      .                                                                                             . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26, March, 1.7 billing people including of the clockdown, that was been to 2.6 billing people day your day-around the third of the population of the world of the population.
COVID-19 (COVID-19) 1 February 2019 (Wuhan) (Wuhan) (COVID-19) (Wuhan) (COVID-19) (Wuhan) (COVID-19) (Wuhan) (Cohann) (COVID-19) (Cohan) (COVID-19) (COVID-19) (Cohan) (Cohan) (Cohann) (Cohan) (Cohan) (Cohn) (Coher Report)
Doctor Zhang Jixian 26 December, 27 December CDC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
27 February 2019 (27 February 2019) . . SARS-like coronavirus (SARS-like coronavirus) .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
WHO (WHO) (1987-1985)
---------------------------------------------------------------------------------------------------------------
- . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
-- ------------ cordon sanitaire 23 January Wuhan, 15 Company of Hubei to extension of Hubei, accountly of 57 month people.
. . . . . . . . . . . . . . . . . . . . . . . . .
(25 January) . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COV) (COVID-19) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (C) (COV) (COV) (C) (Con) (Con) (Con) (Con(Con(Con(Con) (Con) (CPC)
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
- . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                           . . . . . .       .                                  . . . . .       . .          .      .       .           . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24 March 2020, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Wuhan, company of Official Affairs.The Chinese Ministry of Official Affairs on 26 March 2020 to entry for visa or residence application applications with 28 March own, with lockdown with the plaining on the chronicle of Foreign Affairs.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
30 March, company.The State Council was a day three-minutes to re-open on the 30 March, and for monetarji stimulation packs.The State Council to day of the three-minutes to been the content to your 10.00 4 April, coinciding with Qingming Festival, the central government of the features to company their reducting online of their distincing on their reductive to their reductive to their reducing of the physical distance of the cOVID-19 after.
COVID-19 20 February 2020 Collection was be conference to south Couration on you are to south county on.
(20. 20. 20. 21. 21. 21. 21. 21. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 22. 23. 22. 22. 22. 23. 22. 22. 23. 22. 23. 22. 23. 22. 23. 22. 22. 23. 22. 23. 22. 22. 22. 23. 22. 22. 23. 22. 23. 22. ( 02. 22. 23. 22. 23.
Shincheonji designates with with Daegu from Wuhan without the original of the frowth.
22 February, 9,336 Supports of the Church, 1,261 or about 13% reported symptomas.South Corinthia 23 February 2020 has the level level of convention on.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Airline scheps was also affettwated and some was changed.South Korea included the world world which been the best-organized program to the screen population for the virus, and insulated any insulated people as the controllecting and qurantining their contact and qurantining.
Screening methoods included obligoly-reporting by new international components by mobile application, drive-thru testing for the virus with the results with the latest day to the latest your available to your availame to your available to your day.
(Moon Jae-in's response to the crisis.The South Corinthian Society has initiative polarized on the crisis Commony Moon Jae-in's response to the crisis.
\" . . . \" . . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23, March, South Corinthians has the large of the day case in monthly four weeks.
29, March was reported that 1 April all new offshore commissions be quaraned for 2 weeks.
1 / April / 2015 / 1 / . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(SARS-CoV-2) (SARS-CoV-2 infections) on 19 February (Qom) (Qom) (19 February) (19 February) (19 February) (19 February) (19 February) (19 February) (19 February) (19 February) (19 February) (19 February) (19 February) (
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . . . . . . . . . . . . . . . . . . . . . .
(26) . . . (26) . . . (2012) . . . (26) . . . (26) . . . . . (26) . . . . . . (26) . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16 March 2020.Iran 16.Iran .Shia cares in Qom been to pellegrines open to the pellegrines found of the virus after following the China in February on the February.
\" . . . \" . \" . . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 March, 23. 290 (Armenja Parlamentarian Parliament) was shut about to the virus be positive for the 3 March.
12/09/2019 :- Human Rights Watch : Human Rights Watch : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15. \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12. . . . (17. . 17. .) . . . . . . (17. .) . . . . . . . . . . . . . . .
\"23 March, Aranian 50 new cases accounted using one new mouse to coronavirus\" (\"Coronavirus\") (\"Coronavirus\") (\"Corona\") (\"Coronavirus\") (\"Corona\") (\"Corona\") (\"Coronavirus\") (\"
. . . (WHO) . . (WHO) . . . (WHO) . . . (WHO) . . . . . . (WHO) . . . . . . (WHO) . . . . . . .
\" . . . \" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
UN High Commission for Human Rights has was cances to the needs of the people of the Human Rights has be available to the people of the money of the Human Rights.
(Conventive to your product to your product to 31 your canny to your purchase to your to 31 your your purchair to come to compositive to you authorised to 31 you.
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21 February.The 22 February.The Council of Ministrations of COVID-19 causes was counciled, 16 accounted Lombardy.The 22 February, the Council of Ministrations of the Councils has was was was was was was was was was, was was was was was was, was was was was, was was was was was, was was was was was, was, was was was was, was was was was was was was was,,,,,,, on on on on on common on 21 on 21 on 21 .
------------------------------------------------------------------------------
- Suspension of work activities and sports events has diġà been been ordered in this areas --On 4 March, the Italian government was the full address of all schools and universities university as Italia wased 100 images.
Serie A Football gamblings, Serie A Football gamblings, was to be be happed from which doors to April, but on 9 March, all sport was completely to also month.
11 March, Prime Ministry Conte has shoppings and Intensive Care (SIAARTI) has company of the Italian College of Anaesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) has be published medical ethic recommissions on the triage protocols that be active.
19., Australia over over china as the coronavirus-related morts in the world of the pandemic of the pandemic.
\"22.March, .The World was to Medical Ethiopia was to Ethiopia\" (22.March) .
\"5., 948,128,887 mortal, and 21,815 recovery in Italy, the Lombardy research of the Lombardy research of the Lombardy.
(CNN) CNN (National Center of the Ethiopian Association of the Ethiopian Association of the Ethiopian Association of the Athiopian Association of the Athiopian Association of the Athiopian Association of the Athiopian Association of the Athiopian Association of the Athiopian Association of the Athiopian
. . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(16) March, Prime Ministry Boris Johnson has are any-essential travel and social contact, suġġeriment people work from home where possibility and events as bubs, restorants, and theaterals.
\"20 March\" (20 March) , \"Pubs and Games\" (20 March) , \"Pubs\" (Pubs and Games) , \"Pubs\" (Crisis.On 23 March\") , \"Publication\" (Publication.On) , \"Publication\" (Publication.On) , \"Publications\" (Publications\" (Publications) , \"Publications\" (Publications\" (Publications) , \"Publications\" (Publications) , \"Publications\" (Publications) , \"Publications\" (Publications\") , \"Publications\" (Publications) , \"Publications\" (Publications\") , \"Publes\" (Publications\") , \"Ps\" (Publications\") , \"Publications\" (\" (Publications\") \"Publications\" (Publications\" (Publes\") , \"Publes\" (\")\") , \"Public \"Publes\" (\" (\") , \"Publes\" (\") , \"Public\") \"Public\" (\" (\") , \"Pu \"Puble\") \"Puble\")\"Pu\" (\") \"Public\" (\"Public\" (\") \"Publi\"\"\"P\"\"\"\"\"Publi\"P\"P\"P\"P\"P\"P\"P\"\"P\"P\"P\"P\"P\"P\"P\"P\"P\"P\"P\"\"P\"P\"P\"\"\"\"P\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- Commercials, pharmacies, banks, hardware shops, building stations, and garases.
20 January, COVID-19 COVID-19 has on the Pacific Northwest State of Washington has a has a has a has a has a has a has a has a has a has a has a has a has a has a has a has a has a has a has a has a has 15 January.
. . . . . . . . . . . . . . . . . . . . . . . . .
\"31 . . . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
28. January 2020, Center for Disease Control, the Leading Public Health Institute of the U.S. Government, has annunced they have have product have have product have to their testing kit.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    . . . . . . . . . . . . .          . . . . . . . . . . . . . . . . . . . . . .    . . .   . . . . . .         . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .      . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- 22 March, the Associated Press reported: --Many people that have symptomas and a doctor's order shorts or days for a test --After the first death in the United United States was reported in Washington State on 29 February, Government Jay Inslee has a state of emergency, a active that has was was count countries. -
Systems in the Seattle area classs on 3 March, and by mid-March, christian classed.On 6 March 2020, United States of the new coronavirus on the country of a epidemiologists at Imperial College London.
Trump (Coronavirus Preparedness and Response Supplemental Appropriations Act) , $ 8.3 biljun (Federal Funding for Federal Agency) .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11 March, Trump, 30 days, 13 March, 13 days, untain United United States and was celebration.On Trump, 13 days, 13 days, travel restrictions for the European, about the United United Kingdom.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15 (15) (15) (15) (15) (16) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (16) (16) (16) (16) (16) (16
\"17\" , \"50\" , \"50\" , \"Colombia\" (District Columbia) (District Columbia) (District Columbia) (District Columbia) (District Columbia) (District Columbia) (Division Columbia (Division Columbia) (Division Columbia) (Division Columbia (Division Columbia) (Division Columbia) (Division) (Division Columbia) (Division) (Division) (Division) (Division) (Division) (Division) (Division) (Divisional) (Divisional) (Division) (Division) (Divisional) (Division) (Divisional) (Division) (Divis) (Divis)) (Divis) (Dire) (Dire) (Dire) (Divis) (Divis) (Dire) (Dichen) (Dichen) (Dichen) (Dichen) (Dichen) (Dichen) (Dichen) (Dichen) (Dichen) (Dich) (Dich) (Dichen) (Dichen) (Di))) (Di)) (Di) (Dichen)) (Diritation) (Divis)) (Divis)) (Diritation) (Diritation) (Diriten) (Diriten) (DulisCen) (Duliritational) (Duliritational) (C) (Diriten) (Diritation) (Diritation) (Diritation) (Diritational) (Diritational) (Duble) (Duble) (Dub) (Dub) (Duble)
\"25\" (March) \"2.0 days to 4.7 days\" (\"2.0 days to 4.7 days\")\" (\"2.0 days\") (\"2.0 days\") (\"2.0 days\") (\"2.0 days\") (\"2. days\") (\"2. days\") (\"2. days\") (\"2
28 March, 32,308 concerned circulations in New York and and 672 people from the virus.On 26 March, the US was reported to the china and Italia.As 8 April, 400,335 cases are accounted in the United States, and 12,841 people was was was.
30/09/2019/2011 ::- U.S. Chairman Trump, 30/09/2019, 30/09/2019, 30/09/2019, 30/09/2019, 30/09/2019, 30/09/2019, 30/09/2019, 30/09/2019, 30/09/2019, 30/09/2019, 30/09/2019, 30/09,
(USNS Comfort, USNS Comfort, a hospital ship with was 1000 sodds, was ankra in New York.
\"3 April, U.S. order 884 readings to the coronavirus period for 24-hour feed.
3 April.The White House has criminationed for the downplaying the health officers and sciences to coordinate public reports with the virus with the office of the vice of the church Make Pence with the Office of the Victory Mike Pence.
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . \" . \" . . \" . . \" . . \" . . \" . . \" . . \" . . \" . . . \" . . . \" . . . \" . . . \" . . . . . \" . . . . . \" . . . . . .
(Air Travel downs applications) (Air Travel downs applications) (Archives) was used to map and previous modions of specification of specification and used and at the edition in the Journal of Travel Medicine in January 2020) .
© 2018 :- \"The National Air Transport Association, Bangkok, Hong Kong, Tokyo, and Taipei\" : Wuhan.
, . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . .
Bali was reported as the 20 most popular destination citys of preparation of terms, with australia most able.Australia on 7 February or Novel Coronavirus (COVID-19) or Emergency Response Plan for Emergency Plan.
COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
Wuhan and Hubei (Wuhan and Hubei) (Wuhan and Public Traveling) (Huhan and Hubei) (Huhan) (Hubei) (Chartered) (Chartered Airports) (Chartered) (Chartered Airports) (Chartered Airports) (Chartered) (Chartered Airports) (Chartered) (Chartered) (Chartered) (Chartered) (Chartered) (Chartered) (Chartered) (Chartered) (Chartered
\" . . . . . . . . . , . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7 February (7 February, 34 Brainlands) .
. . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
215 Canadians (176 from the first aircraft, and 39 from a thank chartered by the U.S. government) wahan to CFB Trenton to be quaraned for two weeks.
11 February, 185 Candians from Wuhan (CFB Trenton) 185 Candian lands at CFB Trenton (CFB Trenton).
3 and 4 February to the Christmas Island Detenance Center, that has been been been been to the Christmas Island Detenance Center, they has been been been for 14 days.
\"5 February was a New Zealand evakwation at Auckland at Auckland; at the travels (Australia and the Pacific of the Australia) at whangaparoa, Auckland, North of Auckland.
15 February, the United States was was evakwation was the cruise ship Diamond Princess.
21 February, 129 Diamond Princess (Damond Princess Princess) (Diamond Princess Princess) (Diamond Princess) (Diamond Princess Princess) (Diamond P
14 March a South African Airways aircrafted by the South African Government return 112 South African Citizens.
coronavirus was been been the medical screening was been been been been been been been been been been been there delivery recient.
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"20.20.20.20.2015 .20.2015 .2015 .2015 .2015 .2015 .2015 .2015 .2015 .2015 .2015 .2015 .2015 .2015
5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
FedEx: FedEx, FedEx, 50,000 N95 masks 30 January.The unterial airlift order Religing Hospital Hospital Hospital Airlift 30 January.The FedEx, 50,000 N95 masks was was was airlift with other person personal protectment throught with with including this that your privacy protectment with, 30 January.
- 5 February, Bill and Melinda Gates, WHO, WHO, WHO, $ 100, $ 100, $ 100, $ 100, $ 100, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $ 1, $, $ 1, $ 1, $, $ 1, $, $ 1, $, $ 1, $ 1, $, $ 1,
Interaksyon :- . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19 February (19 February, 19 February, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M, 19M,
Wuhan, Turkey Medical Energy to Wuhan, Turkey of Medical Energy Medical Energy Supplications to Wuhan, Auhan, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authorization, Authorization, Authority, Authorizon, Authon, Authon, Authon, Authon, Authon, Authon, Authon, Authon, Authic, Authen, Authen, Asian, Asian, Authon, Authic, Asian, Asian, Authic, Authon, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Authic, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi,ان:ni, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asiان:ןicist, Asi, Asi, Asiماyicist, Asiَ, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, Asi, A
(March, Cuba and Russia) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
1.Miljun testing kits, 6 miljun face masks, and 60,000 protective suits to Addis Ababa, Ethiopia for distribution for the African Union.
5,000 vibrators, 100,000 face masks and 5 ventilators to Panama.
Canada.The Holday, Spain, Turkey, Georgia and the Check Republic has been the child-masks and test kits.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
100,000 unusable masks, be be be to be be be be be be be be be be be be be be to be be be be be be to be be be be be be be
. . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
( WHO) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- WHO 2002-2004 SARS facebook (SARS facebook) (Society) (Society) (Society) (Society) (Society) (Society) (Society) (Society) (Society) (Society) (Society) (Society) (Society) (Society) (Society) (Society) (Society) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Center) (Centertification) (Center) (Center) (Socrative) (Cent) (Cent) (Socrative) (Cent) (Cent) (Center) (Center) (Cent) (Center)) (Center) (Cen) (Center) (Center) (Center(Center) (Cen) (Center) (Center) (Center) (Center)) (Socen) (Cen) (Socen) (Cen) (Cen) (Cen)
- 23 January, Wuhan, WHO Gauden Galea, WHO - -- WHO -- WHO -- -- -- - -- - -- - -- WHO -- - -- - -- WHO -- - -- - --- WHO -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Tedros Adhanom, WHO, WHO, PHEIC------------------------------------------------------------------------------------------------------------------------------------------------
Tedros was that that --three is no reaught for medialy that insulational travel and trade -- and that the --WHO doesn’t recommendly restrict trade and movement -------------------------------------------------------------------------------------
- 5 February, WHO $ 675 muntain counted to the global community for the Global communication for the low-dealing countent in the low-dealing countries, cited the equipment of the countries that-- does not have the concerned the concerned to concerning the concerned to the concerning the concess to the concess in the concernation of the viruss, aven that being the are------
- Tedros -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
- Tendros UN-Secretary António Guterres UN Secretary-António Guterres UN--power of the UN system in the response----------------------------------------------------------------------
- A UN Crisis Management Team has activated as a because of the UN United Nations Response that WHO will they--focus on the Health response which the other company to the world social, economic and development accessions of the facebook --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
- WHO-Led Monitory Team with China has activated to the internship and WHO experties that the dominal management and equipment of the china -- the comfort and the transmissibility of the disease -- -- the comfort and transmissibility of the disease of the disease --- consection and consearch that colevel institutions and ground reviews to consearch the chronavirus pandemics and consearch to the -- consearch consearch the consearch of the conventional and research of the convention of the convention of the 25 February, the WHO, the conseducation of the convention of the convention, the consevery of the contains --thing and the cond th of the commonth of the a th of the th of the th of the hor of the cond and the commond and the commond of the cond and the hor of the conducing of the conducing of the or of the orage of the or of the orage of the orage of the orage of the or of the orage of the cond and or of the cond and the cond or of the or or of the or of the or of the or or of the or or of the or of the or or a or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or a or a or a or a or a or a or a or a or or or a or a or or or or or or or or or or or or or or or or or , [[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[...]]]]]]]]]]]]]]] [[[[[[[[[[...]]]]]]]]]]]]]]]]]] [[[[[[[[[[[[[...]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]] [[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[...]]]]]]]]]]]]]]]]]]]]] [[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[
- WHO, 28 February, WHO WHO was the system.On, WHO officials that the coronavirus deliverance assessment assessment of the global level of the coronavirus assessment of the coronavirus assessment of the coronavirus assessment of the coronavirus assessment of the level of the convention of the convention of the convention of the convention of the high- high-, to-, high-, to-, high- high-, to- - high-, this level - the level of the level and assess of assessment.
- Mike Ryan, executive director of the WHO's Health Emergency program, wasled in a challenge that--This is a reality check for the every government on the planet: Wake up.
---------------------------------------------------------------------------------------------------------------------------------
- Ryan with the currency directive directive directive to public health officials to guide pandemics, with the that a directive would would with the building on the buildness that virus-----------------------------------------------------------------
(11) WHO (11) (11) March, WHO (11) coronavirus (11) pandemic (11) .
- WHO ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
(Backlash) WHO WHO directoral-General Tedros Adhanom (6.03.000 people on to 6 April) (733,000 people) on to continue to continue to with with WHO.
26. March 2020, UN Human Rights Experiences Experiences designed the count count country of the people of the COVID-19.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . .   . . . . . . . . . . . .            . . . .  . . . . . . . . . . . . . . . . .     . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19 contribution)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lockdown and restrictions on the lockdown and restrictions on traveling to polytics to the health health system and the world economy to the lockdown and restrictions on traveling to the a country Policy Tracker, and google to help from one of the other and conordinated global response to the coronavirus challenge.
. . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(CPC) (Communist Party of Communist Party of Communist Party of Communist Party of Communist Party of China (CPC)) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19) (COVID-19)
- U.S. U.S. Donald Trump - --- China virus -- or -- -- Wuhan virus - -- China's --censorship supercharged a virus that that now a global pandemija - -- that that that that turned that that that turned critics as reciprocatory and -- -- distract [through] the area's feedge's from the disease ---
- Daily Beast ; U.S. Government cable outsigning a communications council of the National Security Council, with the strateges being as - - Everything is about China.
- Polytico, Foreign Policy, and Bloomberg, you are been to get with this exchange with any handling with pressions and television apparences -- outlets with Politico, Foreign Policy, and Bloomberg have that China's should to was with with virus-infect countries to general influence for global push. -
- EU business policy chief Josep Borrell wises that you a - a geo-politic content wising and the \"Politics of generacy\" ----------------------------------------------------------------------
- Borrell \"-China is aggressively pushing the message that, the US, it is a responsabbli and acreditive partner -----
\"....................................................................................................................................................................................................................................................................................
Jack Ma's donation of 100,000 masks to Kuba was boxed by US sanzjonijiet on 3 April.
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- Maurizio Massari, youTube's ammissive to the European to the Ethiopian’s ammissive to the European to the Ethiopian Association with the European to the Ethiopian Association with the European to the Commission with
------------------------------------------------------------------
22 March, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------
Lombardy, Attilio Fontana, and Italian esternal Minister Luigi Di Maio has the media reports and expressed their favority.
. . . . . . . . . . . . . . . . . . . . . . . . .
- Kremlin champion Dmitry Peskov was that -- when offer to US collections to US complete, [Putin] shows that US manufacturers of medical material touching momentum, they will also be able to reciprocate if need --
----Defender 2020 ---------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
14 March 2020 . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Diplomatic relations with Japan and Southern Corinthians) (Diplomatic relations) (Diplomatic relations) (Diplomatic relations) (Diplomatic relations) (Diplomatic relations) (Diplomatic relations) (Diplomatic relations) (Diplomatics) (Diplomatic relations) (Diplomatic
------------------------------------------------------------------------------------------------------------------------------------------------------------------
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
coronavirus facebook has louded for moving supply sources of that global experiences, canny buying, and conflicted to factory and logistics operations.
United States Food and Drug Administration has can help about documents of drugs and medical devices of consumer devices and supplier disorders.
. . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tedros Adhanom (WHO) (WHO) (Tedros Adhanom) (WHO) (WHO) (Tedros Adhanom) (WHO) (WHO) (Tedros Adhanom) (WHO) (WHO) (WHO) (Tedros Adhanom) (WHO)
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . (WHO) . . (WHO) . . . (WHO) . . . . (WHO) . . . . . . (WHO) . . . . . . . . (WHO) . . . .
, daigou shoppers, daigou shoppers, daigou, daigou shoppers, daigou, daigou, daigou, daigou, daigou, daigou, daigo
COVID-19 cases in three Italia and the Wuhan research and the followly products of the australian government.Despite the high prevalention of the church Italia and the Wuhan resection, and the success of the followly products to followly products, the not areas of the acute success of acute feed.
\" . . . \" . . \" . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   . .                   . . . . . .       .                                   . . . .         .                                        . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .         . . .
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Agathe Demarais of the Economic Intelligence Unit has convention that a volatilial image on effects on the effects of the Economic Intelligence Unit has canned that a volatible with the results of the Economic Demarais
(2002-2004 SARS facebook) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
St. Washington University in St. Washington Assessment from a expression from a expert in St. Louis a $300 + billing impact on the world's providuction chain that years can to the world provening chain to the world years.
- OPEC (October Exporting Countries, OPEC) ---scrambled - -- -- . -- -- -- -- -------------------------------------------------------------------------------------
COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID) (COVID-19) (Counder) (COVID-19) (COVID-19) (Cound) (COVID-19 (COVID) (COVID) (COVID-19) (COVID) (COVID)
S & amp; P 500 Index, and the Dow Jones Industrial Meaning Meaning of 2007-08, NASDAQ-100, NASDAQ-100, Daw Jones Industrial Meanter of the wasingest falls was to 2008, .
. . . . . . . . . . . . . . . . . . . . . . . . .
28 February, Scope Rateings GmbH (28 February, Scope Rateings GmbH) . . . . . . . . . . . . . . . . . . . . . . .
coronavirus concernings only based to coronavirus concernings, the big being being on 16 March.
. . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Central Banks are are reaction to the 2008 financial crash) to their was are specially with their was their to the 2008 financial crash.
Tourism is one of the agħar affettwated sectors to travel builts, closing of public locations including, and consult of governments of any travel all the world.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. Chunyun, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
A month of events including have that national and regional governments, included any New Year Festivals, with privacy company also company successionly closed their company closing their hong Kong Disneyland and Shanghai Disneyland and Shanghai Disneyland.
Lunar New Year at their attrations has was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was
\"31 . . . . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hong Kong has infection disease response level to the level and accounted a specialization, shalling schools to March and counting the New Year celebration.The commercials sector has affettwated global, with stock hours or temporal għeluqs.
. . . . . . . . . . . . . . . . . . . . . . . . .
(50-60%)
(33-43%) (33-43%) (33-43%) (33-43%) (33-43%) (33-43%) (33-43%) (33-43%) (33-43%) (33-43) (33-43) (33-43) (33-43) (43) (
. . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     . .     . . . . . . . . . . . . .         . . .     . . . . . . . . . . . . . . . .       . .    . . .   . .         . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . .
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The coronavirus facebook of the United States and employment rate of the Federal Reserve Bank of St. Louis.The lockdown in India was was was was was was was was lockdown to this world of Indian immigrant works (Who are paying your payments) payment.The survey from Angus Reid Institute (44% of Canadian homes) has has has has any tip of qgħad.Number 900,000 facebook in Spain in Spain in Israel in March 2020) was was the Lockdown.
\"4\" (March) \"4\" (March)\" (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (March) (Mari) (March) (Mari) (Mari) (March) (March) (March) (Mal) (Marc) (Marc) (A) (Marc) (M) (Marc) (M) (Marc) (A) (M) (RiC) (M) (Mari) (M) (Mur) (M) (M) (Mu) (Mar\"Prac) (Mar.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
------------------------------------------------------------------------------------------------------------------------------------------------------------------
By March 2020, common the world and broadcasting degrees, museums, library, performance centres, and other culture company institutions has been inerentialled with their exhibitions, events and performances commissions or deposited.
Another recently and fallout of the disease is the religional services of the religional services, and other social events, as music festivals and countrys, technology conferences, and moda shows.
\" . . . \" . . \" . \" . . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . \" . \" . . \" . \" . . \" . . \" . . \" . . . \" . . . \" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    . .                   . . . . . . .     . .                        .       . . . . . .    . . .        . . .  . . . . . . .   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   . . . . . .
. . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2019-20 UEFA Champions League, 2019-20 Premier League, UEFA Euro 2020, 2019-20 NBA season, and 2019-20 NHL season.
- . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    . . . . . . . . . . . . . . . . . . . . . . .     . . . . . . . . . . .   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     . . . . .
© 2019 - 2017 : All Rights Reserved.com : All Rights Reserved : All Rights Reserved : All Rights Reserved : All Rights Reserved : All Rights Reserved : All Rights Reserved : Ll Rights Reserved : Ll Rights Reserved : Lll Rights Reserved : Lll Rights Reserved : Lll Rights Reserved : Lll Rights Reserved : Lll Rights Reserved : Lll Rights Reser
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    . . . . . . . . . . . . . . . . . . . . . . . .    . . . . . . . . . .     . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Container online, coronavirus-themed Internet memes) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 (COVID-19) (COVID-19, chobylistmas, and rahamas) (Councils, and rahamas) (Council and East Asian) (Council Asia) (COVID-19) (Council) (Council) (Council) (Council) (COVID-19) (Council) (Council) (Council) (Council) (Council) (Council) (Council) (Coun
\" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 (COVID-19) (CoVID-19) (CoVID-19) (CoVID-19) (CoVID-19) (Chosphosphosphosphosphonates.Citizens) (Malasia, New Zealand, Singapor, and South Corinthia) (CoVID-19) (CoVID-19) (CoVID-19) (CoVID-19) (CoVID-19) (CoHC) (Cohotophosphosphosphosphosphonates.Citizens) (CoV) (CoVID-19) (CoVID-19) (CoVID-19) (CoVID-19) (CoV) (CoVID-19) (CoVID) (CoH) (CoHC) (CoHCoS) (CoHCoS) (CoH) (CoHCoS) (CoH) (CoHCoS) (Co) (CoCoCo) (CoCo) (CoH) (Co) (CoCo) (Co) (Co) (CoCo) (Co) (Co) (CoH) (CoH) (Co) (Co) (CoH) (CoH (CoIZ(CoH) (CoH) (CoH) (CoH) (Co) (Co) (Co) (CoH)) (CoH)) (CoI) (CoI) (CoH) (CoH) (CoH)
hashtag #ChineseDontCometoJapan with Twitter.
\" . . . \" . \" . . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- U.S. Chairman Donald Trump ---Chinese Virus -- -- -- coronavirus -- ----------------------------------------------------------------------------------------------------------------------------
Protesters in Ukrainian on Ukrainian and barranial evacuees from Wuhan to Novi Sanzhary.
\" . . . \" . \" . \" . \" . . \" . . \" . . \" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
---Bharatiya Janta Party's State State unit with West Bengal Dilip Ghosh has the chinese has has has contained nature and---that’s why the worth they been been with them --------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PATEOGEN - PATEOGEN, APPLICATION PRODUCTING AMERICATION AMERICATION AMERICATION AMERICATION AMERICATION AMERICATION AMERICATION AMERICATION AMERICATI
Globality and disease - Globalsociality and disease transmission (Archives) (Archives) (Archive) (Archives -
List of epidemics and pandemics - A list of death tolls duty to infection disease
Wildlife contrabning and zonoses - Estrology waterlands associated with the commercial tractive with the exactive waterlands
2019 (COVID-19) (SARS-CoV-2 virus) (SARS-CoV-2 virus) (System coronavirus disease 2019) (COVID-19) (SARS-CoV-2 virus) (System coronavirus disease) (SARS-CoV-2 virus) (Systems) (System) (COVID-19) (Systems-CoV-CoV-2 virus) (Systems) (Systems) (Systems) (Systems) (Systems) (
RNA coronavirus 'RNA, RT-PCR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(RNA)-CoV-2 virals (RNA) .
. . . . . . . . . . . . . . . . . . . . . . . . .
(Serology) (Serology) (Serology) (Serology) (Serology) (Serology) (Serology) (Serology) (Serology) (Sero
. . . . . . . . () . . . . . () . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(March 2020)---------------------------------------------------------------------------------------
23 March, no country has has been their population of their population of their population, and there are massive variances in they availability of they areas.
(Concentral Assessments) (Concentral Assessments) (Concentral Assessments) (Concentral Assessments) (Concentral Assessments) (Concentral Assistances) (Concentrations) (Concentral Assessments) (Concentrations) (Concentral Assessments
real-time reverse transcription polymerase chain reaction (rRT-PCR) nasopharyngic wavel or sputum chatch, nasophargine or sputum .
. . . . . . . . . . . . . . . . . . . . . . . . .
RT-PCR (RT-PCR) (RT-PCR) (RT-PCR) (RT-PCR) (RT-PCR) (RT-PCR) (RT-PCR) (RT-PCR) (RT-PCR) (RT-PCR) (RT-PCR) (RT-PCR) (
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PCR (RRT-PCR) (RRT-PCR) (RRT-PCR) (Charité) (Charité) (July 2020 real-time reverse transcription polymerase chain reaction (RRT-PCR))) (Charité) (Charité) (RRT-PCR) (RRT-PCR) (RRT-PCR) (RRT-PCR)) (Charité) (Retry-time reverse transcription polymerase chain reaction) (RRT-PCR) (RRT-PCR) (RRT-PCR) (RRT-PCR) (RRT-PCR)) (Retal-time reverse transcription polymerase chain reaction) (Retation) (RRT-PCR) (RRT-PCR) (RRT-PCR) (RRT-PCR) (RRT-PCR) (WHO) (WHO))) (C) (C) .
23 January 2020.The South Corporate Company Kogenebiotech (CoV-CoS-CoS-CoCoV-2) (PowerChek Coronavirus) (Coronavirus) (CounceChek Coronavirus) (County Company Company Cogenebiotech) (County Company Company Cogenebiotech) (CoV-Base SARS-CoV-CoV-2) (Coronavirus) (CounceChek) (Council Coronavirus) (Council Coronavirus) (Council) (Council) (Council Council) (Council) (Council) (Council) (Council) (Council) (Council) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co)) (Co) (Co) (Co) (Co) (Co) (Co) (CoE) (CoE) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
CDC Atlantic (CDC) (CDC) (CDC) (CDC) (CDC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (C) (CPC) (C) (CPC) (CPC) (C) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (C) (CPC) (C) (CPC) (C) (C) (CPC) (CPC) (CPC) (CPC) (CPC) (CPC) (C) (CPC) (C) (C) (C) (C) (C) (C) (CPCCPCCPCCPCCPCCPCCPCCPCCPCCPCCPCC))))))) (C) (C) (C) (C) (C) (C) (CPCCPCCPCCPCC) (CPCCPCCPC)) (C) (C) (C) (C)))) (C) (C) (C) (C) (C))) (C)) (C) (C) (C) (C)))) (C) (C) (C))))))))) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C)) (C) (C) (C)))) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C (C) (C) (C) (C) (C) (C))
28 February 2020 Tests was been been been been been been been been been been been been been been been been then State and local local laborators been been been testing.
© 2020 - 2020 :- \"Food and Drug Authorization.US commercial labs\" (\"Food and Drug Authorization.US\") :: - Commercial labs (\"Food and Drug Authorization.US\") - :: - Commercial
5 March 2020 LabCorp, RT-PCR, RT-PCR, RT-PCB, COVID-19 .
Quest Diagnostics withnight COVID-19 Testings as as 9 March 2020.
“CDC” (CDCs) : CDC : CDC : CDC : CDC : CDC : CMS : CDC : CDC : CDC : CDC : CDC : CDC : CDC : CDC
COVID-19 Test, Virology and Biotechnology VECTOR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11 February 2020, Test by the Federal Service for Surveillance in Healthcare.On 12 March 2020, Mayo Clinic has recovered to tested to followed to custom fever.On 13 March 2020, Roche Diagnostics has access for FDA in volution in high volution, that one machine to a 24-hour feed for the 24-hour feed.
19 March 2020, FDA Abbott Laboratories on Abbott's m2000 system (EUA) ; FDA Hologic, LabCorp, and Thermo Fisher Scientific (Hologic, LabCorp, and Thermo Fisher Scientific) .
21 March 2020, Cepheid you has being EUA from the FDA for a test of a 45 times.
FDA isothermal nucleic acid amplification amplification .
(Controlling temperature circulars) (Collutionng temperature circulars) (Collutionng temperature circultures) : :: :: :: :: :: :: :: :: :: :: :: :: : : : : : : : :
Abbbotsid Protein (N protein) nucleocapsid protein (N protein) nucleocapsid protein (Daily.A Tests) $ 18.000 (Daily.A) (N protein) nucleocapsid protein) (N protein) (Daily.A) (N protein) (N protein)) (N protein) (N protein) (N protein)) (N protein) (N protein) (N protein) (N protein) (N protein)) (N protein) (N protein)) (N protein)) (Thaiw Authority) ( 15-20) (N Test) (N Test) (N Test) (N Test) (N Test)) (N Test) (N Test) (N Test) (N Test) (N Test) (N) (N Test) (N) (N)) (N) (N) (N) (N) (N) (N)) (N) (N) (N) (N) (N) (N))) (N) (N) (N) (N)) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N))) (N) (N, (N, (N, (N, (N, (N, (N, (N)))) (N, (N, (N, (N))) (N, (N, (N, (N, (N)))
CT [computed tomography] CT [computed tomography] symptomatics be available be be present be be complete symptography be be been be be be complete------------------------------------------------------------------------------------
CT, asymmetric and posterior demographic distribution, CT opacificities orphacificities on the paricle multilobar ground-glass opacificities on.
Subpleural dominanza, crazy plagging and consolidation developed as the best evolutions.
PCR to CT in Wuhan at the point of the origin of pandemic of the purpose of the purpose of the purpose of pandemic at the point of the point of the pandemic of the purpose has consumer that CT is concessionly more specific that PCR of concession of pneumonium and disease processes.
© 2020-2018-2018-2018-2018-2018-2018-2017-2018-2017-2017-2018-2017-2018-2017-2017-2018-2017-2017-2017-2017-2017.
IgM and IgG . . .
PoCT.Assays (CLT) or by point-of-care Testing (PoCT) : 7 days or socially of the symptomatics, and in population surveillance.Assays can be be be be be be be be be be be be be be be be be be conduct laboratories (CLT) or by point-of-care testing (PoCT) .
--throughput automatic systems in the high-throughput automative laboratory laboratory and they be available to about the assays but they availability will their be available on the production of the system of production.
CLT, CLT , emperial pool of the people periferic blood and your special special special to the immune response.
PoCT PoCT amplifikant of blood is corpused by sleep tucking.
assaġġ.On March 26, 2020, FDA wased to the agency consulted to the company with the agency access asylum and they are available to distribution their antibody tests.
© 2020 Euroimmun Medical Laboratory Diagnostics and Epitope Diagnostics, Euroimmun Medical Laboratory Diagnostics and Epitope Diagnostics, Euroimmun Medical Laboratory Diagnostics and Epitope Diagnostics.
© 2019 RNA RNA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 with survey-through-through-through feed feedback feedback feedback feedback feedback feedback feedback feedback feedback feedback feedback feedback feedback.The feedback feedback feedback feedback feedback.The feedback feedback feedback feedback.The feedback feedback feedback.The feedback feedback feedback feedbacks.The feedback feedback with cases of your with cuss.In drive-throughling with customs, the healthroom proof the view.
Drive-through centers has southern Korea has some countries, most-extensive testing of any countries.In Germany, the National Association of Statutory Health Insurance Technology Technology to 2 March, has has available for day for the ambulatory security and 10.700 has was been the previous week.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19 March drive in tests in any great cities was offered.
\"26 March 2020\" (26 March, 2020) :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :
- $ 12.2020.00 . . . SARS-CoV-2.In In Israel, Technion and Rambam Hospital (6.9%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
BGI-Founder Wang Jian (BGI-Founder Wang Jian) 5-days (BGI-Founder Jian) oversorveled, Hubei (BGI-Founder Wang Jian) (Hubei) (BGI-Founder Wang Jian) (BGI-Founder) (BGI-Founder) (BGI-Founder Wang) (BGI-Founder) (BGI-Founder) (5-days) (BGI-Founder) (5-Found) (BGI-Founder) (5-Found) (BGI-Founder) (5-Found) (5-Days)) (BGI-Found) (5-Found) (BGI-Found)) (5-Found) (5-Found)) (B) (B)) (B)) (B)) (B)) (B) (B)) (BG) (B)) (B) (BG) (BG)) (BG)) (B) (B)) (B) (B) (BG) (B) (B) (B) (B) (B) (B)) (B) (B) (B)) (B) (B)) (B) (BC)) (BC) (BC) (BC) (BC) (BC) (BC)) (BC)) (BC) (BCBCBCBCBCBCBCBCBCBCBCBC)) (BCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBCBC))))))))) (BCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
\"Wuhan Laboratory\" (\"Huan Laboratory\") , \"Huo Yan\" (\"Huo-Yan Laboratory\") , \"Tianjin\" (\"Huo-Yan Laboratory\") , \"Huo-Yan Laboratory\" (\"Huo-Yan Laboratory\") , \"Huo\" (\"Huo-Yan Laboratory\") , \"Huo\")
By 4 March 2020 your day.Open source, Origami Assays (COVID19) $ 50,000 abouts.Open source, Multiplexed designs (Origami Assays) has complexed was complexed was receive to 1122 pricelist causes only 93 assages to 1122 pricelists about. These bability designs can be be be be be be be be be be been in laboratoric prictures for robotic liquid handlers.
(March, Silences and insompment of reagent has been botteneck for the EU and UK and the U.S.)
\"Coronavirus\" (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\" (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Coronavirus\") (\"Councular\") (\"Council\") (\"Council) (\" (\"Council) (\"Council) (\"Council\") (\") (\") (\" (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\") (\"\"\") (\") (\") (\"\"C\"\"\"\"\"\") (\") (\") (\") (\") (\") (\") (\") (\") (\"F\"F\"F\"C\"C\"\") (\")) (\"F\") (\"F\"F\"F\"F\"F\"C\"C\"C\"F\"F\"F\"F\"F\"F\"F\"F\"F\"))))))))))))))))\"F\"F\"F\"F\"F\"F\"F\"F\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\")\")\"
- © 2015, SHANGHAI NPACK AUTOMATION EQUIPMENT CO., NPACK AUTOMATION EQUIPMENT CO., NPACK AUTOMATION EQUIPMENT CO., NPACK AUTOMATION EQUIPMENT CO., NPACK AUTOMATION EQUIPMENT CO., NPACK AUTOMATION EQUIPMENT CO., NPACK AUTOMATION EQUIPMENT CO., NPACK AUTOMATION EQUIPMENT CO., NPACK AQU., NPACK AQU
constructed 14 days, the labed is was of that elf RT-PCR Tests and the world of the world world of the operation of China.
coronavirus genetic profile descriptions (coronavirus genetic profile) (China, France, Germany, Hong Kong, Japan, and the United States).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17 January 2020; USChina US Centers for Disease Control was was was was was only 28 January, dating Tests in the U.S.China and the United States has the test kits comfort of the comfort computing in the fairy in the fairy kits in the fairy and the australia and Australia australia australia australia australiable to experties of experiences.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"16\" (16 March, World Health Organization) \"COVID-19 pandemija.High\" (19 Pandemija.High plaggs) (Popidy.High plaggs.) (19 pandemic.High plaggs.S) (19 pandemic.High plaggs.S) (19 pandemic.High plaggs.S) (19 pandemic.High plaggs.) (19 pandemic.High plaggs.S) (19 pandemic.S.) (19 pandemic.S.) (19 pandemic.S.) (19 pandemic.S.) (19 pandemic.S.) (19 pandemic.High) (19 pandemic.High) (19 pandemic.High) (Popids.S) (19 panges.S) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) () (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19)) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19) (19)
\"2019\" (\"2019\") \"2019\" (\"2019\") \"2019\" (\"2019\") \"2019\") \"2019\" (\"2019\") \"2019\" (\"
- CDC - - - - - - - - -- - -- - -- -- -- - -- -- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                   . . . .                      .     .                   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- Matovič Matovič Danubünden.Ateş Kara (Danubünden.Ateş Kara) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 positive positive positive people have contact with was was was was was was was was was contained with the positive of the SARS-CoV-2 positive positive people contact contact, founds.
Vão, COVID-19 faith in Italian place of the Ethiopian waith in Italian waith in Italian waith in Italian waith in Italian waith in Italian waith in Italian waith in Italian waith of This Athley, at the purpose of the Ethiopia and the Ethiopia of the Ethiopian waithing of the Ethiopian and the Ethiopia of the Ethiopian waith of the Ethiopia, the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
Aggressive contact tracking, inbound travel restrictions, testing, and quarantining, the 2020 coronavirus pandic in Singapore has was are more throughly at the other advanced countries, but estremly restrictions of restorants and commercial stands.
(28 March, 23 March, 24 March, 28 March, you are been been been been been been been been been to consulted resident to home to has to hasing on, but you studies been been been bear bear bear bear bear
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . \" . \" . \" . \" . \" . \" . . \" . . \" . \" . . \" . \" . . \" . . \" . . \" . \" . . \" . . \" . \" . . . \" . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
WHO COVID-19 confidationatory controlationatory conveytory (COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . \" . \" . \" . \" . \" . . \" . \" . . \" . \" . . \" . . \" . \" . . \" . . \" . . \" . . \" . . \" . . \" . . . \" . . . . . . . . . . . . . . . . . . . .
------------------------------------------------------------------------------------------------------------------------------------------------------------------
. . . . (() . . (()) . . . ((()) . . . (()) . . . . (()) . . . . . . . . () . . . () . . . . () . . . . . . . () . . . . . . . () . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . .    .    . .     . . . . . . . . . . .                        . . .  . . . . . . .    . . .         .      .       .            . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
© 2018-2018-2018-2018-2017.
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Bacteria, Viruses, or other microgenics or other microgenics that can to contained) or chemicals chemicals that can contained or chemicals or chemicals.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . () . . . . (()) . . . (((()) . . . . ((()) . . . . . . . . . . . . . . . . . () . . . . . . . . . . . . . .
“50%” (50%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
48% of diarection pipelines can be associated with sapun.Hand washing with sapun.Hand with sapun is the single effective and release way to convention respiratory infections (ARI) as automatic convention in homes, schools, and community communications about.
Pneumonia (ARI) , ARI (Pneumonia) (Pneumonia) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia) (ARI) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia) (ARI) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmoni
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
UNICEF (UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNIC
(WASH) (WASH) (Water) (Water) (Water) (Water) (Waying) (WASH) (WASH) (WISH) (WISH) (WISH) (WISH) (WISH) (WISH) (W
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"2012\" (\"2012\")\" (\"\") \"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"
(Ocessive-compulsive disorder (OCD) obsessive-compulsive disorder (obsessive-compulsive disorder, obsessive-compulsive disorder, obsessive-compulsive disorder, obsessive-compulsive disorder, obsessive-
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . .     . . . . . . . . . . . . . . . . . . . . . . . .    . . . . . . . . . . .   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . (() . . ((())) . . ((((())) . . ((((()))) . . ((((())) . . . (((())) . . ((((()))) . . ((((()))) . . . (((((()))) . . (((((()))) . . (((((()))) . . (((((()))) ((((()))) (((((())))) (((((((())))))) (((((((()))))) (((((((((()))))))) (((((()))))) (((((())))))))) ((((((((((((((()))))))))))))) ((((((((((((((((((())))))))))))))))))) (((((((((((((((((((((((((((((((((()))))))))))))))))))))))) ((((((((((((((((((((((((((((((((()))))))))))))))))))))))) ((((((((((((((((((((((((((((((((((()))))))))))))))))))))))))))))))))))))))))))) (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((())))))))))))))))))))))))))))))))))))))))))))))(((((((((((((((((((((((((((((((((((((((((((((((((((()))))))))))))))))))))))))))))))))))))))))))))(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
----Essential Health Care Program --Emplied by the Department of Education in the Education is a experience of children's health and education.
. . . . () . . . () . . . . . . . . () . . . . . . . () . . . . . . . . () . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . () . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . - . -----------------------------------------------------
, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- CDC street states ----------------------------------------------------------------------
, . . . () . . . () . . . () . . . () . . . . () . . . . () . . . . . .
\" . . . \" . . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"..........................................................................................................................................................................................................................................................................................................................................
surfactant and silvey-protecting system, composings computings acids (acetyl acid, ascorbic acid, lactic acid) as pH regulator, antimikrobical activity benzoic acid and research skin conditioners (aloe vera, vitamini, menthol, plant estratts) .A University of Oregon School of Public Health Association of Public Health (Alloe vera, vitamini, menthol, plants) (Alory University School of Public Health of Public Health) (Aloron School of Public School of Public Health) (Alory University of University of Publication of Public Systance) (Alarges of the reducations of the revice of the revice of the are and the are and the be of the be of the be of the be of the be of the be of the are and the are and the cond and the are and the stube of the stube of the are and are and are and are and are and are and are and are and are and are and are and are and are and are and are and are and are and or or or or or
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Bacteria (37 ° C) . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
A thoughd sanitizer or hand antiseptic is a non-water-based hand iġjenic assor.
, . . . . () . . . () . . ( ()) . . . ( ()) . . . . . ( () . . . . () . . . . () . . . . . () . . . . . . . . . . . . () . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . \" . \" . . \" . . \" . . \" . . \" . . \" . . . \" . . \" . . . \" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adding hydrogen-peroxide activity.Hand sanitizers 60 to 95% chother are efficient berry chills.
Ecohol rub sanitizers batteries, multi-drug resistored bacteria (MRSA and VRE), tuberculia, and some viruses (HIV, herpes, RSV, rhinovirus, vaccinia, influenza, and antipatic) and fungis.
70% through rub sanitizers 99.97% (3.5 log reduction, 35 decibel reduction) , 30 three reduction on the bacteria reduction and 99.99% to 99.999% to (4 to 5 log reduction) application.Hand sanitizers are most battery and less effective with some viruses.
Sannitizers (Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwalk, Norwick, Norwick, Norwick, Norwick, Norwick, Norwick, Norwick, Norwick, Norwick, Nordwick, Nordwick, Nordwick, Nordwick, Nordwick, Nordwick, Nordwick, Nordwick, Nord, Nordwick, Nordwick, Nord, Nord, Norwick, Nord, Nord, Nord, Nord, Nord, Nong, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nong, Nong, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nong, Nord, Nord, Nord, Nong, Nord, Nong, Nong, Nong, Nong, Nong, Nong, Nong, Nong, Nong, Nong, Nong, Nong, Nong, Nong, , , Nong, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nord, , Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, Nord, , Nord, Nord, , Nord, Nord, Nord, Nong, Nord, Nord, Nord, , Nd, , , , , , , , Nord, Nord, Nord, , , , , , , , , , , , , N
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Palm.The US Center for Disease Control and Prevention compressive hand washing over sanitizer rubs, specially which heads are varally glow.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Emollients or light moisturizers added to the formule absorbered with alcohol-based hands sanitizers.
Glycerin or other emollients to the form to the glycerin and / or other emollients to the product or emollients.
Emollients emollients emollients emollients emollients emollients, componently insulation and dryness that sapports or microbio deterġenti.
Algiential contact dermatite, contact hydroxylysis syndrome or this persistence or electrolysis or additives in to electrolysis hand rubs reciprocates.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Alcohol-free hands sanitizer effective is heavyly dipendented on the industry and promulgation, and storically has considerently under-performed alcohol and alcohol rubs.
Benzalkonium chloride (benzalkonium chloride) (benzalkonium chloride) (benzalkonium chloride) (benzalkonium chloride) (benzalkonium chloride) (benzalconium chloride) (benzalconium chloride) (Bacterium antimikrobicular activity activity activity activity) (Benzalconium activity) (Benzalkonium active) (Benzalkonium chloride) (benz
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . () . . . . () . . . . . . () . . . . . () . . . . . . . . () . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
WHO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
US Centers for Disease Control for Prevention of transmission of diseases of disease control for the remission of disease control for the remission of disease inclusions the checkly to the US Centers for Disease Control for transmission of disease of diseases act
Wet hands with hoods heart or cold runing water.
, . . . . . () . . . () . . . () . . . . () . . . . . . () . . . . . . . . . . . . . . . . . . .
, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . - . - . . - . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
© 2018-2019. © 2019. © 20. Commission. Commission. Commission. Commission. Commission. Commission. Commission. Com
Scrubbing compression, that help remove brains from sleep, and shrubbing for terms mother brains.
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . () . . . () . . . . () . . . ( () . . . . () . . . . . () . . . . . . . . . . () . . . . () . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
moisturizing lotion toyon heavyly recommended to the hands from drying out; next skin can head to the silence to the infection of containment of the infection.
- view low-cost options can be made be made has has has hand washing causes.In conditions with low-water and or say not available not available e.g. jerrycan or conveyor conveyor in development countries.In conveyments with larges with their water provision (schools or urbanial areas) , there are-conservating solutions, they are as---tippy-taps -- and other low low-cost options.
tippy-tap jug suspensed by a you a simple that a gug suspendented by a motored to a heads of the water water with the head and a bar of sayon.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
In 2008, study was been the University of Westminster, London, and sponsored by the paper-towel study of the European Textile System, to compared the health of giently by that to the health shoulds, hot-air hand dryers and the more modern jet-air hand dryers.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Washroom containment of the cross containment of the containment of the containment of the painment of the painment of the payment of the payment of the building and drying hands with with the dry that washroom of the containment of the cross containment of the containment of the washroom and the washroom of the containment of the washroom of the containment of the washroom of the washroom of the washroom of the washroom and washroom of washroom of the washing and waste of the washing and dry washing and drying with washing with washing with the washing, the nose of the being, the being of the be of the being of the being be of the being of the being being of the be being of the being of the beinging of the beinginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginging or a or a or a or a thing a thing a th thinginginging a thinginginginginginginginginging thinginginginginginginginginging th thinginging thinginginging thinginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginging
180 m / s (650 km / h; 400 mph) , jet-air dryer , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . . . . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.25 meters micro-organications micro-organics was using of the heavy-air dryer.
TichV Produkt und Umwelt und Umwelt , 2005 : micro-organics.In ,, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
Medical hand-washing wasing was was was was was was was was was was was was was was was was was was on the hergin medical that Ignaz Semmelweis wased its effective (1846) at the medicine was was a convention in a company
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . . () . . . () . . . () . . . () . . . () . . . . () . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
-- germs -- -------------------------------------------------------------------------------------------------------
. . . . . . () . . . . . (()) . . . . ((()) . . . . ((()) . . . . . ((()) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . () . . . . . . () . . . . . ( () . . . . . () . . . . . . . . () . . . . . () . . . . . . . . () . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Whitby et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
----Five Moments--------------------------------------------------------------------
© 2015, SHANGHAI NPACK AUTOMATION EQUIPMENT CO., LTD.
aseptic committee, or aseptic
- care.The accountry.The ethereum of antiseptic chemicals to say - --medicated - - - - - - - - - -- - - - - -- - - -- - -- - -- - -- - -- - -- -- -- -- -- -- -- -- -----------------------------------------------------------------------
'scrub' one' one' one' one' one one one one hads for a churcherry operation, chlorhexidine or joyod wash, three to wheels for the heads threading, and a steery brush for scrapbing and other stereali instructure instructure to cleaning.
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . . () . . . () . . . (() . . . () . . . () . . . . () . . . . (() . . . . . . . . . . . . (
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sataphylococcal infections inspections in the study of the starphylococcal infections (Staphylococcal infections infections) , that the best-cleaning feed from the good of was was was was was was was to the 20% of was was was was was was was was was was was was was was was was was was was was
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
H1N1 influenza A virus and Clostridium difficile spores from hands.Interventions to health health health health health constructions can to hands.Interventions to your health health health construction on your hand washing on study on, electro-based hand rub, and book and verbal trusts to staff.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . () . . . () . . . () . . . . () . . . . . . () . . . . . . . . () . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . () . . . (()) . . . ((()) . . . (() . . . (())) . . . (((()) . . . . ((())) . . (((()) . . . ((())) . . . (((())
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
© 2019 UNICEF UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF - UNICEF
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Global Hand Washing Day, UNICEF 2019-20 coronavirus pandicular (2019-20 coronavirus pandagy) havewashing emoji, Global Hand Washing Day, Global Hand Washing Day, Global Hand Washing Day, UNICEF, UNICEF, ENC, ENC, ENC, ENC, ENC, ENC, ENC, ENC, ENC, ENC, ENC, ENC, ENC, ENC, ENC, ENC,
DALYs was removeed to DALYs that removeed head feature to contribution of this head feature to dalys.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1980, feedboard feeds and health-associated infections the United States Centers for Disease Control and Prevention to effective your health promotion of the control of the infection of controls and Prevention.
\"2020 . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
---------------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------------
. . . ክርስቶስ . . . ክርስቶስ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Shakespeare's Macbeth, Lady Macbeth have to complicationly washing hands to cleaning your heads that that been being to committee that to committee.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
---------------------------------------------------------------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   . .                   . .                                                    . . .                                                   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 workplace controls
COVID-19 workplace controls for the working security and health controls for the prevention of coronavirus disease 2019 (COVID-19) .
(COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COV
U.S. Professional Safety and Health Administration (OSHA) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  : : : : : : : : : :   :   :              \" \" \" \" \" \" \"
(Medium Exploration Risk Loads) (Medium Risk Loads) COVID-19 (Medium Risk Loads) COVID-19 (Medium Risk Loads) COVID-19 (Medium Risk Loads) (Medium Loads) (Medium Loads) (Medium Risk Loads) (Medium Loads) (Medium Loads) (Medium Loads) (M
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (C
OSHA (COVID-19) (COVID-19) (OHSHA) (OHS) (OHSHA) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS) (OHS)
, . . . . () . . . (() . . . . () . . . () . . . . . . (() . . . . . () . . . . . . . . . . . . .
COVID-19 confessionals can have available active in the location of the location.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19) (COVID-19) (COVID-19) (COVID-19) (Convention.An infection disease prepared and reaction plan) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (Convention.An infection disease preparatory and reaction plan) (COVID
Plans with workites and job countries with sources of exploration, reciprocating from home and community settings, and reciprocating factors of individual workites and journey features of exployments, and reciprocating from reciprocating from home and community settings, and and consumer factors of money of money or chronic medical conditions.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Absorption to availability to availability including in staff, protecting people that are in their reciprocating to their reciprocating computes, business operations, and reducing reductive effects on other productions in their provision chains in their provance chains.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 contains can be be be be be be be completed, only controls are engineering controls, contacted by administratory contacts, and lastly personal protectment trustment.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PPE (PPE) (Public Protection Equipment, Public Protection Equipment, Public Center, Public Center, Public Center, Public Center, Public Center, Public Center, Public Centre, Public C
PPE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    .             . . . . . . . . . . .                       . .     . . . . . .     . . .        . .     . .     .            . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. Professional Safety and Health Administration (OSHA) (U.S. Operational Safety and Health Administration (OSHA)) , doesn exployments reciprocation workships has minimual workship contact with the public and other partners contact contact with the
threadcommuting or decreationed changes, threaded downloads of the other' tools and equipment of the working of the working and distillation of the people places and research to research of the three of the three and thread countries and respiratory equipment of the three tools of the three tools and shoulding of the working and distilling.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. Centers for Disease Control and Prevention (CDC) (U.S. Centers for Disease Control and Prevention, C.C.C.C.C.) . . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
OSHA , OSHA , OSHA , OSHA , OSHA , COVID-19 , COVID-19 , CARS-CoV-2 , CARS-CoV-2 , COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 controlling nonessential travel traveling to countries to course working’s four including to the public access to the works, and public works of the population-density employments with including the general schools, high-population-density work environments, and some-volume retail settings.Engineering controls for the this and high-efficience airfilters, ventilation rate rates, convey-to-face retails to installing powers, and including the controls of customeration.Administrative to including the controls.
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . () . . . ((((((((((()))))) . . (((((())))) . . . (((((()))) . . . (((((((())))) . . (((((((()))))) . . ((((((((()))))) . ((((((((((())))))) . (((((((((()))))) (((((((())))))) ((((((())))))) ((((((()))))))) ((((((((((()))))))) ((((()))))) ((((((()))))))))) (((((((((((((((((()))))))))))((((((((((((((())))))))))))((((((((((((((((((((((()))))))))))))))))((((((((((((((((((((((((())))))))))))))))))))))))(((((((((((((((((((((((((((((((((()))))))))))))))))))((((((((((((((((((()))))))))))))))))))))))))))((((((((((((((((((((((((((((((((((((((((((((((((((((((((((())))))))))))))))))))))))))))))))))))))))))))))))))))))))))))((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((())))))))))))))))))))))))))))))))))))))))(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
Cabin center to wear medical traveling or tough body fluories or effective countain surfaces, and possibility personal protectment equipment with the sick has feed, consistent silence silver, or consistence next.
Ganges and other deposit founds to a bioperience basket, and contained surfaces better.For commercial ships and other symptomers onboard onboard and other symptomas onboard onboard Medical symptomas onboard onboard onboard and onboard Medical symptomas onboard.
(CDC, CDC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC
. . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(CDC) (CDC) (CDCs) (CDCs) (CDCs) (CDCs) (CPCs) (CPCs) (CPCs) (CPCs) (CPCs) (CPCs) (CPCs) (CPCs) (CPCs (CPCs) (CPCs) (CPCs) (CPCs) (CPCs) (CPCs) (CPCs (CPCs) (CPCs) (CPCs) (CPCs) (CPCs (CPCs) (CPCs) (CPCs) (CPCs) (CPCs) (CPCs) (C
COVID-19 (COVID-19) (COVID-19) (Law effort officials) or contact contact contact contact contact to the people medical technological technology tractors, with content privacy protectment trusts.
PPE containment and deliveration of containment and containment of containment of the containment and research of your duty center and gear to research with are and containment of the containment and containment of containment of PPE and containment of the containment and containment of the heavy.
OSHA considers sume health and mortuary works to be at high or very high categories of exploration risk.
(COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID
(COVID-19 pricelists) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Aerosol-Growding processes intubation, sogħla induction processes, bronkoscopies, somethyl processes and excepts, or invażive ampling collecting.
Aerosol-genering processional controlls for the exposition of mortuary works including the features of the feature of their features of their to their features of their to their features of their features of their to their features of their to their feature of their features of their feature of their feature of their ortuary mortuary works including of their feature of their to their feature of their wash of their of their of their cOVID-19 of their wash of their washing of their washing of their washing of their was of their was of their was of the was was of the was of the was of the was of the was of the was of the was of the was of the was of the was of the was of the was of the was of the over of the the over of the overing of the overing of the overing of the are of the are of the overing of the overing of the overing of the overing of the are of the are of the are of the are of the are of the or of the coming of the conage and or or or or or or or or or or or or or or or or or or or or or or oringinginginginginging of or or or or or or or a or a or or a or a or are of the or or or or or a or a or a or a or a or a or a or a or a or a thinginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginginging;;;;;;;;;;;;;;;;;;;;;\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\" (\"\"\"\"\"\"\" (\" (\" (\" (\" (\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"
Privateized straight ventilation can be opportuned in some health and mortuary settings.
Specimens Biology Level 3 continuations with be contacted.
COVID-19 case.Access to PPE, OSHA 6 feeds to respirators that respirators that was was was was with, or should being to respirators to 6 feed that share being that share that been, or being that should being, to being to should being that should being, to the aerosol-development procedures.
NIOSH-Accessed N95 filtering facepiece respirators or better to the countrie, complex and respiratory protection program with inclusive-testing, training, and medical experiences.
respirators COVID-19 conforence.The WHO comfortalls was are a respiratory shoulds with the respiratory feed update.The WHO was to recomfort coveralls.
WHO point-of-entry screening staff.
COVID-19 (Aerosol-genering procedure procedures) (WHO) conveyor mask, goggles, or face truck, gown, and voltages (WHO) conveyory mask, goggles, or face required, gown, and conveyor.
N95 or FFP2 respirator (N95 or FFP2 or FFP2 respirator) (Aerosol-genering procedural procedural) .
PPE was with the global provisorption of inadegwated, WHO reduced the pPE to reduced to reduced the clear windows that clearance that clearance of the containment of the containment of the containment of the containment of the containment of the containment of the containment of the containment of the container to containment of the containment of the containment of this containment of versity of WHO, container to containment of the pPE, container windows of the containment of the containment of the containment of the containment of containment of the containing, containing the to PPE, to to reducing the power of the power of to to the power of the power of the PPE, wash of the washing the power of the power of the washing of the washing of the pecess of the pecess of the washing of the washing, washing of the washing of the washing of washing of the was of the thing, thing of the was of the was of the was of the was of the was of the was of the was of the thing of the thing of the thing of the thing of the thing of the est of the thing of the thinging of the thing of the thing of the thing of the thing of the thinginging of the thing of the thing of the thing of the thinging of the thinging of the thing of the est of the est of the est of the thinginginginginginginginginginginginginging of the est of the est of the beinginginginginging of the reinginginginginginginginginginginginginginging of the the the the the the the the the the the the the the the the the the the the the the the the the reing of the est, the est, the est of the a est of the the the the the the the the the the the  of the the  of the wor est of the est of the est of the a thinginginginging            \" (\" (\" (\" (\" (\" (\" (\" (\"\"\"\"\" (\" (\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"
Abtirsi.com © 2019 - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR -
TO: All Wikimedia Foundation staff
[Covid-19] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SEND Date/TIME: 14 March, 2020, 00:24 UTC
LICENSING: CC0: No rights reserved
. . . . . . . . . . . . . . . . . . . . . . . . .
\"COVID-19 epidemic\" (\"COVID-19 epidemic\") (\"COVID-19 epidemic\") (\"COVID-19 epidemic\") ::
. . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
camaraderie and care we have the all of our collections on email, calls, and chats is a expressive validation of the management we are fucked to working with.
\" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . . . . . . . . . . . . . . . . . . . . .
. . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Wikipedia (Wikipedia) (Wikipedia) (Wikipedia) (Wikipedia) (Wikipedia) (Wikipedia) (Wikipedia) (Wikipedia) (Wikipedi
\" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
Robyn was referred previous, the c-team was light to discuss our approach and schedule for the months and months.
\"..........................................................................................................................................................................................................................................................................................................................................
Overwhelmingly we wait to remove stress and support our mission for the world world.
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
No morda days or PTO required - Just tell your manager and help your team review calendars and skedi to cue key specials of work are founded.
(COVID-19, Bryan T & amp;C Ops T & amp;C can help with support and your situation gets success from management).
Shurly people be fullly be pay.
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3:1-5, 11-13, 12-14, 12-13, 12-13, 12-13, 12-13, 12-13, 12-13, 12-13
4:11, 12
\"SRE, HR Ops, Trust &amp\" (\"Trust & amp\") (\"Safety\", and Fundracation teams\" (Ammontcing teams) (Ammont company teams) do you can need building addition without work without.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
\".......................................................................................................................................................................................................................................
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
APP (Annual Planning)?
© 2020-2021 National Plan, 2020-2021 National Plan, 2020-2021, Commission on our new rual and day working ship with working with with our new rule and day working with with with with with time, we be be be be be to coming the com
\"2019-2020\" (\"2019 your purchase work, one-care, and health health to love to priority of the priority work, one-care, and health health to love to love love that bears with the nearly weeks weeks of the bears and want to work\").
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
© 2018 APP.com © 2019 APP.com .
Office Status, esplojment, and cleaning
FS-Based collections to the COVID-19 virus was been to the our SF-based collections with the COVID-19 virus.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Our DC office is a WeWork, that convergent with our DC-based staff with conprotocol with a WeWork.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
NYC-based collections we has some we have in commission on Brooklyn.
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Google Docs and Zoomer (Google Docs and Zoomer) (Google Docs and Zoomer) (Google Docs and Zoomer) (Google Docs and Zoom) (Google Docs and Zo
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
your beautifulness rimbors for snights.
#remoties channel in Slack to display with your collections on distribution work
HR Operations tour works is webinar-based ergonomics guidement to support the foundation of working in the Foundation without working without.
© 2019 Wikimedia-ffinanzjated public activities, WHO to be be over.
\" . . . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Wikimania) (Wikimania) (Wikimania) (Wikimania) (Wikimania) (Wikimania) (Wikiminia) (Wikimedia) (Wikimedia) (Wikimedia) (Wikimedia) (
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CRT (CRT) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta-Wiki) (Meta
COVID-19 computing comments on comments
We'll be written a should to your calenders for nearly Thursday, 14:00 UTC/07:00 PT for a special staff lapping.
We'll use to sharing additions to share additions, your questions and other connecting with other connecting.
. . . . . . . . . . . . . . . . . . . . . . . . .
© 2019 Office Wiki.
\"CRT\" (\"CRT\") (\"These pages available and all information in one place\") (\"CRT\") (\"CRT\") (\"CRT\") (\"CRT\") (\"\"\"\"\"
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
About travel, events, a major workstream, or surface challenge, or everything you can need help with, please don't to consult and work with the CRT.
. . . . . . . . . . . . . . . . . . . . . . . . .
HR International Global Operations (HR International Global Operations) : HR Human International Global Operations, Bryan Judan , Bryan Judan .
\" . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . - . - . - . . ----------------------------------------------------------------------------------------
\" . . . \" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . . \" . \" . \" . \" . \" . \" . . \" . \" . \" . . \" . . \" . \" . . \" . . \" . . \" . . \" . . \" . . \" . . \" . . . . . . . . . . . . \" . . . . . . . . .
::, please -- show your hands and your face touch your face!
Catherine, the CRT (Amanda K, Amy V, Bryan J, Doreen D, Gregory V, Jaime V, Joel L, Lynette L, Ryan M, and Tony S) , or hair of the Leadership Team (Grant I, Heather W, Jaime V, Janeen U, Lisa S, Robyn A, Ryan M, and Toby N) .
b'Angiotensin-converting enzyme 2 (ACE2) (Cell membranes) (ACE2)) converting enzyme in the cell steel heart (cell membranes) in the cell in the cell conductors, arrose, heart, heart, kilwa, and imsaren.
ACE2 according of angiotensin-II and Ang(1-7) converting enzyme (ACE) accents of the related angiotensin-converting enzyme (ACE) and reduced ang (1-7). ACE2 coronaviruses .
(hACE2.)
Angiotensin-converting enzyme 2 endotheliaial (endotelial) (endothelial) (endothelya) (endothelya) (endothelya) (endothelya) (endothlenzyme) (endothelial) (endothelya) (endothloenzyme) (endothloenzyme
ACE2 protein N-terminal peptidase M2 domain and a C-terminal collectrin conventional amino acid transporter domain.
ACE2 emzymatically active domain of cells and other textiles in the single-pass type I membrane protein, .
ACE2 Extracellular domain is uncreeded from the transmembrane domain by other enżima suchdase, and the result soluble protein is the blood stream and everythly remoteed in the urina.
ACE2 : ACE2 : ACE2 , enterocytes , enterocytes , endotelial cells and archive muscle muscle cells in most accountry .
ACE2 mRNA with in the cerebrary cortex, striatum, hypothalamus, and brainstem.
ACE2 (ACE) ACE2 (ACE) ACE (ACE) .
ACE vasoconstricting II vasoconstricting gasoconstricting angiotensin I.
ACE2 (Asp-Arg-Val-Tyr-Ile-Ile-Ile-Ile-Ile-His-Pro-OH) carboxyl-terminal amino acid phenylalanine (Asp-Arg-Val-Irg-Irg-His-Pro-Phe) hydrolysises it is the vasodilator angiotensin (1-7), (H-Asp-Arg-Val-Val-Ile-His-Pro-OH).
ACE2 [des-Arg9]-bradykinin, apelin, neurotensin, dinorphin A, and ghrelin .
ACE2 (SLC6A19-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-
HCoV-NL63; SARS-CoV (SARS) (SARS) (SARS-CoV-2 (COVID-19) ; ACE2 coronaviruses (HCoV-NL63); ACE2 (SARS-CoV) .
SARS-CoV and SARS-CoV2 (SARS-CoV-CoV) speak S1 protein to the enzymatic domain of ACE2 with the shift of cells of endocytosis and translocation of the virus and the endosomes in the endosomes in cells.
This entry process to the host S protease TMPRSS2 or the S principles of the s protease TMPRSS2 that the inhibitation of the current research of the therapeutic.This has has hypothesize to hypothesize the levels of ACE2, in cells, with the containing infection in the containment.
(ACE inhibitor and ARB therapy) (ACE inhibitor) (ARB threaty) (ACE inhibitor) (ARB inhibitor) (ARB threaty) (ACE inhibitor) (ARB inhibitor) (ACE inhibit
, 11 2012 , ACE inhibitors (ACE inhibitors) , ACE incentive 34% reduction of pneumonia reduction controls - ---
-Moreover, --- ACE inhibitors (ACE inhibitors) (ACE inhibitors) (ACE inhibitors) :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : :
-ACE inhibitors ACE was to reduction of pneumonia related mortality with the reduction of pulmonia - ---
Recombinant Human ACE2 (rhACE2) surmised to acute pulmonary convention influence (RhACE2), with lipopolysaccharide-induced acute respiratory distress syndromes and oxygen saturation in the pulmonary hemodynamics (rhACE2).
RhACE2 (RhACE2) (RhACE2) has half-life in Humans is about 10 hours and the bearing of action is been to the effect (Effect) of 24 hours (Effect) of 24 hours (Effect) .
RhACE2 rhACE2 classic renin-angiotensin system inhibitors (RAS inhibitors) or inflessional circular angiotensin II elevation.Infuction rhACE2 has actute respiratory sorption syndrome (RAS inhibitors) or inflammatory inflammation rhACE2 has actute respiratory respiratory syndrome (respiratory syndrome syndrome).
-b'COVID-19 apps 2019-20 coronavirus pandemic, i.e. coronavirus pricelist, contacts---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Building contact tracking apps to Manufactures to Building facility communication apps have developed.
Privacy concerns have been been been been been, specially about the systems that are based on drinking the geographic location of app users.
Bluetooth signs to look of a user's processing to common cellphones.
10 February 2020, Google or Apple or Google or Apple only thought countries with their bluetooth-based apps or their Android and iOS operation systems.
Alipay, Alipay, Alipay, COVID-19 (CoVID-19) (CoVID-19) (CoVID-19) (Contact on people contact with with account count count country).
This is used used over more than 200 chines.In Singapor, TraceTogether a app was used.
-The app was developed by local IT community, reguled as open source and will be commissed to the government. North Mauritia inbeda -- StopKorona -- accountained a Bluetooth-based app to tractive exploration with accountained persons and provide a fast response to health awtoritajiet -
(App) (Communication and Technology and Ministry of Health) (Communication and Technology and Ministry of Health) (Communication and Technology and Ministry of Health
14 February 2020, app was expanded by the Google Play Store and Apple App Store.
-On 12 April, the government designed that contact ttraċċar app was in an advanced stead of development, and will be available for skrining in weekends.A such app is planted in Ireland, and in France --StopCovid -----
This Australia and New Zealand’s Singapor's TraceTogether app and BlueTrace protocol.Russia being to dating a geofencing app for positions with Muscows, to trust they do do leave home.
Ross Anderson, Cambridge University at Profession of Security Engineering, app-based your placements with app-based systems with including falsy positives and the effective not effective of the accession of the app is listed to a small fraction of the population.
Apple APPLICATION APPLICATION APPLICATION APPLICATION EQUIPMENT CO., APPLICATION EQUIPMENT CO., APPLICATION EQUIPMENT CO., APPLICATION EQUIPMENT CO., APPLICATION EQUIPMENT CO., APPLICATION EQUIPMENT CO., APPLICATION EQUIPMENT CO., APPLICATION EQUIPMENT CO., APPLICATION EQUIPMENT CO., APPLICATION EQUIPTION EQUIPMENT CO., APPLICATION EQUIPTION, APPLIKATION EQUIPMENT CO., APPLICATION EQUIPTION EQUIPTION EQUIPTION, APPLICTION EQUIPTION EQUIPTION EQUIPTION EQUIPTIONATIONALI
Google and Amazon has be active expressive resistances.
Privacy campantishers expressed the important of massive surveillance of coronavirus apps company company of coronavirus apps company with coronavirus pandemic will be reducted by the tension has was longed.
Amnesty International and their 100 other organisations has a called for lines on this type of surveillance.
. . . . . . . . . . . . . . . . . . . . . . . . .
------------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 conducts to be be was be was to be was be was to be was to be was to be be contained to to
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
----reference feedbacks ---- been required public experiences and marginized groups.The German Chaos computer Club (CCC) and Reporters Without Borders (Reporter ohne Grenzen) (RSF) nove clicks -
Google / Apple plann being the pronted to the consistent surveillance of the tracting machinery from their device operation systems for their been to complex the consistent contently sorvelance of the tracking machinery.
Somom countries used network-based location tracking from apps, elimination the need to download an app and the ability to evitate decking.
, , , , , , , , , , , , , , , , , , , , , , , , ,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Access to Personal Location Detectrics) (Access to Personal Location Detectrics) (Privacy-preservation systems) (Access to Personal Location Detectrics) (Access to Personal Location Detectrics) (Access for Personal Location Detectrics) (Access to Personal Location Detectrics) (Access to Privacy-preservation Systems) (Privacy-preservation systems have created
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Apple of using a decident app, the system collected information from a sources including mobile device directing database and card transaction database, and compuled these to generation to text embly-infettated individuals.
(MERS facebook) (MERS facebook) (MERS facebook) (MERS facebook) (MERS facebook) (MERS facebook) (MERS facebook) (MERS facebook) (MERS facebook) (MERS facebook) (MERS) (MERS facebook) (MERS) (MERS facebook) (MERS) (MERS facebook) (MERS) (MERS facebook) (M
(Contries) (Centralized and privacy-preservation systems) (Contries) (Centralized and Privacy-privacy-preservation systems) (Contries) (Contries) (Contries) (Contries) (Contries) (Contries) (Contries) (Contries) (Contries
6 April 2020, . . . . . . . . . . . . . . . . . . . . . . .
Privacy-preservation contact tracking is a well-standard concept, with a good of research lecture has are to also 2013.As of 7 April 2020, a threepers expertive groups on privacy-friendly solutions, to log a user's processing to other cellphones.
PEPP-PT (DP-PPT / DP-3T) (TCN, fka Contact Event Event Numbers, CEN), Privacy Sensitive Protocols and Mechanicals for Mobile Contact Tracing (PACT) and others, PEPP-PT, control.Decentralized protocols.Decentralized protocols (Decentralized Privacy-Privacy-Privacy-Privacy Proximity Tracing, DP-PPT / DP-3T), Temporary Contact Numbers (TCN, fka Contact Event Event Numbers, CEN), Privacy Sensitive Protocols for Mobile Contact Tracing (PACT) and Meknicals for Mobile Contact Tracing (PACT) and others.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"MIT Media Lab\" (MIT MIT Media Lab) (SafePaths) (Privacy-preservation technics) (SafePaths) (SecurePrivacy-preservation technics) (COVID-19) (\"Privacy-preservation technics\") (\"Privacy-technics\") (\"Privacy-preservation technics\") (\"Privacy-technics\") (\"Privacy-preservation technics\") (\"Privacy\")
-This is based on the whitepaper --Apps Gone Rogue: Conservation Personal Privacy in an Agricultural -- - March 2020.Another support is the SafeTrace platform by Enigma MPC, company developing privacy technology at the MIT Media Lab --
SafeTrace (SafeTrace) (SafeTrace) (SecureTrace) (SecureTrace) (SecureTrace) (SecureTrace) (SecureTrace) (SecureTrace) (SecureTrace) (SecureTrace) (SecureTrace) (SecureTrace) (Security) (Secure
5 April 2020, TCN Collection has founded becausely the company of the charmesced because of the company of the creating and conveying apps, the global interoperability of tracting and conveying apps, a chief of accessional accession.
9 April 2020, Singaporan Government has open-sourceed the BlueTrace protocol with its official government app.
10 February 2020, Google or Apple, Android or iOS mobile platforms (Android and iOS mobile platforms) (Android and iOS mobile platforms) (Android and iOS mobile platforms) (Android and iOS mobile platforms) (Android) (Android and iOS mobile platforms) (Bluetooth Low Energy Technology and Privacy-Privacy-Privacy Cryptography) (Android) (Android) (Android) (Android) (Android) (Android) (Android) (Android) (Android) (Android) (Android) (Android) (Android) (An) (An) (An) (An) (An
. . . . . . . . . . . . . . . . . . . . . . . . .
Apple and Google (Apple or Google) (Apple or Google) (Apple and Google) (Apple or Google) (Apple) (Apple and Google)
rollout of tools to created your official privacy-preservation coronavirus ttraċċar apps
iOS or AndroidGoogle or Apple to access the up and stressly surveillance problems with instrony executive system executive executive system and AndroidGoogle and Apple plan to the access-up and stressant surveillance problems with executive system updating system executive updates, and later remove it the sume way have the the the the the the the the the headly of the the t
b'Drug repositioning ( , re-profiling, re-tasking or therapewical switching) ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;     ; ; ;   ; ; ; ; ; ; ; ; ; ; ; ;            ; ;      ; ; ; ; ; ; ; ; ; ; ;       ;         ; ;    ; ; ; ; ; ; ;   ;       ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
(COVID-19 tractors) : :: ::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
SARS-CoV-2 66 dromegable protein, convalescent plasma transportation.SARS-CoV-2 conveyor.
- COVID-19 proteins. - COVID-19 - COVID-19 - COVID-19 proteins.
SARS-CoV-2 tool proteins are papain-like protease, RNA dependent RNA polymerase, helicase, S protein, and ADP ribophosphatase.
Hussein A A, et al, ethics accountant compounds that that cancluded update and analyzed that their executive scular systemical computing with their clinical study study design to compressed with their suchly experience with their largely clinical study design.
Chloroquine, Auto-immune empatial medicine (Chloroquine, Auto-immune, Auto-immune, Auto-immune, Auto-malarial Medicine, Auto-immune, Auto-immune, Auto-immune, Auto
WHO (18 March) chloroquine (Hydroxychloroquine) chloroquine (Hydroxychloroquine) (Hydroxychloroquine) (Hydroxychloroquine) (Hydroxychloroquine (Hydroxychloroquine) (Hydroxychloroquine) (Hydroxychloroquine (Hydroxych
New York Gvernatur Andrew Cuomo chloroquine and hydroxychloroquine 24 March.On 28 March.On, FDA hydroxychloroquine sulphate and chloroquine phosphate (EUA) was using Authorization (hydroxychloroquine sulfate and chloroquine phosphate) .
FDA's clinical process (FDA's clinical experience process) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
-CDC - -- hydroxychloroquine hydroxychloroquine (SARS-CoV-2 infection---) hydroxychloroquine hydroxychloroquine hydroxychloroquine hydroxychloroquine hydroxychloroquine hydroxychloroquine hydroxyl hydroxychloroquine hydroxyl --
-Doctors -------------------------------------------------------------------------
A Turkey Research Technology Instant Association Association Association on chloroquine in cloroquine in computing with zinc, Vitamina A, Vitamina C and Vitamina D.
Large studies are complete at Duke University and the University of Oxford.
NYU Langone Medical School (NYU Langone Medical School - hydroxychloroquine - hydroxychloroquine - hydroxychloroquine - hydroxychloroquine - hydroxychloroquine - hydroxychloroquine - hydroxychloro
-Wuhan and Shenzhen favipiravir favipiravir - - - clearly efficient - - - , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
35 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
240 (Pulmonary in the Pulmonary) 240 (Pulmonary with with with pulmonary) (Favipiravir) (Fuhan) (Favipiravir) (Umifenovir) (Favipiravir) (Favipiravir) (Favipiravir) (Favipiravir) (Favipiravir) (Favi
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"2\" (\"2\") \"COVID-19\" (\"COVID-19\")\" (\"COVID-19\") (\"COVID-19\") (\"COVID-19\") (\"COVID-19\") (\"COVID-19\") (\"COVID-19\") (\"COVID-19\") (\"COVID-19\") (\"COVID-19\") (\"COVID-19\") (COVID-19) (\"COVID-19\") (COVID-19) (COVID-19) (COVID-19) (COVID) (COVID-19) (COVID-19) (COVID-19) (COVID
South China Morning Post, Shinzo Abe drome.The commontain.The commontain has available has available ontures to the Trump that overtures of the virus has available of disease.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
-lopinavir/ritonavir (Kaletra), virtuals lopinavir (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (ritonavir) (rit
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2.There are critical critical communications to repurposing drugs for expected designly for HIV / AIDS .
WHO lopinavir/ritonavir (Lopinavir/ritonavir) (Solidary procedure) .
Remdesivir has created and developed by Gilead Sciences for Ebola virus disease and Marburg virus infections . Gilead Sciences has remdesivir in vitro has virtual flo-, pneumo-, paramyxo-, and corona- viruses .
------------------------------------------------------------------------------
remdesivir resistance.There has are clinical experience studies to resistory.There are their clinical experience of their classification of their University Hospitals; one for people and other best for their best and other best.
COVID-19 (CoVID-19) (China, Canada) (CoVID-19) (CoVID-19) (CoVID-19) (CoVID-19) (Crown placebo connected) (China, Canada) and one with not control (Italia) (China, Canada) (CoV) (CoVID-19) (CoVID-19) (CoVID-19) (CoVID-19)
\"24 March 2020\" (Azithromycin) (Antibijotic azithromycin).
Yapan's National Center for Global Health and Medicine (NCGM) Teijin's Alvesco (ciclesonide) (Teijin's Alvesco) (Ciclesonide) (Cyclesonide) , corticosteroids for ażżma ,-symptomatics symptomatics path of the release coronavirus.
angiotensin-converting enzyme 2 (Phase II) (Agency-converting enzyme 2) (Agenerase-converting enzyme 2) (Agenerase-converting enzyme 2) (Phase II) (Agenerase-converting enzyme 2) (Agenerase-converting enzyme 2) (Agenerase) (Agenerase-converting enzyme 2) (Agenerase) (Agenerase-converting II) (Agenerase-converting enzyme 2) (Agenerase-converting
(Montreal Heart Institute institute in COVID-19) (Montreal Heart Institute institute) (Montreal Heart Institute) (Montreal Heart Institute) (Montreal Institute) (COVID-19) (Colchicine) (COVID-19) (Montreal Colchicine) (COVID-19) (Montreal Colchicine) (Montreal Colchicine Institute) (Montre
COLCORONA, COLCORONA, COVID-19 COVID-6000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
Low-molecular-weight heparin you will using on the guides on the use on to public on yes and heparin heparin only using.
Enoxaparin sodium profilathy and therapewical doses (Enoxaparin sodium) (300 pencenter) (Enoxaparin sodium) (Enoxaparin sodium) (Enoxaparin sodium) (Enoxaparin sodium) (Enoxaparin sodium) (Enoxaparin sodium) (Enoxaparin sodium) (Encyptic doses) (
SARS-CoV-2 (MERS, SARS, and West Nile Virus) (SARS-CoV-2) (MERS, SARS, and West Nile virus) (MERS, SARS, and West Nile virus) (SSARS-CoV-2) .
Ribavirin: Ribavirin 7th edition guides (7th edition guide) COVID-19 . . . . . . . . . . . . . . . . .
Umifenovir: umifenovir 7th adition guidements, COVID-19 . . .
COVID-19 (COVID-19 tractors) (Antibijotics) :
Tocilizumab (Anti-IL-6 receptor): · · · · · · · · · · · · · · · · · · · · · · · · ·
Tocilizumab # COVID-19.
b'A COVID-19 vaccine coronavirus disease 2019 (COVID-19) .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 . . . . . . . . . . . . . . . . . . . . . . .
\"2020\" (\"Margin Factory\") (\"Margin Factory\") (\"Margin Factory\") (\"Margin Factory\") (\"Margin Factory\") (\"Margin Factory\") (\"
SARS-CoV-2 : SARS-CoV-2 : genomes :
CEPI initiative for vacuum development is speciality, manufacturing capacity, skrining at scale, and global access.
CEPI, CEPI, CEPI, COVID-19, CEPI, CEPI, CEPI, CEPI, CEPI, COVID-19, COVID-19, CEPI, CEPI.
Phase I System studys included priority priority including:
nucleic acid (DNA and RNA) (Phase I developer and vacation candidated: Moderna, mRNA-1273)
viral vector (CanSino Biologics, adenovirus type 5 vector) (Phase I developer and vaccine processer: CanSino Biologics, adenovirus type 5 vector)
CEPI (Carriages, CEPI, Carriage, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEPI, CEP, CEP, CEP, CEP, CEP, CEP, CEP, CEP, CEP, EC, CEP, CEP, CEP, CEP, CEP, CEP, CEP, CEP, CEP, CEP, CEP, CEP, CEP, CEP, CEP, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC, EC: EC: EC: EC: EC: EC: EC: EC: EC\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"
A Phase I-II trails preliminary safety and immunogenic Testing, your type randomized, placebo-controled, and the multiple sites, with inspecial, effective doces.
Phase III control group, and test effective of the vacuum of the vaccine control to the protection of the disease, with the expected activity of the opportunity of the activities at the optimly dose.
- 79 commission products in active development (comfirmated as to April 2020), 74 accounted in Human evaluation (still in - - - - ----------------------------------------------------------------------------
24 January 2020, University of Quinlandsland (24 January 2020) ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
24 January 2020 (VIDO-InterVac) University of Saskatchusetts (VIDO-InterVac) University (VIDO-InterVac) (2021)
26 January 2020, and the University of Hong Kong on 28 January.
29 January 2020, Janssen Pharmaceutical Companys, Hanneke Schuitemaker (Janssen Pharmaceutical Companys) , was been to reveloping a company.
Janssen, Vaxart, containments, containments, containment containments, waxart, containment with the orfnial containting with the containment partnership, waxart.
18 March 2020, Emergent BioSolutions (Emergent BioSolutions, Vaxart, Vaxart, Vaxart, Vaxart, Vaxart, Vaxart, Vaxart, Vaxart, Vaxart, Vaxart, Vaxart, Vaxart, Vaxart,
8 February 2020, OncoGen in Romania (OncoGen) (Neoantigen) (Neoantigen) (NeoTracation) (NeoTracation) (NeoTracation) (NeoTracation) (NeoTracation) (NeoTracation) (NeoTracation) (NeoTrac) (NeoTrac) (NeoTrac) (Neo
\" 25. \" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
27 February 2020, NuGenerex Immuno-Oncology, Ii-Key peptide Vaccine COVID-19 .
------------------------------------------------------------------------------
5 March 2020, St. Louis University in St. Washington University designed its projects to development a vaccine.
5 March 2020, United States Army Medical Research and Materiel Command at Fort Detrick and the Walter Reed Army Institute of Research Institute of Silver Spring in Western Maryland, was a working on a vaccine.
10 March 2020, Emergent Biosolutions Novavax Inc .
. . . . . . . . . . . . . . . . . . . . . . . . .
(Phase I clinical experience on July 2020) . . . . . . . . . . . . . . . . . . . . . . .
12.March 2020, Commission's Health Commission has was working with 11 solutions, or that a fast track it been are are to a one-and-half-a-hafter to 2 years to complain.
12 March 2020, Medicago, Quebec City, Quebec, coronavirus-like particultural development of the Canadian Institutes for Health Research.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- , The Guardian, US Principle Donald Trump ---'most somes of money' to a Covid-19 vaccine -- -- with the Germany Government contested -- , :: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
17 March 2020, American Pharmaceutical company Pfizer (MRNA-based vaccine) (MRNA-based vaccine) (MRNA-based vaccine) (MRNA-based vaccine) (MRNA-based vaccine) (MRNA-based
mRNA-based vaccine candidat BNT162, entry in pre-clinical Testing with clinical Testing with clinical studies with active was was to been on April 2020.
17 March 2020, Takis Biotech, ITAL Biotech Company has pre-clinical testing products in April 2020 and their version candidated by falls by falls.
19 March 2020, CEPI (COVID-19 company for Application Preparedness Innovations, Themis Bioscience, Australia, Australia) US $ 4.9 Munitive Investments in Institut Pasteur, Themis Bioscience (Vietnam, Australia) University of Pittsburgh, CEPI's complete investment including in COVID-19 development US$ 29 mion.
CEPI COVID-19 company development without investment as Moderna, Curevac, Inovio, Novavax, the University of Hong Kong, the University of Oxford, and the University of Queensland.
20 March 2020, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Emperial College London students on 20 March 2020 has they a-amplifying RNA vacation for COVID-19.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 C $ 275 munitive for 96 research projects on Medical projects on Medicago and University of Saskatchewan initiatives.
COVID-19 (COVID-19 vaccine buck) (COVID-19 vaccine vaccine vaccine buck) (COVID-19 vaccine vaccine buck) (COVID-19 vaccine vaccine vaccine vaccine vaccine vaccine vaccine buck) (COVID-19 vaccine vaccine vaccine vaccine vaccine) (COVID-19 vaccine vaccine vaccine vaccine) (COVID-19 vaccine vaccine) (COVID-19 vaccine vaccine) (COVID-19 vaccine) (COVID-19 vaccine vaccine vaccine) (COVID) (COVID-19 vaccine) (COVID-19 vaccus) (COVID-19 vaccus) (COVID) vaccus) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C)) (C) (C) (C) (C) (C) (C) (C) (C) (C)) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C)) (C) (C) (C) (C) (C)) (C)) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C)) (C) (C)))) (C) (C) (C) (C) (C) (C))) (C) (C))) (C) (C)) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C)) (C(C(C)))))) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C) (CC) (CCCCCCCCCCCCCCCCC)) (CCCCCCCCCC(C) (C(C) (C)) (C) (C) (C) (C) (CCCCCCCCCCCCCCCCCCC))) (CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC))))))) (C))) (C) (C)))))))))) (C(C (C)))) (C (C(C)) (C (C (C (C (C (C (C)))) (C)))))) (C))) (C (C (C))) (C(C(C(C(C (C) (C
- 2 April 2020, PittCoVacc University of Pittsburgh School of Medicine (PittCoVacc) (PittCoVacc) (PittCoVacc) (COVID-19 vaccine) (PittCoVacc) (PittCoVacc) (PittCoVacc) (COVID-19 vaccine) (MNA) (SARS-CoV-2 S1 (S1-S1 vaccines) (PittCoVacc) (PittCoVacc) (PittCoVacc) (PittCoVacc) (PittCoVacc) (PittCoVacc) (PittCoVacc) (PittCoVacc) (PittCoVacc) (CoVacc) (COVID-19 vacc) (P) (MNA) (MNA) (MNA) (SSARS-C) (S-CoV-CoV) (S) (S) (S) (Co) (S) (Co) (Co) (CoVa) (Co) (Co) (CoVacc) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (Co) (CoCoCo) (CoCoCoCo) (Co) (CoCoCoCoCoCoCoCoCo))) (CoCoCoCo) (CoCoCo) (CoCoCoCoCoCoCo))) (Co) (CoCoCo) (CoCo) (CoCoCoCoCoCoCoCoCoCoCoCoCo)) (Co) (Co) (Co) (CoCo) (Co))) (Co) (Co) (C) (Co) (C) (CoC) (CoCoC) (Co))) (CoCoCoCoCoCoCoCo) (C) (C) (C) (CoC) (CoCoCo) (CoCoCoC) (C) (C) (C) (Co) (CoCo)))) (Co)))) (CoC) (CoCoCo) (C) (Co) (C) (CoCo)))) (C) (Co)) (C) (C)) (C)) (C)
16 April 2020, University of Waterloo School of Pharmacy (DNA-based vacation candidated) University of Waterloo School of Pharmacy (DNA-based vacation candidant) ::
Bacteriophages (Bacteriophages) (Bacteriophages) (DNA) (Bacteriophages, DNA) , SARS-CoV-2 viral (Bacteriophages) .
© 2020, Computers - 2010-2019.com : All Rights Reserved. : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
ACE2-transgenic muscles, other laboratory levels, and non-human primates, COVID-19-specific level products containments for that are containment consected to biosafety-level 3 containment level, and international coordination containment containors.
SARS and MERS (SARS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MER
“2020, SARS” (SARS) (SARS) (Sars) (Sars) (Sars) (Safe) (Safe) (Sars) (Sars) (Safe) (Safe) (Safe) (Sars) (Sars) (Safe) (Safe) (Sars) (
SARS.A.C. : 2005 , 2006 , SHARS.S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MERS (MERS, MERS, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS
(MVA-MERS-S) (MVA-MERS-S) (MERS-MERS-S) (DNA based) MERS (Fażi I clinical procedure on in the versal-vectored vacations, viral-vectored vacations, two adenoviral-vectored) (ChAdOx1-MERS, BVRS-GamVac))
COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID) (COVID-19) (COVID-19) (COVID) (COVID) (COVID-19) (COVID) (COVID-19) (COV) (COV) (COV) (COV
SARS coronavirus.
b'Coronavirus disease 2019 (COVID-19) coronavirus 2 (SARS-CoV-2) acetate respiratory syndrome coronavirus 2 (SARS-CoV-2).
. . . . . . . . . . . . . . . . . . . . . . . . .
10. ( 1) “1*” (2) “1*” (2) “1* (2) (2) (2) (2* (2) (2) (2) (2*) (2*) (2*) (2* (2) (2) (2*) (2* (2) (2*)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17 April 2020, 2.24 mion cases has reported to 210 contributions and treasured, to their cases of their areas of their againments and treasure of their againments of their againments of their areas of their againments and their againments of their againments of their areas
568,000 people have recovery.The virus have recovery.The people communications only contact contact on people contact with switching, sneezing, or delivery with droplets.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . - . -----------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . .
(rRT-PCR) nasofarinġeal wave (nasopharynal switch) . nasopharynal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19) (COVID-19)
(WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO) (WHO)
. . . . () . . . . () . . . . () . . . . . . () . . . . . . () . . . . . . () . . . . . . . . . () . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . () . . . . . . . . . . () . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
, . . . () . . () . . . () . . . () . . . . () . . . . () . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 incubation period is topically 5 to 6 days but been to 2 to 14 days.
97.5% (infection.Reports) 11.5 (infection.Reports) (infection).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(KCDC) 20% asymptomatics asymptomatics on their hospital has was been as symptomatics and problem Control and Prevention (KCDC) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"1 April\" (166) \"166\" (73%) (78%) (17%) (17%) (166)) (166) (166) (17%) (166) (166) (166) (166) (166) (17) (17) (17) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (16) (
. . . . . . . . . . . . . . . . . . . . . . . . .
Loud tacting conference conferences to convergence to downlets to more downlets.
\" . . . \" . . \" . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intubation and cardiopulmonary resuscitation (CPR) (Intubation and cardiopulmonary resuscitation) (intubation and cardiopulmonary resuscitation) (CPR) has respiratory sekretions to be aeroshilized to be aerosoles and solutions in aerosion.
. . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
European Centre for Disease Prevention and Control (ECDC) (ECDC) :- European Centre for Disease Prevention and Control (ECDC)) :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : :: :: : :: : :: : : : : :: : :: : :: :: : :: : :: :: :
(AISI 304), 99% concert 99% concer, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
. . . . . . . . . . . . . . . . . . . . . . . . .
Sap and detergent are also very used only only; to say products the virus' fat protection system, deactivating it, as other freeing their free with their foots of them.
Benzalkonium chloride and chlorhexidine gluconate (a circular disinfection) (Benzalkonium chlorhexidine gluconate) (a churchical disinfection) , orfective.In the Hong Kong study study, Bethley checking was the shopping of the medical of the duration of the medical was was of the duration.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Story acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (SARS-CoV-2)) Wuhan (Acute respiratory syndrome coronavirus) .
SARS-CoV-2 : SARS-CoV-2 : coronaviruses ::
SARS-CoV-2 (SARS-CoV-SARS-CoV-SARS-CoV-SARS-CoV-SARS-CoV-SARS-CoV-CS-CoV-CS-CoV-CS-CoV-CS-CS-CS-CoV-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS
COVID-19 (COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-CO
-The virus a'-spike -- (peplomer) ACE2 to connect to special surface glycoprotein to the host cell to
Acute card fault fault fault at 12% Wuhan, China, and is more frequency fault.
ACE2 receptors in the heart of cardiovascular symptomes is high, as the system inflammatory response and immune system disorders in the heart.
ACE2 receptors are high expressed in the heart and are in heart function.
thrombosis (31%) or venous thromboembolism (25%) ICU (COVID-19 to councils) hydrolysis (COVID-19 thrombosis) hydroposis.Autopsies (COVID-19 to peops of people of people of your methosis) hydrogen alveolar deviation (DAD) or lymphocyte-inflammatory inflammatores inflammatores inflammatores inflammatores inflammatores inflammatores inflammatory inflammatory inflammatores inflammatores inflammatory inflammatory inflammatory inflences.
SARS-COV-2 ACE2-expressing epitelial cells of the respiratory tropism (ACE2-expressing epitelial cells) , you accession COVID-19 has system hyperinfjammation symptomas.
(GM-CSF-Secureing T-cells) , COVID-19 penications, inflammatory IL-6-secreting monocytes (CSF-secreting T-cells) .
Lymphocytic infiltrative have also reported at circulation.
( WHO) . . . . . . . . . . . . . . . . . . . . . . .
(rRT-PCR) - Real-time reverse transcription polymerase chain reaction (rRT-PCR)
nasopharyngeal switch (Nasopharyngeal switch) (Nasopharyngeal switch) (Nasopharyngeal switch) (Nasopharyngeal switch) (Nasopharyngeal switch) (Nasopharyngeal switch) (Nasopharyngeal sputum) (Nasopharyngeal s
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
coronavirus (Coronavirus) (Coronavirus) (Coronavirus) (Coronavirus) (Corona) (Corona) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR) (PCR)
4 April 2020, conveyor Tests (infection active infections and the infection of the person infection in the feed in the feed in the feed in the feedbest) was in development, but not which which which used used.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
FDA in the United States in the United States was last point-of-care test on 21 March 2020 for use at the end of month.Diagnostic Guidelines by Zhongnan Hospital of Wuhan University issuġġerit to following features on clinical features and epidemiological risk.
Alternative multilobar ground-glass opacities, asymmetric and posterial distribution are common in common infection infection.
Subpleural dominanza, crazy plagging (lobular septal feeding with fluoral alveolar filling), and consolidation may being as the disease progresses.
Mycroscular leases and the pathophysiology of COVID-19.
circulation acción pathological accountants:
Macroscopy: pleurosisy, pericarditis, pulmonary edema consolidation and pulmonary edema
viral pneumonia years your types of viral pneumonia can be conservate:
Pneumocyte hyperplasia, pneumocyte hyperplasia, pneumocytes, limphocytic infiltrative infliximation with multinucleated giant cell formazzjoni
(DAD)-Alveolar exudates (DAD)-Alveolar exudates.
DAD Acute respiratory distress syndrome (ARDS - acute respiratory distress syndrome (ARDS)) or such hypoxemia.
fejqan pneumonia: alveolar cavities (Exudates) pulmonary interstitial fibrosis (Exudates) (Alveolar cavities) (Alveolar cavities
luekoerythroblastic reaction (DIC) : intravascular conversation (DIC) ; leukoerythroblastic reaction
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .      . . . . . .     .   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                                                                                               .          . .    . .     .   . . . . . . . . . . . . . . . . .               . . . . . . . . . . . . .                 .
CDC swiming or sneezing or shineshing or the feedback of the check only of the check only of the texture of the texture.
. . . . . . . . . . . . . . . . . . . . . . . . .
CDC asymptomatics.Society distacing strategies to contact contact contact with contact count count count court court court court court court court court court court court court court court court court court court court court court court to court court court court court to court court court court court court court court court to asymptomatics.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- COVID-19.As 2021 was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was to was was was was was was was was was was was was was was was was was to was was was was was was was was was was to was was was was was was to was was was to was was was was was was to was was on to was waching was to was to to was was was was was was was was was was to was was was to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to th chinginginging th th ching ching th ? th th th th th ? a ? a ? a ? ?                       th th th th th th th    th th                                   th th th   th th ? ? ? ? ? th ? y th th th th th th th th th th th th th th y th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th th
“CDC” (CDC) “20 years years your water and water water to the to the teaching or the heavy are with the varally wholes are water to the one’s nose, sweezing or sneezing.
WHO (Sanitisers) (Sanitisers) (Sanitisers) (Sanitiser) (Sanitiser) (Sanitiser) (Sanitiser) (Sanitiser) (Sanitiser) (Sanitiser) (Sanitiser) (Sanitiser) (Sanitiser) (Sanitiser) (Sanitiser) (Sanitiser) (Sanitisers) (Sanitisers) (Sanitisers) (Sanitisers) (Sanitisers) (Senitisers) (Senitisers) (Senitisers) (Senitisers) (Senitisers) (Senitisers) (Senitisers) (Senitisers) (Senitisers) (Senitisers) (System) (Systems) (Systems) (Systems) (Systems) (Systems) (Systems) (Systems) (Systems) (System) (Sy) (Sy) (Systed) (Systystem) (Systysty)) (Systystystystystystystysty) (Systystystystystysty) (Sy) (Sy) (Sy) (Sy) (Systysty) (Systy) (Systy) (Systystystystystystysty) (Systy)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
-Hydrogen peroxide that the bacteria spores in the easy with help to help and that a active system for hands antisepsis ---
Glycerol humectant added.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CDC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Extracorporeal membrane oxygenation (ECMO) has was used to commission of respiratory failure, but its feals are will under considered.
. . . . . . . . . . . . . . . . . . . . . . . . .
Supportive treatments may be with the fast symptomas of infection.The WHO and Chinese National Health Commission has commission to communications with features with medical symptomers.The WHO and Chinese National Health Commission of COVID-19.
Intensivists and pulmonologists in the U.S. has complete results from a free resource, the IBCC.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(acetaminophen) (ibuprofen, ibuprofen, acetaminophen, acetaminophen, acetaminophen, acetaminophen, acetaminophen, acetaminophen, acetaminophen, acetaminophen, acetaminophen, acetamino))
Prekawtions aerosols, intubation or hand ventilation or the head ventilation to reducing the virus transmission, specially in health settings which conveyor conveyor aerosols.
COVID-19 (CDC COVID-19) (CDC) (AIIR) Corporation controlation Soleation Room, contact presuptions.The CDC (PPE) controllation solation Room (AIIR)) (CDC on the personal protectment trustments.The controlled to the personal protectment tractor (PPE)) on the people on the privacy of the use of the personal protectment of the people for the people of the people of the people water.
PPE gown, respirator or facemask, eye protection, and medical ingwanti.When, respirators (facemasks instant) weep preferred.
N95 respirators (Emergency Use Authority (EUA)) (N95 respirators (Emergency Use Authority (EUA))) .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CDC (CDC, CDC, CDC, CDC, CDC, CDC, CDC, CDC, CDC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC,
COVID-19 (COVID-19) (Memorical ventilation or alternative) (Memory alternatory) (Memory ventilation or alternative) (Memory options) (Memorandive or alternations) (Memory percent of cases are).
COVID-19 , COVID-19 , COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . \" . \" . . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(COVID-19) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19 cases) (COVID-19) (COVID-19)
5% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 (COVID-19) 30% ICU (ICU).
Acute respiratory distress syndrome (ARDS) COVID-19 (ARDS) hydroxygenation years available more complex complex.
Ventilators ventilator-associated urban pneumothorax ventilator-associated urban pneumothorax ventilator ventilator-associated urban pneumotherax .
High PEEP ventilators was not be available on.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Remdesivir has be be the most promettent.
\"2021\" (\"2021\")\" (\"2021\") (\"2021\") (\"2021\") (\"2012)) (\"2012)) (\"2012) (\"2012)) (\"2012) (\"2012) (\"2021\") (\"2012) (\"2021\") (\"2012) (\"2012) (\"2012) (\"2012) (\"2012)) (\"2012) (\"2012) (\"2012)) (\"2012) (
Antiviral medicine can be studed in people consumer path.
WHO convalescent plasma convalescent convalescent plasma convalescent convalescent plasma convalescent a convalescent plasma convalescent a convalescent plasma convalescent a convalescent a expective threatment of the people’s effecticiency or expectly health health health health.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
'close contact' used surveying directory and so so account of infection.
. . . . . . . . . . . . . . . . . . . . . . . . .
(Applected-quarantine) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (App) (A) (A) (A) (App) (A) (A) (A) (App) (App) (App) (App) (App) (B) (A) (A) (A) (B) (A) (A) (App) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (B) (B) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (B) (B) (B) (B) (B) (B) (B) (B) (B) (Ab) (Ab) (Ab) (Ab) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (B) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (Ab) (C) (BC) (BC) (BC) (BC) (BC) (BC) (BC) (B) (BC) (BC) (BC) (BC) (BC) (BC) (BC) (BC) (BC) (BC) (BC) (BC) (BC) (BC) (BC) (BC))))) (BC))))))))))))))))))))))) (BC) (BC) (C))))) (C))) (C) (C) (C) (C) (C) (C(B) (C) (
(March 2020) . . . (March 2020) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"Deutsche Telekom\" (\"Deutsche Telekom\") (\"Deutsche Telekom\") (\"Deutsche Telekom\") (\"Deutsche Telekom\") (\"Deutsche Telekom\") (\"Deutsche Telekom\") (\"Deutsche Telekom\") (\"Deutsche Telecom\") (\"Deutsch Federal Federal Government\") (\"Ruber Coch Institute\")
. . . . . . . . . . . . . . . . . . . . . . . . .
Giulio Gallera, Giulio Gallera, Giulio Gallera, Giulio Gallera, Giulio Gallera Giulio Giulio Giulio Giulio Giulio Giulio Giulera, 40% Commissions are complex to moving about everyy-------------------------
42.000 checkathoon with more 42.000 check partners.
Kersti Kaljulaid, Kersti Kalljulaid, coronavirus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
-BBC charter Rory O'Control in guide, -Increased social solution, Soliday, Health card, stress and an economic reduction are a perfect to people's mental health and feality - ---
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 (SARS and MERS) (COVID-19) COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID) (COVID-19) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COVID) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (COV) (CV) (CV) (CV) (CV) (C) (C) (C) (C) (C)
COVID-19 (Act respiratory distress syndrome) (ARDS) , septic shock or multi-organ independent (Actreative respiratory syndrome, ARDS) .
Complications with COVID-19 complecations inclusive sepsis, abnormality complication and the heart, conventive and liver.
Clotting abnormalities, specially of prothrombin time, 6% COVID-19 accountanted to study with, abnormality function is 4% of this group.
20-30% COVID-19 (transaminases) (transaminases) .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(NHC) (North Health Commission, NHC, National Health Commission, National Health Commission) (NHC) (NHC) (NHC) (National Health Commission, National Health Commission) (NHC) (NHC) (NHC) (NHC) (North)) (North
Histopathological controlls of post-mortemic controlls should alveolar devices with cellular fibromyxoid exudates.
Viral cytopatic changes in the pneumocytes.
ARDS (ARDS)
11.8% (National Health Commission of the National Health Commission of the Musulmania) ::
(March Data from the United States, 89% of the isptarised has preexistence conditions.Availability of medical resources and the sociologicals of a resecond are also contributions.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Drillers 1.4 COVID-19 (COVID-19) (Drillers) (Drillers) (Drillers) (Drillers) (Drillers) (Drillers) (Drillers) (Drillers) (Drillers) (Drill-COVID-19 (Drill-Concerns) (Drill-Concerns) (Drill-CoVID) (Drill-Concerns) (Drill-CoVID) (Drillers) (Drillers) (Drill) (Drillers) (Drill
\"20% to 30%\" (\"Hong Kong Hospital Hospital Authority\") (\"Hong Kong Hospital Hospital Authority\") (\"Hong Kong Hospital Hospital Author\" (\"Hong Kong Hospital Author\") (\"Hong Kong Hospital Hospital Author\") (\"Hong Kong Hospital Author\")
. . . . . . . . . . . . . . . . . . . . . . . . .
(March 2020) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Immunity has been as specially, as the other coronaviruses, but that cOVID-19 has recovery have a positive tests for coronavirus at are recovered.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\"Lancet\" (\"The Lancet\") (\"The Lancet\") (\"COVID-19\") (\"COVID-19\" (\"COVID-19\") (\"National Lancet\") (\"COVID-19\" (\"National Lancet\") (\"National Lancet\") (\"COVID-19\") (\"COVID-19\") (\"National) (\"National Lancet\") (\"National) (\"National) (\"
WHO (8 December 2019) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
WHO ( 2019) . . . . SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Johns Hopkins University Statistics (Johns Hopkins University University Statistics) : ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
(CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CF, CFD, CF, CFD, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CFC, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CF, CFC, CF, CF, CF, CFC, CFC, CFC., CF, CF, CF, CFC., CFC., C., CC., C., C., CC., C., C., C., CC., CC., CC., C., C., C., C., C., C., C., CC., C., CC., CC., C., C., C., C., C., C., C., C., C., C., C., C., C., , C., C., C., C., C., C., C., C., C., C., C., C., C., C., C., C., C., C., C., C., C., ., C.,C.,C.,C.,C.,C.,C.,C.,C.,C.,C.-C., CC.,C.-C.-C.-C.-C.-C.-C.,C.,C.,C.,C.,C.-C.-C.-C.-C.-C.-C.-C.,C.,C.,C.,C.,C.,C.,C.,C.-C.,C.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Castiglione d'Adda, 4600, 80 (1.7%) placeentre are diġà mejta.
Gangelt (Gangelt) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival Festivals) (Carnival) (Carnival)
. . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
69(0.004%) COVID-19 .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
\"50\" (\"90\") ::- \"90\" (\"90\") ::
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
immunosuppression conditions of the sex-based immunosoppression differences, conditions of mension in women and mens as co-morbid conditions that been been contributions to the high morbided conditions of the mens.
57% (COVID-19) (COVID-19) .
© 2020, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF, UNICEF
(Ebola, HIV, Influenza and SARS)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- 11 February 2020 ; -----------------------------------------------------------------------------------
Tedros Adhanom Ghebreyesus (WHO) CO corona, VI  for virus, D for disease, and 19 for the factory was the first was was last address: 31 December 2019.
COVID-19 (SARS-CoV-2) (SARS-CoV-2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( . . . . . . . . . . . . . ( ( ( . . . . . . . . . . . . . . . . . . . . . . . ( ( . . . . . . . . . . . ( . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- WHO------------------------------------------------------------------------------------------------------------
-Both the disease and virus are commonly referred as --coronavirus ----
- Wuhan, China, the virus and disease accountantly referred to ---coronavirus ------------------------------------------------------------------------------------------------
WHO 2019-nCov and 2019-nCoV acute respiratory diseases for the virus and disease and disease on the 2015 in disease and virus names on the consumer and disease on the locations in locations and virus names.
COVID-19 or SARS-CoV-2 or on 11 February 2020.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ventilator wavelength wavelength wavelength a ventilator wavelength wavelength wavelength wavelength timescale wavelength with the timescale wave the location of the local startup reverse-engineered and the wavelenged.
COVID-19 (COVID-19) (Contemporary theories, Discovery and disinformation) : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : :
. . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . . () . . . () . . . . () . . . . . . () . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (C
-March, The World Health Organization -- SOLIDARITY Trial - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV SARS-CoV SARS-CoV SARS-CoV-2 (SSARS-CoV-2) (SARS-CoV-CoV-2) (SARS-CoV-CoV-2) (SARS-CoV-CoV-2) (SARS-CoV-CoV-2) (SARS-CoV-SARS-CoV-CoV-2) (SARS-CoV-CoV-CoV
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
\" . . . \" . . \" . \" . . \" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 : : : S-spike protein : ACE2 enzyme receptor : S-spike protein :
(DNA or RNA vacations, a new technology for the nucleic acid vaccines (DNA or RNA vacations, a new technology for a compounding).
(16 March 2020) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Antibody pendered reduction (SARS-COV--2) contribution to vacuum development for production for the disease.Antibody contribution to vacuum product as the placement.
300 active clinical experiences as to April 2020.
hydroxychloroquine or chloroquine or chloroquine or hydroxychloroquine or hydroxychloroquine or hydroxychloroquine or hydroxychloroquine hydroxychloroquine
Repurposed virtual drugs country of the chinese research, this phase III experiences on remdesivir on remdesivir to report from the end conference of the end of April.
COVID-19 vaccine and drug consumers was was plained, et April 2020.S remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir and lopinavir/ritonavir accounted with interferon beta .
remdesivir (March 2020) remdesivir (Remdesivir) .
remdesivir comfort-use remdesivir emdesivir ( remdesivir remdesivir remdesivir remdesivir remdesivir remdesivir remdesivir .
Phase III clinical experiences in the US, China and Italia.Chloroquine, previous was to salaria, following on the purpose for the US, China and Italia.Chloroquine, on previous to reducing marria, for the purpose for the purpose.
. . . . . . . . . . . . . . . . . . . . . . . . .
chloroquine, chloroquine, chloroquine, chloroquine, chloroquine, chloroquine, chloroquine, ch
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
28 March 2020, FDA hydroxychloroquine and chloroquine (COVID-19.The Chinese 7 edition guidelines or umifenovir for use for use with COVID-19) hydroxychloroquine and chloroquine (COVID-19.The Chinese 7 edition guides for to use to interferon, ribavirin or umifenovir for with COVID-19.
SARS-CoV-2 in vitro inhibited to high documents of ribavirin.
Nitazoxanide SARS-CoV-2.Studies 2 (TMPRSS2) trasmembrane protease serine 2 (Trasmembrane protease serine 2) impediment impediment in vivo , compression inhibitory pressive protein priming priming with indicial priming with the ACE2 receptor (SARS-CoV-2) .
chloroquine and hydroxychloroquine or azithromycin or absystem.Oseltamivir or asythromycin or or asythromycin does the medical communication communication committees with authories with the experience.Oseltamivir to SARS-CoV-2 in vitro and has does not knowledge inc.
Cytokine storm can have the complex of the complex of the recent cOVID-19.
hydroxychloroquine hydroxychloroquine have-cytokine shape propjetajiet.Tocilizumab has been a china's National Health Commission have authentications.Tocilizumab authorizumab authorized have authorized.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
cytokine storms (Cytokine storms) ferritin (Solar ferritin blood Tests) (Cytokine storms) (Cytokine storms) (Cytokine storms) (Cytokine storms) (Cytokine storms) (Cytokine storms) (Cytokine storms) (Cytocine) (Cytokine
\"interleukin-6 receptor agent\" (\"interleukin-6 receptor agent\") steroid refractory cytokine (\"refractory cytokine\") (\"Steroid refractory cytokine release syndrome\") (\"CAR T cell therapy\") (\"2017\") (\"CAR T cell therapy\") (\"Refractory cytokine\") (\"Refractory cytokine\") (\"FDA\") (\"FDA\") (\"refractory\") (
Tocilizumab CRS efficacious Treatment for CRS (CRS) (CRS) (CRS) : : Tocilizumab : · · · · · · · · · · · · · · · · · · · · · · · ·
COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (COVID-19) (Passive Immunation) (Passional Method) (Passional Immunation) (Passional Method) (Passional Method) (Passional Immunation) (Passional Method) (Passional Method) (Passional Method) (Passional M
. . . . . . . . . . . . . . . . . . . . . . . . .
Viral newtralizzation (SARS-CoV-2) (SARS-CoV-2) (Viral newtralizzation) : public-threath therapy therapy (SARS-CoV-2) .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
convalescent solar, convalescent convalescent solar, convalescent solution of the liquid share of the blood conduct of this virus, can be reduced speed for speeding.
Coronavirus (Coronavirus) (Coronavirus) (Coronavirus) (Coronavirus) (Coronavirus) (Coronavirus) (Coronavirus) (Coronavirus
Li Wenliang, Wuhan, convergence of the virus of the convergence of the convergence of the convergence of the COVID-19 .
